JOINT MEETING ESH-ISH
HYPERTENSION
ATHENS 2014

JUNE 13 - 16, 2014 - ATHENS, GREECE
Megaron Athens International Conference Centre

IN COOPERATION WITH
Asklepion General Hospital Athens

24th European Meeting on Hypertension and Cardiovascular Protection

25th Scientific Meeting of the International Society of Hypertension

IN COOPERATION WITH

www.hypertension2014.org
JOINT MEETING ESH-ISH
HYPERTENSION
ATHENS 2014
JUNE 13 - 16, 2014 - ATHENS, GREECE

IN COOPERATION WITH:

Asklepion General Hospital Athens

UNDER THE PATRONAGE OF:

Ministry of Health and Social Solidarity

CONGRESS VENUE:

Megaron Athens International Conference Centre
Contents

4 Welcome Letter

7 General Information and Acknowledgements
  8 ESH Council 2013-2015
  9 ISH Council
  10 HSH Council
  11 Hypertension Athens 2014 Committees
  12 Scientific and Organising Secretariat
  13 Abstract Reviewers
  17 Sponsors Acknowledgements

19 Meeting Outline
  20 Industry Sponsored Satellite Symposia
  21 Industry Sponsored Minisymposia
  23 Industry Sponsored Educational Session
  23 Industry Sponsored How-To Session
  24 Meetings of the HSH for the Greek Doctors
  26 ESH Awards
  27 ISH Awards and Prizes
  29 Investigators’ Grants
  33 Meetings
  35 ESH Working Groups Business Meetings
  36 ESH Working Groups

41 Timetable
  42 Friday, June 13
  44 Saturday, June 14
  48 Sunday, June 15
  52 Monday, June 16

57 Congress Information
  58 Congress Venue
  60 Exhibition
  62 Exhibition Areas
  64 General Information
  68 Registration Information
  70 Opening Ceremony and Reception

73 Scientific Information
  74 Hypertension 2014 Credits
  75 Guidelines for Chairpersons and Speakers
  76 Poster Sessions
  79 Poster Area

81 Scientific Programme
  82 Friday, June 13
  87 Saturday, June 14
  148 Sunday, June 15
  203 Monday, June 16

251 Investigator Generated Satellite Symposia

255 Index of Chairpersons, Speakers and Authors
Welcome Letter

Dear Friends, Dear Colleagues,

It is a great pleasure for us to welcome you to the Joint Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) – in collaboration with the Hellenic Society of Hypertension and the Cardiology Department of Asklepeion Hospital - which takes place in Athens, Greece, June 13-16, 2014.

The meeting will cover a large area of knowledge in the field not only of hypertension, but also other conditions related to hypertension such as: dyslipidemias, diabetes mellitus, obesity, obstructive sleep apnea, coronary heart disease, heart failure, atrial fibrillation and new antithrombotics, peripheral arterial disease, COPD, sexual dysfunction etc.

As you know, the European and International Society of Hypertension meetings are the largest scientific events in hypertension worldwide, as they usually gather a huge number of participants all majorly or exclusively involved in hypertension and cardiovascular prevention at different levels.

Delegates come from all over the world, and most worldwide authorities in the field of high blood pressure and related diseases are involved. This makes this event the most appropriate forum for reporting and discussing all emerging important diagnostic and therapeutic approaches with experts from all around the world.

The congress is expected to be a great success despite the difficult conditions within the field, having received more than 2,300 abstracts from 87 countries; an all-time record in the history of this congress. Among the countries that stand out in terms of scientific work submission and delegate participation, apart that of Greece, are Russia, Italy, France, Spain, China and Japan.

With more than 30 scientific activities daily in parallel sessions, including Breakfast Workshops, Joint Sessions with other Societies, Topical Workshops, Mini Symposia, Teaching Seminars, Clinical Cases, How-To-Sessions, Meet-The-Expert Sessions, Oral and Poster presentations and Satellite Symposia, undoubtedly is going to be the most important meeting in its field for years on.

This important event is held in Greece, the country of Asclepius and Hippocrates, who stated in their teachings that "Το προλαμβανειν προτιμοτερον του θεραπευειν εστι - prevention is preferable to curing (Hippokrates 460-377 B.C.)" and thus still today, these words are as current as ever in global medical thinking.

Athens, the cradle of classical thought, world culture, science and democracy is ready to welcome you and give you not only the ability to exchange views and information with experts from around the world, but also the opportunity to experience Greek history and hospitality.

We count on your participation from June 13 to 16 in Athens: do not miss the opportunity to meet experts in your field from around the world.

Our motto is "we will all be there"!

A.J. Manolis  
Chairman of the Organising Committee

A.F. Dominiczak  
ESH President

E.L. Schiffrin  
ISH President
GENERAL INFORMATION AND ACKNOWLEDGEMENTS

8 ESH Council 2013–2015
9 ISH Council
10 HSH Council
11 Hypertension Athens 2014 Committees
12 Scientific and Organising Secretariat
13 Abstract Reviewers
17 Sponsors Acknowledgements
ESH Council 2013–2015

**EXECUTIVE OFFICERS**
- G. Mancia (Italy) - Chair, ESH Educational Committee
- G. Parati (Italy) - Coordinator Working Group Activities
- D.L. Clement (Belgium) - ESH Representative for contacts with the EU Officers

**MEMBERS**
- E. Agabiti Rosei (Italy)
- M. Azizi (France) - ESH Hypertension Specialist Programme
- M.J. Caulfield (United Kingdom)
- B. Jelakovic (Croatia) - ESH Excellence Centres Programme
- P.M. Nilsson (Sweden)
- M.H. Olsen (Denmark)
- P. van de Borne (Belgium)
- R. Cifková (Czech Republic) - Ex-officio representative of the WG on Hypertension & the Heart of ESC
- G. Grassi (Italy) - Ex-officio ISH Representative

---

ISH Council

**EXECUTIVE OFFICERS**
- E.L. Schiffrin (Canada)
- L.M. Burrell (Australia)
- A.J. Ramirez (Argentina)
- R.E. Schmieder (Germany)
- S.B. Harrap (Australia)
- B. Carlberg (Sweden)
- D. Prabhakaran (India)
- A.E. Schutte (South Africa)
- R.M. Touyz (United Kingdom)
- J.G. Wang (China)

**MEMBERS**
- G. Grassi (Italy)
- H. Haller (Germany)
- C.H. Kim (South Korea)
- G. London (France)
- B. Ouwene (Netherlands)
- N.R. Poulter (United Kingdom)
- K. Shimamoto (Japan)
- N. Stern (Israel)
- M.A. Weber (USA)

**EXECUTIVE OFFICERS**
- G. Mancia (Italy) - Chair, ESH Educational Committee
- G. Parati (Italy) - Coordinator Working Group Activities
- D.L. Clement (Belgium) - ESH Representative for contacts with the EU Officers

**EX-OFFICIO MEMBERS**
- L. Landsberg (USA) and A. Zanchetti (Italy)

**PLANNING**
- J. Chalmers (Australia)

**APSH REPRESENTATIVE**
- T.O. Morgan (Australia)

**ESH REPRESENTATIVE**
- J. Redon (Spain)

**WHL REPRESENTATIVE**
- N. Campbell (Canada)

**HYPERTENSION NEWS**
- L.H. Lindholm (Sweden)
Hypertension Athens 2014 Committees

**President**
A.J. Manolis (Greece)

**Honorary Presidents**
H.P. Gavras (USA)
G. Mancia (Italy)

**Vice Presidents**
- D. Vlahakos (Greece)
- A. Pittaras (Greece)
- G.S. Stergiou (Greece)
- C. Tsioufis (Greece)

**ESH President**
A.F. Dominiczak (United Kingdom)

**ISH President**
E.L. Schiffrin (Canada)

**HSH President**
A.J. Manolis (Greece)

**Local Organising Committee**
- M. Doumas (Greece)
- T. Makris (Greece)
- A. Mitrakou (Greece)
- C. Zamboulis (Greece)

**Scientific Programme Committee**
**Chairpersons:** G.S. Stergiou, C. Tsioufis (Greece)

**Members:**
- A. Benetos (France)
- I. Gavras (USA)
- H. Grassos (Greece)
- M. Kallistratos (Greece)
- K. Kyfnidis (Greece)
- P. Kokkinos (USA)
- J.B. Kostis (USA)
- N. Madias (USA)
- P. Nihoyannopoulos (United Kingdom)
- V. Papademetriou (USA)
- D. Papadopoulos (Greece)
- M.V. Papavasileiou (Greece)
- L.E. Poulimenos (Greece)
- C. Vlachopoulos (Greece)
General Information
and
Acknowledgements

The ESH Council, the ISH Council and the Local Scientific Committee gratefully acknowledge the following referees for their help in reviewing the abstracts:

R. Accetto
E. Agabiti Rosei
L. Alcocer
I.A. Ali
L. Amar
E. Ambrosioni
F. Angeli
P. Aranda
W.J. Arendshorst
M. Arici
D.J. Aristizabal
P. Armario
R. Asmar
A. Avolio
M. Azizi
G.L. Bakris
M. Banach
M. Barton
E. Belin De Chantemele
J.N. Bella
I. Ben-Dov
A.E. Berbari
E. Berge
M. Bertagnolli
G. Bilo
J. Bisognano
H.R. Black
P. Blankestijn
J. Boggia
G.W. Booz
C. Borghi
P. Bousquet
P. Boulouque
B. Braam
S.M. Brand
M.W. Brands
J. Brugal
M. Briet
N.J. Brown
H.R. Brunner
W. Bscata
D. Burger
M. Burnier
L.M. Burrell
M. Bursztyn
V.M. Cachofeiro
D.A. Calhou
J.D. Cameron
D. Campbell
V.M. Campese
R.M. Carey
B. Carberg
O.A. Carretero
G. Castoldi
M.J. Caulfield
G. Ceolotto
A.R. Chade
F.J. Charchar
I. Chazova
S. Chen
C.Y. Cheung
J. Chin-Dusting
R. Cifkova
D.L. Clement
A. Coca
J. Cockcroft
M.L.G. Correia
S. Cruz-Flores
J.T. Cunningham
D.M. Cusi
C. Cuspidi
D. Czarnecka
A.A. Da Silva
B. Dahlof
A. Damasceno
A.H.J. Danser
S.T. Davidge
K.P. Davy
M. De Buyzere
A. De La Sierra
G. de Simone
R. Dechend
J. Deinum
S. Del Prato
General Information

Acknowledgements

T. Kuznetsova
K. Kyfnidis
D.T. Lackland
B.B. Lamarca
L. Landsberg
P. Lanetlme
P. Larochelle
S. Laurent
I. Lazareva
A. Lejnieks
D. Lemogoum
J.W.M. Lenders
B. Levy
Y. Li
M.L. Lindsey
G.Y.H. Lip
T.E. Lohmeier
C. Lombardi
L.M. Lonati
G. London
D. Lovic
E. Lurbe
J.R. M'Buya-Bambu-Kabangu
F. Magrini
T. Makris
J.M. Malion
G. Mancia
A.J. Manolis
F. Mantero
N. Martell-Caros
F. Mattace Raso
J.L. Mehta
P.A. Meredith
E. Mervaala
M.C. Michel
A. Mimiran
B.M. Mitchell
G.F Mitchell
A. Mitrafou
R. Mo
P.A. Modesti
T.O. Morgan
A. Morganti
R. Morishita
B.J. Morris
J.J. Mourad
M.L. Muiesan
M.J. Mulvany
P. Munroe
K. Narkiewicz
L.G. Navar
P. Nihoyannopoulos
P.M. Nilsson
A. Nishiyama
G. Norton
J. Nussberger
K. Rahmouni
L. Raij
M.K. Raizada
A. Ramirez
A. Rappelli
G. Reboldi
J. Redon
C. Reid
E. Reisin
R. Rettig
General Information

The ESH Council, the ISH Councils and the Local Scientific and Organising Committee would like to express their gratitude to all those who have generously contributed to the Scientific Programme:

Sponsors Acknowledgements

MAJOR SPONSOR

SPONSORS

BORYUNG PHARMACEUTICAL
OMRON HEALTHCARE EUROPE
THE MENARINI GROUP

SUPPORTERS

Abbott
A&D Company Limited
Alam Medical
AstraZeneca Hellas
AtCor Medical
Axelife
Bayer Healthcare
Bayer Hellas
Boehringer Ingelheim
BP Lab
Bristol Myers Squibb
Custo med
CVRx
Daichi Sankyo
Elpen
Esaote
Excemed
Foracare Suisse
Fukuda Denshi
GAP Pharmaceutical Hellas
Hemo Sapiens
Immunodiagnostics Systems
I.E.M.
Konstantaras Medical Publications
Meditech
Medtronic
Microlife
Novartis Hellas
Pfizer
Pharmanel
Recordati
Sigma Medical
SMT Medical Technology
Somnomedics
SpaceLabs Medical
Specifar
St. Jude Medical
Suntech Medical
Uscom
Wisepress
MEETING OUTLINE

20 Industry Sponsored Satellite Symposia
21 Industry Sponsored Minisymposia
23 Industry Sponsored Educational Session
23 Industry Sponsored How-To Session
24 Meetings of the HSH for the Greek Doctors
26 ESH Awards
27 ISH Awards and Prizes
29 Investigators’ Grants
33 Meetings
35 ESH Working Groups Business Meetings
36 ESH Working Groups
Meeting Outline

SATURDAY, JUNE 14
hrs 11.00 – 12.00
Banqueting Hall
The path forward with renal
denervation
Supported by an unrestricted educational
grant by Medtronic

SATURDAY, JUNE 14
hrs 11.30 – 12.30
Nikos Skalkotas Hall
Epidemiological, clinical and
biochemical advances in the diagnosis
of primary hyperaldosteronism
Supported by an unrestricted educational
grant by Immuno Diagnostic System

SATURDAY, JUNE 14
hrs 14.30 – 15.30
Banqueting Hall
Clinical implication of pulse wave
analysis: PWV, AI and central blood
pressure
Supported by an unrestricted educational
grant by Omron Japan

SATURDAY, JUNE 14
hrs 14.30 – 15.30
Nikos Skalkotas Hall
Arterial stiffness from research to
clinical application
Supported by an unrestricted educational
grant by Fukuda Denshi

SATURDAY, JUNE 14
hrs 14.30 – 15.30
Dimitris Mitropoulos Hall
Managing the AF patient with
hypertension – implications for clinical
practice
Supported by an unrestricted educational
grant by Bayer Healthcare

Industry Sponsored
Satellite Symposia

FRIDAY, JUNE 13
hrs 15.00 – 17.00
Banqueting Hall
Effective fixed solutions: one, two,
three... Goal!
Supported by Daiichi-Sankyo

FRIDAY, JUNE 13
hrs 15.00 – 17.00
Nikos Skalkotas Hall
The latest ARB Satellite Symposium in
ESH-ISH 2014
Supported by Menarini

SATURDAY, JUNE 14
hrs 12.45 – 14.15
Alexandra Trianti Hall
Triple combination in hypertension:
reaching new goals
Supported by Boryung pharm

Industry Sponsored
Minisymposia

SATURDAY, JUNE 14
hrs 11.00 – 12.00
Banqueting Hall
The path forward with renal
denervation
Supported by an unrestricted educational
grant by Medtronic

SATURDAY, JUNE 14
hrs 11.30 – 12.30
Nikos Skalkotas Hall
Epidemiological, clinical and
biochemical advances in the diagnosis
of primary hyperaldosteronism
Supported by an unrestricted educational
grant by Immuno Diagnostic System

SATURDAY, JUNE 14
hrs 14.30 – 15.30
Banqueting Hall
Clinical implication of pulse wave
analysis: PWV, AI and central blood
pressure
Supported by an unrestricted educational
grant by Omron Japan

SATURDAY, JUNE 14
hrs 14.30 – 15.30
Nikos Skalkotas Hall
Arterial stiffness from research to
clinical application
Supported by an unrestricted educational
grant by Fukuda Denshi

SATURDAY, JUNE 14
hrs 14.30 – 15.30
Dimitris Mitropoulos Hall
Managing the AF patient with
hypertension – implications for clinical
practice
Supported by an unrestricted educational
grant by Bayer Healthcare

SATURDAY, JUNE 14
hrs 15.30 – 16.30
Banqueting Hall
Unlocking the potential of home blood
pressure monitoring
Supported by an unrestricted educational
grant by Omron EU
**Industry Sponsored Minisymposia**

**SATURDAY, JUNE 14**
hrs 16.00 – 17.00
Nikos Skalkotas Hall
*Can the antihypertensive treatment modify the microvascular damages and protect the target organs in hypertension? An open discussion*
Supported by an unrestricted educational grant by Recordati

**SATURDAY, JUNE 15**
hrs 16.00 – 17.00
Nikos Skalkotas Hall
*Can the antihypertensive treatment modify the microvascular damages and protect the target organs in hypertension? An open discussion*
Supported by an unrestricted educational grant by Recordati

**SATURDAY, JUNE 14**
hrs 16.00 – 17.00
Nikos Skalkotas Hall
*Can the antihypertensive treatment modify the microvascular damages and protect the target organs in hypertension? An open discussion*
Supported by an unrestricted educational grant by Recordati

**SATURDAY, JUNE 15**
hrs 11.00 – 12.00
Alexandra Trianti Hall
*Filling a gap in the management of systolic hypertension*
Supported by an unrestricted educational grant by Servier

**SUNDAY, JUNE 15**
hrs 11.00 – 12.00
Alexandra Trianti Hall
*Filling a gap in the management of systolic hypertension*
Supported by an unrestricted educational grant by Servier

**Industry Sponsored Educational Session**

**SUNDAY, JUNE 15**
hrs 15.30 – 17.00
Banqueting Hall
*What’s the role of hyperuricemia in patients’ CV Risk profile?*
Supported by an unrestricted educational grant by The Menarini Group

**Industry Sponsored How-To Session**

**SATURDAY, JUNE 15**
hrs 14.30 – 15.30
Conference Suite II - MC2
*Long term blood pressure measurement: is Riva-Rocci still acceptable? A new method for continuous, undisturbed blood pressure measurement (beat-to-beat)*
Supported by an unrestricted educational grant by Somnomedics
Meetings of the HSH for the Greek Doctors*

FRIDAY, JUNE 13
09.45 Opening
10.00 Round Table I
Diagnosis: how to assess in hypertensives
11.00 Round Table II
Hypertension and organ damage: optimal treatment
12.00 Break
12.30 Round Table III
Hypertension in special populations
13.00 D. Athanasiades Memorial Lecture
13.30 Satellite Symposium
Management of thrombosis with rivaroxaban
Sponsored by Bayer-Hellas
14.30 Break
15.30 Satellite Symposium
25 years patient centric innovation in hypertension: from monotherapies to triple combination
Sponsored by Novartis-Hellas

SATURDAY, JUNE 14
18.30 Satellite Symposium
Stroke prevention in non valvular atrial fibrillation: improving patients outcomes
Sponsored by Bristol Myers Squibb – Pfizer

*ALL THESE SESSIONS ARE IN GREEK LANGUAGE ONLY, WITH THE EXCEPTION OF THE NOVARTIS-HELLAS SATELLITE SYMPOSIUM THAT IS IN ENGLISH

Three key journals in Hypertension

Editors: J.B. Park (Seoul); H. Suzuki (Saitama)
A transdisciplinary approach to basic and clinical vascular research
The journal Pulse publishes reviews and original papers in the field of vascular research. The trans-disciplinary approach of the journal fosters collaboration in relevant areas including cardiology, nephrology, neurology, endocrinology and diabetology, gerontology and general medicine. Submissions from all areas of vascular research, including but not limited to epidemiology, pathophysiology, diagnostics, therapeutics and prevention, are welcome.
www.karger.com/pls

Editors-in-Chief: U. Pohl (Munich); G.A. Meiningler (Columbia, Mo.)
A source of current research
The Journal of Vascular Research publishes original articles and reviews of scientific excellence in vascular and microvascular biology, physiology and pathophysiology. The scope of the journal covers a broad spectrum of vascular and lymphatic research, including vascular structure, vascular function, haemodynamics, mechanics, cell signalling, intercellular communication, growth and differentiation.
www.karger.com/jvr

Editor-in-Chief: J.S. Borer (New York, N.Y.)
An invaluable aid in understanding and treating heart disease
Cardiology features:
• First reports on original clinical, preclinical and fundamental research
• ‘Novel Insights from Clinical Experience’
• Topical comprehensive reviews in selected areas of cardiovascular disease
www.karger.com/crd
**ESH Awards**

**BJÖRN FOLKOW AWARD AND LECTURE**
The Björn Folkow Award has been established with the collaboration of AstraZeneca in recognition of the contribution made by Björn Folkow to cardiovascular physiology and pathophysiology. The award is given to a person who has carried out important original research on pathogenesis of hypertension.

**ALBERTO ZANCHETTI LIFE ACHIEVEMENT AWARD**
The Award is given to a scientist with a lifelong high quality scientific research in the field of hypertension.

**PETER SLEIGHT AWARD**
It consists in a research grant of Euro 20,000,00 made available by Boehringer Ingelheim. It is conferred to one or more investigators who have made an important contribution to research and education in the fields of hypertension and cardiovascular protection.

**ESH HONORARY MEMBERSHIP**
ESH Honorary Membership is given to scientists who have made extraordinary contributions to research in hypertension or who have given exceptionally important support to the activities of ESH.

**PAUL MILLIZEW AWARD**
The Award is conferred by the French Society of Hypertension to a French scientist acknowledged for his accomplishments in the field of hypertension.

**TALAL ZEIN AWARD**
The Talal Zein Foundation has established the "Talal Zein Award" to be presented annually to a distinguished scientist from a Mediterranean country, in recognition of outstanding work related to basic science, epidemiology, pathophysiology or therapy of hyper-tension and related cardiovascular diseases.

**“ALBERTO FERRARI” POSTER PRIZES**
Each day, the best 10 posters will be awarded with € 500 each. Winners will receive notification of the prize by email after the end of the meeting. List with names of awardees will be posted online, always at the end of the meeting, on the following website: www.hypertension2014.org, www.eshonline.org. The prizes are dedicated to the late Prof. Alberto Ferrari in recognition of his great contribution to the organization of the ESH meetings in Milan.

**ISH Awards and Prizes**

**FRANZ VOLHARD AWARD AND LECTURESHIP FOR OUTSTANDING RESEARCH**
This award and lectureship was endowed by Farbwerke Hoechst in 1972 to commemorate the centenary of the birth of Franz Volhard. The award is made biennially to a person or persons who, in the opinion of the ISH Awards Committee of the ISH, shall have initiated in the field of hypertension or in a related discipline, a concept which remains of current interest.

**ISH ROBERT TIGERSTEDT LIFETIME ACHIEVEMENT AWARD**
Presented biennially, on the recommendation of the ISH Awards Committee to a person, persons or institution responsible for distinguished work relating to the aetiology, epidemiology, pathology or treatment of high blood pressure. The achievements of the recipient should reflect distinguished contributions in research, teaching or clinical activities relating to the aetiology, epidemiology, pathology or treatment of high blood pressure and successful mentorship of younger colleagues.

**ASTRAZENECA AWARD**
Presented biennially on the recommendation of the ISH to a distinguished investigator responsible for outstanding work related to clinical pharmacology and therapy of arterial hypertension.

**ISH DEVELOPING WORLD AWARD**
This award is for a researcher in the developing world* who has done outstanding work in the region. (*based on the resource poor countries, zones and territories defined by hinari)

**ISH PAUL KORNER AWARD** (supported by the High Blood Pressure Research Foundation)
The award shall be presented biennially on the recommendation of the ISH Awards Committee to a person who has demonstrated outstanding contributions to research on Hypertension in the broad field of Neuroscience.
ISH Awards and Prizes

AUSTIN DOYLE AWARD (supported by Servier Australia)
This award was established to mark the contribution of Austin Doyle, Past-President of the ISH and Founding Chairman of the High Blood Pressure Research Council of Australia. Awarded to a graduate, who is within 5 years of postgraduate qualification. The recipient will be judged to have given the best original presentation relevant to clinical medicine, at the ISH Biennial Scientific Meeting.

DISTINGUISHED MEMBERSHIP AWARD(S)
Awarded to members who have given outstanding service to the ISH and have made unusually distinguished contributions to experimental and clinical research in hypertension.

HONORARY MEMBER AWARD(S)
Awarded to members who have given outstanding service to the ISH and have made unusually distinguished contributions to experimental and clinical research in hypertension.

ISH NEW INVESTIGATOR COMMITTEE ORAL PRESENTATION AWARDS (supported by Daiichi-Sankyo)
Established in 2012 to encourage New Investigators and recognise excellence in scientific contribution at the ISH Biennial Scientific Meetings. Awarded to New Investigators judged from a group of finalists to have given the best oral presentations.

ISH NEW INVESTIGATOR COMMITTEE POSTER PRESENTATION AWARDS (supported by Daiichi-Sankyo, Clinical Science, Hypertension Research and Journal of Human Hypertension)
Established in 2012 to encourage New Investigators and recognise excellence in scientific contribution at the ISH Biennial Scientific Meetings. Awarded to New Investigators judged from a group of finalists to have given the best poster presentations.

ISH INTERNATIONAL FORUM PRIZES (supported by Daiichi-Sankyo)
ISH International Forum Poster Prizes will be awarded in:
- Basic science
- Clinical science
- Population science
These prizes represent a strong and ongoing commitment by the ISH through the International Forum to recognise and reward the best research from all across the globe.

Investigators' Grants

Alfieri C. (Italy)
Alonzo C. (Argentina)
Andrica F.M. (Romania)
Antoniou M. (Greece)
Antza C. (Greece)
Anyfanti P. (Greece)
Apostolopoulou C. (Greece)
Arranz C. (Argentina)
Avdonina N. (Russia)
Azipan E. (United Kingdom)
Bai H. (Japan)
Belshi X. (Albania)
Benczúr B. (Hungary)
Bhatia J. (India)
Blanchard A. (Switzerland)
Blicher M. (Denmark)
Bosuyc J. (Belgium)
Bozic N. (Slovenia)
Brescacin L. (Argentina)
Broda D. (Argentina)
Bruno R.M. (Italy)
Burazor I. (Serbia)
Caligiuri S. (Canada)
Caravita S. (Italy)
Cardoso C. (Brazil)
Carty D. (United Kingdom)
Caruso G. (Argentina)
Casonova F. (United Kingdom)
Cavka A. (Croatia)
Chatzikyrkou C. (Germany)
Chaudagar K. (Slovak Republic)
Chen Y. (Sweden)
Chowdhury E. (Australia)
Christofidou P. (United Kingdom)
Clark C. (United Kingdom)
Comotti T. (Italy)
Cosic A. (Croatia)
Cozma A. (Romania)
Currie G. (United Kingdom)
Daraban A.M. (Romania)
Davern P. (Australia)
De Ciucicis C. (Italy)
De Nardo D. (Italy)
De Rosa M.L. (Italy)
Dhaouadi N. (France)
Diacoum N. (Moldova)
Dimas G. (Greece)
Djordjevic D. (Serbia)
Dobrowolski L. (Poland)
Dogotar O. (Russia)
Domenig O. (Austria)
Drenjanevic L. (Croatia)
Ekart R. (Slovenia)
El Bikai R. (Canada)
Engelen L. (Netherlands)
Estato V. (Brazil)
Fadl Elmula F.E. (Norway)
Fernandes-Rosa F. (France)
Friedrich S. (Germany)
Frunza S. (Romania)
Frydas A. (Greece)
Gadaleta Caldarola C. (Italy)
<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medrano P.</td>
<td>[Spain]</td>
</tr>
<tr>
<td>Menne J.</td>
<td>[Germany]</td>
</tr>
<tr>
<td>Mian M.O.R.</td>
<td>[Canada]</td>
</tr>
<tr>
<td>Michel F.</td>
<td>[South Africa]</td>
</tr>
<tr>
<td>Mihalj M.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Milanov S.</td>
<td>[Serbia]</td>
</tr>
<tr>
<td>Mirabito K.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Modesti P.A.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Mogi M.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Mori F.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Mozos I.</td>
<td>[Romania]</td>
</tr>
<tr>
<td>Muller M.</td>
<td>[Netherlands]</td>
</tr>
<tr>
<td>Nakamura T.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Nakaoka H.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Navar L.G.</td>
<td>[USA]</td>
</tr>
<tr>
<td>Negrea S.</td>
<td>[Romania]</td>
</tr>
<tr>
<td>Neupane D.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Niiranen T.</td>
<td>[Finland]</td>
</tr>
<tr>
<td>Nikolaidou B.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Nikolov A.</td>
<td>[Bulgaria]</td>
</tr>
<tr>
<td>Nishiymama A.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Nosalski R.</td>
<td>[Poland]</td>
</tr>
<tr>
<td>Novak S.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Novella S.</td>
<td>[Spain]</td>
</tr>
<tr>
<td>Oguchi H.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Ohri S.</td>
<td>[Bulgaria]</td>
</tr>
<tr>
<td>Ohosawa M.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Olde Engberink R.</td>
<td>[Netherlands]</td>
</tr>
<tr>
<td>Ott C.</td>
<td>[Germany]</td>
</tr>
<tr>
<td>Padhee M.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Palatini P.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Palma Dos Reis R.</td>
<td>[Portugal]</td>
</tr>
<tr>
<td>Panov D.</td>
<td>[Russia]</td>
</tr>
<tr>
<td>Paradis P.</td>
<td>[Canada]</td>
</tr>
<tr>
<td>Pavlova E.</td>
<td>[Russia]</td>
</tr>
<tr>
<td>Pereira A.</td>
<td>[Portugal]</td>
</tr>
<tr>
<td>Pereira T.</td>
<td>[Portugal]</td>
</tr>
<tr>
<td>Platek J.</td>
<td>[Poland]</td>
</tr>
<tr>
<td>Potthoff S.A.</td>
<td>[Germany]</td>
</tr>
<tr>
<td>Premuzic V.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Prestes P.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Procopciuc L.M.</td>
<td>[Romania]</td>
</tr>
<tr>
<td>Ptinopoulo A.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Puccia G.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Radekovic S.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Radic J.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Rana S.</td>
<td>[India]</td>
</tr>
<tr>
<td>Rasic L.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Regecova V.</td>
<td>[Slovak Republic]</td>
</tr>
<tr>
<td>Richards J.</td>
<td>[USA]</td>
</tr>
<tr>
<td>Rios F.</td>
<td>[United Kingdom]</td>
</tr>
<tr>
<td>Romero C.</td>
<td>[Argentina]</td>
</tr>
<tr>
<td>Rosenbaum D.</td>
<td>[France]</td>
</tr>
<tr>
<td>Sabayan B.</td>
<td>[Netherlands]</td>
</tr>
<tr>
<td>Sain M.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Saladini F.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Salles G.F.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Sampson A.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Samuelsson A.M.</td>
<td>[United Kingdom]</td>
</tr>
<tr>
<td>Santisteban M.</td>
<td>[USA]</td>
</tr>
<tr>
<td>Sarenc D.</td>
<td>[Serbia]</td>
</tr>
<tr>
<td>Sarközi A.</td>
<td>[Hungary]</td>
</tr>
<tr>
<td>Satoh F.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Satoh M.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Schastlivenko A.</td>
<td>[Belarus]</td>
</tr>
<tr>
<td>Secchia T.M.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Sedaghat S.</td>
<td>[Netherlands]</td>
</tr>
<tr>
<td>Galarza C.R.</td>
<td>[Argentina]</td>
</tr>
<tr>
<td>Gavrilaki E.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Georgiannos P.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Gessi V.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Gosk M.</td>
<td>[Poland]</td>
</tr>
<tr>
<td>Gotia S.L.</td>
<td>[Romania]</td>
</tr>
<tr>
<td>Graham L.</td>
<td>[United Kingdom]</td>
</tr>
<tr>
<td>Grigore C.</td>
<td>[Romania]</td>
</tr>
<tr>
<td>Griserylj I.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Gruve I.</td>
<td>[Bulgaria]</td>
</tr>
<tr>
<td>Gutkowska J.</td>
<td>[Canada]</td>
</tr>
<tr>
<td>Haller S.</td>
<td>[USA]</td>
</tr>
<tr>
<td>Haris Shaikh L.</td>
<td>[United Kingdom]</td>
</tr>
<tr>
<td>Head G.A.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Hirohama D.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Hornslien A.O.</td>
<td>[Norway]</td>
</tr>
<tr>
<td>Hristova K.</td>
<td>[Bulgaria]</td>
</tr>
<tr>
<td>Illic Begovic T.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Ioannidis A.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Isaykina O.</td>
<td>[Russia]</td>
</tr>
<tr>
<td>Ivanov M.</td>
<td>[Serbia]</td>
</tr>
<tr>
<td>Ivkovic V.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Iwahori T.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Jain S.</td>
<td>[Canada]</td>
</tr>
<tr>
<td>Jakovljevic B.</td>
<td>[Serbia]</td>
</tr>
<tr>
<td>Jusufovic M.</td>
<td>[Norway]</td>
</tr>
<tr>
<td>Kanbara Y.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Kanellos I.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Kapil V.</td>
<td>[United Kingdom]</td>
</tr>
<tr>
<td>Karanovic D.</td>
<td>[Serbia]</td>
</tr>
<tr>
<td>Karanovic S.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Karpetas A.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Kelty T.</td>
<td>[USA]</td>
</tr>
<tr>
<td>Kempny P.</td>
<td>[Argentina]</td>
</tr>
<tr>
<td>Kibel A.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Kim J.Y.</td>
<td>[South Korea]</td>
</tr>
<tr>
<td>Kistner L.</td>
<td>[Germany]</td>
</tr>
<tr>
<td>Klich-Raczk A.</td>
<td>[Poland]</td>
</tr>
<tr>
<td>Kobayashi T.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Koid S.S.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Konoshita T.</td>
<td>[Japan]</td>
</tr>
<tr>
<td>Konstantinidis G.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Korostovtseva L.</td>
<td>[Russia]</td>
</tr>
<tr>
<td>Kostic S.</td>
<td>[Serbia]</td>
</tr>
<tr>
<td>Krotin M.</td>
<td>[Serbia]</td>
</tr>
<tr>
<td>Kruger R.</td>
<td>[South Africa]</td>
</tr>
<tr>
<td>Kuczeriskz M.</td>
<td>[Poland]</td>
</tr>
<tr>
<td>Kuznetsova T.</td>
<td>[Belgium]</td>
</tr>
<tr>
<td>Lang D.</td>
<td>[Austria]</td>
</tr>
<tr>
<td>Lankhorst S.</td>
<td>[Netherlands]</td>
</tr>
<tr>
<td>Lee H.Y.</td>
<td>[South Korea]</td>
</tr>
<tr>
<td>Leite F.</td>
<td>[Portugal]</td>
</tr>
<tr>
<td>Lemogoum D.</td>
<td>[Belgium]</td>
</tr>
<tr>
<td>Lenders M.</td>
<td>[Germany]</td>
</tr>
<tr>
<td>Leone D.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Leppie M.</td>
<td>[Croatia]</td>
</tr>
<tr>
<td>Li L.</td>
<td>[China]</td>
</tr>
<tr>
<td>Lim K.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Lim N.K.</td>
<td>[South Korea]</td>
</tr>
<tr>
<td>Lip S.</td>
<td>[United Kingdom]</td>
</tr>
<tr>
<td>Lu X.</td>
<td>[China]</td>
</tr>
<tr>
<td>Lyamina N.</td>
<td>[Russia]</td>
</tr>
<tr>
<td>Maniero C.</td>
<td>[Italy]</td>
</tr>
<tr>
<td>Markava I.</td>
<td>[Belarus]</td>
</tr>
<tr>
<td>Marketou M.</td>
<td>[Greece]</td>
</tr>
<tr>
<td>Marques F.</td>
<td>[Australia]</td>
</tr>
<tr>
<td>Mcbride M.</td>
<td>[United Kingdom]</td>
</tr>
<tr>
<td>McDonnel B.</td>
<td>[United Kingdom]</td>
</tr>
</tbody>
</table>
Meetings

JUNE 13
Friday, June 13 | hrs 07.45–08.45
Meeting Room 2
ISH Executive Meeting

Friday, June 13 | hrs 08.00–11.30
Room Santorini 1–2 at Hilton Athens
ESH Council Meeting

Friday, June 13 | hrs 08.45–09.30
Meeting Room 2
ISH Awards Committee

Friday, June 13 | hrs 09.30–10.30
Meeting Room 2
ISH New Investigator Committee

Friday, June 13 | hrs 10.30–11.30
Meeting Room 2
ISH Scientific Council

Friday, June 13 | hrs 11.30–13.00
Meeting Room 2
ISH Membership Committee

Friday, June 13 | hrs 11.30–15.00
Conference Suite I – Room 1
ESH Young Investigator Meeting

Friday, June 13 | hrs 13.00–17.00
Room Santorini 1–2 at Hilton Athens
ISH-WHL Meeting

Saturday, June 14 | hrs 07.30–08.45
Meeting Room 3
ESH-ISH Bid 2020 Meeting

Saturday, June 14 | hrs 11.30–13.00
Meeting Room 3
Board of Management Journal of Hypertension

Saturday, June 14 | hrs 12.45–14.15
Conference Suite I – Room 1
ISH International Forum

Saturday, June 14 | hrs 13.30–14.30
Conference Suite II – MC2
Editorial Board Journal of Hypertension

Saturday, June 14 | hrs 14.30–15.30
Alexandra Trianti Hall
ESH Business Meeting/General Assembly

Saturday, June 14 | hrs 15.45–16.45
Meeting Room 2
ISH-WHL Meeting

Seo J.B. (South Korea)
Serban C. (Romania)
Shatynska-Mytsyk I. (Ukraine)
Shimojo N. (Japan)
Simonini M. (Italy)
Sokolovic S. (Bosnia And Herzegovina)
Song W. (China)
Spiroski D. (Serbia)
Stabouli S. (Greece)
Stafylas P. (Greece)
Stefanski A. (Poland)
Stevanovic A. (Serbia)
Sticchi A. (Italy)
Stoickov V. (Serbia)
Stojanov V. (Serbia)
Subo A. (Bosnia And Herzegovina)
Sung K.C. (South Korea)
Sydorchuk A. (Ukraine)
Tadic M. (Serbia)
Tasic I. (Serbia)
Tautu O.F. (Romania)
Tenekecioglu E. (Turkey)
Teco A. (United Kingdom)
Terzis I. (Greece)
Thieme M. (Germany)
Tikhonoff V. (United Kingdom)
Timasheva Y. (Russia)
Tintea E. (Romania)
Toader D.M. (Romania)
Totaro S. (Italy)
Triantafyllou A. (Greece)
Triantafyllou G. (Greece)
Tsiroupolou S. (United Kingdom)
Tsev S. (Bulgaria)
Tulo A. (Albania)
Turi V. (Romania)
Uneda K. (Japan)
Vakilzadeh N. (Switzerland)
Valieva Z. (Russia)
Van Sloten T. (Netherlands)
Van Varik B. (Netherlands)
Vasic K. (Serbia)
Verheyen N. (Austria)
Vicenczova C. (Slovak Republic)
Vintila A.M. (Romania)
Vrdoljak A. (Croatia)
Vuignier Y. (Switzerland)
Wainford R. (USA)
Wakui H. (Japan)
Wang C. (Japan)
Westerdahl C. (Sweden)
White C. (United Kingdom)
Wohlfahrt P. (Czech Republic)
Wolff J. (Poland)
Wu Q. (China)
Yamamoto M. (Japan)
Yamazato Y. (Japan)
Zdravkovic M. (Serbia)
Zeljkovic Vrnik T. (Croatia)
Zervakakou I.S. (Greece)
Zhang L. (China)
Zheng F. (China)
Zhou J. (United Kingdom)
Zivkovic R. (Serbia)
Zvartau N. (Russia)
Meetings

JUNE 15
Sunday, June 15 | hrs 07.45-8.45
Meeting Room 3
Meeting with WG Coordinators

Sunday, June 15 | hrs 12.30-13.30
Conference Suite 1 – Room 1
ESH Meeting with Presidents of
National Societies and Affiliates
National Societies

Sunday, June 15 | hrs 12.45-14.15
Nikos Skalkotas Hall
ISH General Meeting

Sunday, June 15 | hrs 14.00-15.30
 Conference Suite I – Room 1
ESH SHOT Meeting

Sunday, June 15 | hrs 14.15-15.15
Meeting Room 2
Meeting ISH New Executive

Sunday, June 15 | hrs 18.00-19.00
Dimitris Mitropoulos Hall
ARTEMIS

JUNE 16
Monday, June 16 | hrs 12.45-13.45
Meeting Room 2
ESH Meeting for Excellence Centres

ESH Working Groups
Business Meetings

JUNE 13
Friday, June 13 | hrs 19.00–20.00
Conference Suite II – MC2
ESH Working Group on Endothelin and
Endothelial Factors

JUNE 14
Saturday, June 14 | hrs 13.00–14.00
Conference Suite II – MC2
ESH Working Group on Vascular
Structure and Function

JUNE 15
Sunday, June 15 | hrs 13.00–14.00
Conference Suite II – MC2
ESH Working Group on Hypertension
and the Kidney

Sunday, June 15 | hrs 18.30–19.30
Conference Suite I – Room 1
ESH Working Group on Hypertension
and the Brain
ESH Working Groups

1. Working Group on Blood Pressure in Children and Adolescents
   **Prof. Empar Lurbe**
   Pediatric Department
   Consorcio Hospital General de Valencia
   University of Valencia
   Avenida Tres Cruces
   46014 Valencia - Spain
   T: +34 96 19725214
   E: empar.lurbe@uv.es

2. Working Group on Blood Pressure Monitoring and Cardiovascular Variability
   **Prof. Gianfranco Parati (Secretary)**
   Dept. of Clinical Medicine and Prevention
   University of Milano-Bicocca
   Dept. of Cardiovascular, Neural and Metabolic Sciences
   S. Luca Hospital, IRCCS Istituto Auxologico Italiano
   Via Spagnoli 3
   20149 Milan - Italy
   E: gianfranco.parati@unimib.it

3. Working Group on Endocrine Hypertension
   **Prof. Pierre-François Plouin**
   Hospital European Georges Pompidou
   Hypertension Unit
   20 rue Leblanc
   75908 Paris Cedex 15
   T: +33 1 5609 3771 - F: +33 1 5609 3791
   E: pierre-francois.plouin@egp.aphp.fr

4. Working Group on Endothelin and Endothelial Factors
   **Prof. Gianpaolo Rossi**
   University of Padua
   Department of Clinical Medicine IV
   Policlinico
   Via Giustiniani 2
   35128 Padua - Italy
   T: + 39 049 8213304
   F: + 39 049 8754179
   E: gianpaolo.rossi@unipd.it

5. Working Group on Hypertension and the Brain
   **Prof. Antonio Coca**
   Institute of Internal Medicine (ICMiD)
   Hospital Clinic
   University of Barcelona
   Villarreal 170
   08036 – Barcelona, Spain
   Tel: +34 93 227 5759
   Fax: +34 93 227 5724
   E-mail: acoca@clinic.ub.es

6. Working Group on Hypertension and Cardiovascular Risk Assessment in subjects living in or emigrating from low resource settings
   **Prof. Pietro Amedeo Modesti**
   Department of Critical Care Medicine and Surgery
   University of Florence
   50100 Florence – Italy
   E-mail: pamodesti@unifi.it

7. Working Group on Hypertension and the Heart
   **Prof. Renata Cífková**
   Department Preventive Cardiology (G6 Building)
   Thomayer University Hospital
   Vídenská 800
   140 59 Prague 4 – Czech Republic
   Phone: +420 2 61083694
   Fax: +420 2 61083821
   E-mail: renata.cifkova@ftr.cz

8. Working Group on Hypertension and the Kidney
   **Prof. Peter W. de Leeuw**
   Department of Medicine
   University Hospital Maastricht
   P.O. BOX 5800
   6202 AZ Maastricht – NETHERLANDS
   Fax: +31 43 3875006
   E-mail: p.deleeuw@intmed.unimaas.nl

9. Working Group on Hypertension and Sexual Dysfunction
   **Prof. Margus Viigimaa**
   Centre of Cardiology
   North Estonia Medical Centre
   Sütiste St. 19
   Tallinn 13419 – Estonia
   Phone: +372 511 0070
   Fax: +372 697 1415
   E-mail: margus.viigimaa@regionaalhaigla.ee
10. Working Group on Hypertension, Thrombosis and Arrhythmias
Prof. Enrico Agabiti Rosei
Scienze Cliniche e Sperimentali
I-II Divisione di Medicina
P.le Spedali Civili, 1
25123 Brescia – Italy
Phone: +39 030 3995.251 – +39 030 396044
Fax: +39 030 3388147
E-mail: agabiti@med.unibs.it

11. Working Group on Interventional Treatment of Hypertension
Prof. Kostantinos Tsioufis
Hypertension Unit, 1st Department of Cardiology
University of Athens, Hipokration Hospital
108 Vassilissis Sofia Avenue
11527 Athens – Greece
E-mail: ktsioufis@hippocratio.gr

12. Working Group on Obesity, Diabetes and the High Risk Patient
Prof. Dr. med. Jens Jordan
Director
Institute of Clinical Pharmacology
Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover – Germany
Phone: +49 511 532 2821
Fax: +49 511 532 2750
E-mail: jordan.jens@mh-hannover.de

12. Working Group on Vascular Structure and Function
Prof. Philip Chowienczyk
Department of Clinical Pharmacology
St. Thomas’ Hospital
Lambeth Palace Road
London SE1 7EH – UK
E-mail: phil.chowienczyk@kcl.ac.uk
TIMETABLE

42  Friday, June 13
44  Saturday, June 14
48  Sunday, June 15
52  Monday, June 16
### Friday - June 13, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>CHRISTOS LAMBRAKIS HALL</th>
<th>ALEXANDRA TRIANTI HALL</th>
<th>BANQUETING HALL</th>
<th>NIKOS SKALKOTAS HALL</th>
<th>DIMITRIS MITROPOLOUS HALL</th>
<th>CONFERENCE SUITE I Room 1</th>
<th>CONFERENCE SUITE II MC2</th>
<th>CONFERENCE SUITE II MC3</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.45 - 11.00</td>
<td>Opening</td>
<td>Round Table I</td>
<td>DIAGNOSTIC: HOW TO ASSESS IN HYPERTENSIVES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00 - 12.00</td>
<td>Round Table II</td>
<td>Hypertension and Organ Damage: Optimal Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30 - 13.00</td>
<td>Round Table III</td>
<td>Hypertension in Special Populations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 - 13.30</td>
<td>D. Athanasiades Memorial Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30 - 14.30</td>
<td>Satellite Symposium</td>
<td>Management of Thrombosis with Rivaroxaban Industry Sponsored Session (see page 24)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00 - 17.00</td>
<td>Satellite Symposium</td>
<td>Effective Fixed Solutions: One, Two, Three... IDA! Industry Sponsored Session (see page 20)</td>
<td>Satellite Symposium The Latest ARB Satellite Symposium in ESH-Ish 2014 Industry Sponsored Session (see page 20)</td>
<td>15.30-16.30 Satellite Symposium 25 Years Patient Centric Innovation in Hypertension: From Monotherapies to Triple Combination Industry Sponsored Session (see page 24)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30 - 20.00</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Meetings of the HSH for the Greek Doctors (in Greek language only), with the exception of the 15.30-16.30 Satellite Symposium that is in English.*
## Saturday - June 14, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45-08.45</td>
<td>CHRISTOS LAMBRAKIS HALL</td>
<td>07.15-08.55 Joint Session HBPRCA-ECCR Workshop 1 NEW VARIATIONS ON THE RAS</td>
</tr>
<tr>
<td></td>
<td>CHRISTOS LAMBRAKIS HALL</td>
<td>Breakfast Workshop HIGH BLOOD PRESSURE IN STROKE PATIENTS</td>
</tr>
<tr>
<td></td>
<td>ALEXANDRA TRIANTI HALL</td>
<td>Breakfast Workshop HYPERTENSION AND URIC ACID</td>
</tr>
<tr>
<td></td>
<td>BANQUETING HALL</td>
<td>Breakfast Workshop MANAGEMENT OF HYPERTENSION AND CORONARY HEART DISEASE</td>
</tr>
<tr>
<td></td>
<td>NIKOS SKALKOTAS HALL</td>
<td>Breakfast Workshop GENETIC ARCHITECTURE OF HUMAN HYPERTENSION - WHAT HAVE WE LEARNED AND WHERE ARE WE GOING?</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td>CONFERENCE SUITE I Room 1</td>
<td>09.00-10.30 Joint Session ESH-ISH-CHL CARDIOVASCULAR RISK ASSOCIATED WITH AMBULATORY SYSTOLIC AND DIASTOLIC BLOOD PRESSURE AND HYPERTENSION SUBTYPES</td>
</tr>
<tr>
<td></td>
<td>CONFERENCE SUITE II MC2</td>
<td>09.30-11.00 Joint Session ESH-LASH THE BURDEN OF CARDIOVASCULAR RISK FACTORS IN LATIN AMERICA</td>
</tr>
<tr>
<td>10.30-12.00</td>
<td>CONFERENCE SUITE II MC3</td>
<td>Oral Session ISH NEW INVESTIGATOR COMMITTEE AWARDS</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>ORAL SESSION 1</td>
<td>Oral Session 1A DIABETES</td>
</tr>
<tr>
<td></td>
<td>ORAL SESSION 1</td>
<td>Oral Session 1B ATRIAL FIBRILLATION</td>
</tr>
<tr>
<td></td>
<td>ORAL SESSION 1</td>
<td>Oral Session 1C GENETICS, GENOMICS, PROTEOMICS, METABOLOMICS</td>
</tr>
<tr>
<td></td>
<td>ORAL SESSION 1</td>
<td>Late-Breakers SESSION 1</td>
</tr>
<tr>
<td></td>
<td>ORAL SESSION 1</td>
<td>Oral Session 1D BLOOD PRESSURE MEASUREMENT</td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>ORAL SESSION 2</td>
<td>11.00-12.00 Minisymposium THE PATH FORWARD WITH RENAL DENERVATION Industry Sponsored Session (see page 21)</td>
</tr>
<tr>
<td></td>
<td>ORAL SESSION 2</td>
<td>11.30-12.30 Minisymposium EPIDEMIOLOGICAL, CLINICAL AND BIOCHEMICAL ADVANCES IN THE DIAGNOSIS OF PRIMARY HYPERALDOSTERONISM Industry Sponsored Session (see page 21)</td>
</tr>
<tr>
<td></td>
<td>ORAL SESSION 2</td>
<td>Oral Session 2B AGEING</td>
</tr>
<tr>
<td>12.45-14.15</td>
<td>ORAL SESSION 2</td>
<td>Oral Session 2C CEREBROVASCULAR DISEASES AND COGNITIVE DYSFUNCTION</td>
</tr>
<tr>
<td></td>
<td>ORAL SESSION 2</td>
<td>Oral Session 2D CLINICAL TRIALS</td>
</tr>
</tbody>
</table>

**Teaching Seminar Session 1**
**Interventions in Hypertension**

**Satellite Symposium**
**Triple combination in hypertension: reaching new goals Industry Sponsored Session (see page 20)**

**ISH International Forum Meeting**
## Saturday - June 14, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-15.30</td>
<td><strong>ATTENDED POSTER SESSIONS</strong></td>
</tr>
<tr>
<td>14.30-15.30</td>
<td>Minisymposium: Clinical Implication of Pulse Wave Analysis: PWV, AI and Central Blood Pressure (Industry Sponsored Session)</td>
</tr>
<tr>
<td>14.00-15.30</td>
<td>Minisymposium: Arterial Stiffness from Research to Clinical Application (Industry Sponsored Session)</td>
</tr>
<tr>
<td>14.30-15.30</td>
<td>Minisymposium: Managing the AF Patient with Hypertension - Implications for Clinical Practice (Industry Sponsored Session)</td>
</tr>
<tr>
<td>15.30-16.30</td>
<td>Oral Session 3A: Resistant Hypertension (Large Arteries)</td>
</tr>
<tr>
<td>15.30-16.30</td>
<td>Oral Session 3B: Un locking the Potential of Home Blood Pressure Monitoring (Industry Sponsored Session)</td>
</tr>
<tr>
<td>15.30-16.30</td>
<td>Oral Session 3C: Cardiovascular Risk Factors (Industry Sponsored Session)</td>
</tr>
<tr>
<td>15.30-16.30</td>
<td>Plenary Session - Presentation of ESH Awards</td>
</tr>
<tr>
<td>17.00-18.30</td>
<td>ESH Working Group on Blood Pressure Monitoring and Cardiovascular Variability</td>
</tr>
<tr>
<td>18.30-20.00</td>
<td>ESH Working Group on Hypertension, Endocrine Dysfunction and Sexual Dysfunction (Industry Sponsored Session)</td>
</tr>
<tr>
<td>18.30-20.00</td>
<td>ESH Working Group on Vascular Structure and Function (Industry Sponsored Session)</td>
</tr>
</tbody>
</table>

## Meet-The-Expert Sessions

- Renovascular Hypertension

## Industry Sponsored Sessions

- Unlocking the Potential of Home Blood Pressure Monitoring
- Antihypertensive Treatment Modify the Microvascular Damages and Protect the Target Organs in Hypertension? An Open Discussion
- Stroke Prevention in Non Valvular Atrial Fibrillation: Improving Patients Outcomes

**Meeting of the HSH for the Greek Doctors (in Greek Language Only)**
### Sunday – June 15, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session/Workshop</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45</td>
<td>BANQUETING HALL</td>
<td>07.15-08.55 Joint Session HBPRCA–ECCR Workshop 2 CO-MORBIDITIES OF HYPERTENSION</td>
</tr>
<tr>
<td>08.45</td>
<td></td>
<td>Breakfast Workshop COGNITIVE DYSFUNCTION AND DEMENTIA</td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>09.30-11.00 Topical Workshop THE ROLE OF HYPERTENSION SPECIALIST AROUND THE WORLD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session 4A ORGAN DAMAGE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session 4B OBESITY AND OBSTRUCTIVE SLEEP APOEDEA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>09.30-11.00 Joint Session ESH-ISH-ISVH NEW APPROACHES FOR ASSESSING ARTERIAL AGEING</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session 4C CORONARY HEART DISEASE AND HEART FAILURE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session 4D RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session ISH AUSTIN DOYLE AWARD</td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>Oral Session 5A BLOOD PRESSURE MEASUREMENT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11.00-12.00 Minisymposium BREAKING NEW GROUND IN FIRST LINE MANAGEMENT OF HYPERTENSION Industry Sponsored Session (see page 22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session 5B COMBINATION TREATMENT AND ADHERENCE THERAPY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11.00-12.00 Minisymposium MOVING FORWARD IN RENAL DENERVATION AND SETTING NEW HORIZONS Industry Sponsored Session (see page 22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session 5C ATHEROSCLEROSIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Session 5D ENDOTHELIUM AND MICROCIRCULATION</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joint Session ESH-ASH TREATMENT OF RESISTANT HYPERTENSION</td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td>WORKING LUNCH (BOX LUNCH)</td>
</tr>
<tr>
<td>14.00</td>
<td></td>
<td>WORKING LUNCH (BOX LUNCH)</td>
</tr>
<tr>
<td>12.45</td>
<td></td>
<td>Teaching Seminar Session 2 MANAGEMENT OF HYPERTENSION</td>
</tr>
<tr>
<td>14.15</td>
<td></td>
<td>ISH General Meeting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12.30-13.30 ESH Meeting with Presidents of National Societies</td>
</tr>
</tbody>
</table>
## Sunday - June 15, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Room</th>
<th>Session or Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>MINISTRY OF HEALTH</td>
<td></td>
<td>ATTENDED POSTER SESSIONS</td>
</tr>
<tr>
<td>14.30</td>
<td></td>
<td></td>
<td>Minisymposium FILLING A GAP IN THE MANAGEMENT OF SYSTOLIC HYPERTENSION</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Industry Sponsored Session (see page 22)</td>
</tr>
<tr>
<td>14.30</td>
<td></td>
<td></td>
<td>Meet-The-Expert HOW TO READ A SCIENTIFIC PAPER</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td></td>
<td>Clinical Case Session 2 - AN ADOLESCENT WITH SYSTOLIC HYPERTENSION - FAMILIAL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HYPERTENSION IN A 14-YEAR OLD BOY</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td></td>
<td>Topical Workshop THE POLYPILL IN THE ESH-ESC GUIDELINES AND THE CLINICAL PRACTICE IN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EUROPE</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td></td>
<td>How-To Session LONG TERM BLOOD PRESSURE MEASUREMENT - IS RIVA-ROCCI STILL ACCEPTABLE?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A NEW METHOD FOR CONTINUOUS, UNDISTURBED BLOOD PRESSURE MEASUREMENT (BEAT-TO-BEAT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Industry Sponsored Session (see page 23)</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td></td>
<td>How-To Session HOW TO USE THE NEW ANTIHROMBOTICS IN ATRIAL FIBRILLATION</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td>Topical Workshop RENAL DENERVATION: AN OPTION FOR TREATMENT OF RESISTANT HYPERTENSION</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td>Oral Session 6A PREGNANCY, CHILDREN AND ADOLESCENTS</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td>Educational Session WHAT’S THE ROLE OF HYPERURICEMIA IN PATIENTS’ CV RISK PROFILE?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Industry Sponsored Session (see page 23)</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td>Oral Session 6B EPIDEMIOLOGY</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td>Oral Session 6C NEURAL AND REFLEX MECHANISMS</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td>Oral Session 6D NEW THERAPEUTIC DEVELOPMENTS AND PERIPHERAL VASCULAR DISEASE</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td>Late-Breakers SESSION 2</td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td>Joint Session WHL-WHO-ISH SODIUM REDUCTION</td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td>ESH Working Group ON HYPERTENSION AND CARDIOVASCULAR RISK ASSESSMENT IN SUBJECTS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LIVING IN OR EMIGRATING FROM LOW RESOURCE SETTINGS</td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td>PARIS WORKING GROUP ON OBESITY, DIABETES AND THE HIGH RISK PATIENT</td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td>ESH Working Group ON HYPERTENSION AND THE KIDNEY</td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Topic</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>07.45</td>
<td></td>
<td>Breakfast Workshop HYPERTENSION AND COPD</td>
<td></td>
</tr>
<tr>
<td>08.45</td>
<td></td>
<td>Breakfast Workshop IMAGING OF THE HEART IN HYPERTENSION</td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>Breakfast Workshop AGE, GENDER, RACE AND GEOGRAPHY AS FACTORS FOR MANAGEMENT OF HYPERTENSION</td>
<td></td>
</tr>
<tr>
<td>09.00 - 11.00</td>
<td></td>
<td>Topical Workshop ENVIRONMENTAL FACTORS IN HYPERTENSION</td>
<td></td>
</tr>
<tr>
<td>09.30-11.00</td>
<td></td>
<td>Oral Session 7A THERAPEUTIC ASPECTS</td>
<td></td>
</tr>
<tr>
<td>09.30-11.00</td>
<td></td>
<td>Oral Session 7B HEART AND HAEMODYNAMICS</td>
<td></td>
</tr>
<tr>
<td>09.30-11.00</td>
<td></td>
<td>Oral Session 7C CARDIOVASCULAR RISK FACTORS</td>
<td></td>
</tr>
<tr>
<td>09.30-11.00</td>
<td></td>
<td>Topical Workshop PENDING ISSUES WITH BP MEASUREMENT</td>
<td></td>
</tr>
<tr>
<td>09.30-11.00</td>
<td></td>
<td>Joint Session ESH-ESC RESISTANT HYPERTENSION IN 2014</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>Breakfast Workshop PERIOPERATIVE MANAGEMENT OF HYPERTENSION</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>Breakfast Workshop ORTHOSTATIC HYPOTENSION</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td>Plenary Session DEBATE - DIFFERENT NEW GUIDELINES: WHERE IS THE EVIDENCE?</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td>Working Lunch (Box Lunch)</td>
<td></td>
</tr>
<tr>
<td>12.45</td>
<td></td>
<td>Teaching Seminar Session 3 PARTICULAR QUESTIONS</td>
<td></td>
</tr>
<tr>
<td>14.15</td>
<td></td>
<td>Working Lunch (Box Lunch)</td>
<td></td>
</tr>
</tbody>
</table>

07.45 - 12.30 Plenary Session
12.30 - 14.00 Working Lunch (Box Lunch)
<table>
<thead>
<tr>
<th>Time</th>
<th>CHRISTOS LAMBRAKIS HALL</th>
<th>ALEXANDRA TRIANTI HALL</th>
<th>BANQUETING HALL</th>
<th>NIKOS SKALKOTAS HALL</th>
<th>DIMITRIS MITROPOULOS HALL</th>
<th>CONFERENCE SUITE I Room 1</th>
<th>CONFERENCE SUITE II MC2</th>
<th>CONFERENCE SUITE II MC3</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 - 15.30</td>
<td>ATTENDED POSTER SESSIONS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30 - 15.30</td>
<td>Meet-The-Expert</td>
<td></td>
<td></td>
<td></td>
<td>How-To Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evaluation of Resistant</td>
<td></td>
<td></td>
<td></td>
<td>How to Detect and Manage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td>White Coat and Masked</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hypertension in Practice</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30 - 17.00</td>
<td>Oral Session 8A</td>
<td>Oral Session 8B</td>
<td>Oral Session 8C</td>
<td>Late-Breakers</td>
<td>Oral Session 8D</td>
<td>The Balkanian Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LIFESTYLE CHANGES AND</td>
<td>PUBLIC HEALTH AND</td>
<td>MOLECULAR</td>
<td>SESSION 3</td>
<td>LARGE ARTERIES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SPORT</td>
<td>PHARMACOECONOMICS</td>
<td>BIOLOGY AND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PEPTIDES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00 - 18.30</td>
<td>Oral Session 9A</td>
<td>Oral Session 9B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RESISTANT HYPERTENSION</td>
<td>KIDNEY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday - June 16, 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CONGRESS INFORMATION

58 Congress Venue
60 Exhibition
62 Exhibition Areas
64 General Information
68 Registration Information
70 Opening Ceremony and Reception
The Joint Meeting ESH-ISH Hypertension Athens 2014 is held in Athens at the Megaron Athens International Conference Centre.
An exhibition of pharmaceutical, technical and research products takes place in the Congress Venue throughout the Meeting.

Exhibition opening hours for visitors are:

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, June 13</td>
<td>14.00 – 17.00</td>
</tr>
<tr>
<td>Saturday, June 14</td>
<td>09.00 – 17.00</td>
</tr>
<tr>
<td>Sunday, June 15</td>
<td>09.00 – 17.00</td>
</tr>
<tr>
<td>Monday, June 16</td>
<td>09.00 – 17.00</td>
</tr>
</tbody>
</table>
General Information

LANGUAGE
The official language of the Meeting is English with the exception of the meetings of the HSH for the Greek Doctors, which are held in Greek language. Simultaneous translation is not provided.

LUNCHES
On June 14, 15 and 16, 2014 from 12.30 to 14.00 hrs, box lunches are served free of charge to participants wearing congress badges on Level -1 of the Congress Venue and upon presentation of the related daily coupon lunch (a different coupon for each day) that delegates receive along with the badge. Moreover, during sessions scheduled from 12.45 to 14.15 hrs box lunches are offered outside the meeting rooms, always upon presentation of the daily lunch coupon. Lunch is not included in the reduced registration fee reserved to Greek doctors.

TRANSPORT TICKETS
All regularly registered participants are given a public transport ticket, valid for all lines of buses, metro trains and tram except for the airport lines. Transportation pass is not included in the reduced fee reserved to Greek doctors.

BE CONNECTED!
Three WI-FI areas are available in the Congress Venue. This service is available from June 13 to 16, 2014.
Facebook:ESHAnnualMeetings
Twitter:@ESH_Annual,#ESH2014, #ISH2014, #hypertension

CONGRESS APP: browse the Scientific Programme and discover all important information of the Congress on the free app Hypertension2014 for iPhone/iPad and Android mobile devices.

WEBCASTS
Some selected scientific sessions will be available as webcasts online on www.eshonline.org.

PRESS ROOM
A fully equipped press room (MC3.3, Level -1) is available for registered press attendees from June 13 to 16, 2014. PC and Internet connection are available inside the Press Room. Journalists must first address to the Press Registration desk located in the Secretariat premises: by showing their press card they will receive free registration and scientific material.

OFFICIAL HOUSING BUREAU
AIM GROUP INTERNATIONAL – AIM Congress is at participants’ disposal in the Congress Venue from Friday, June 13 and throughout the duration of the Congress, with regards of hotel booking.

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, June 13</td>
<td>08.30/19.00 hrs</td>
</tr>
<tr>
<td>Saturday, June 14</td>
<td>07.00/18.30 hrs</td>
</tr>
<tr>
<td>Sunday, June 15</td>
<td>07.00/18.30 hrs</td>
</tr>
<tr>
<td>Monday, June 16</td>
<td>07.30/18.30 hrs</td>
</tr>
</tbody>
</table>

LOCAL DMC IN ATHENS
Mideast Travel Worldwide is at participants’ disposal in the Congress Venue from Friday, June 13 and throughout the duration of the Congress.

The following services are provided:
• car/bus transportation in Athens
• car/bus transfer to the Athens Airport
• restaurants in Athens

CLOAKROOM
A cloakroom is at participants’ disposal at their charge. It is located on the Level 0 of the Congress Venue close to Secretariat desks and follows their opening time. Delegates are kindly requested not to leave their personal belongings after the closing.

MEDICAL ASSISTANCE
Participants in need of medical assistance should contact the Info Point located at Level 0, in the exhibition area.

INSURANCE
Congress organisers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.

INSURANCE
Congress organisers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.
General Information

NO-SMOKING
Smoking in the Meeting area is not allowed.

MOBILE PHONES
Delegates are kindly requested to set their mobile phones on silent mode in the Halls where scientific sessions are being held.

SHIPMENT
MERKUR LOGISTIC has been appointed as international freight forwarder, custom broker and on-site handling agent.

The following is an overview of the services which can be provided by MERKUR LOGISTIC:
• transport arrangements by road, air or sea
• storage of empty boxes
• transport arrangements for return shipments
• loading and unloading
• porterage, trolley, transpallet in the Exhibition Area.

MERKUR LOGISTIC staff is at your disposal on site in the Exhibition Area for any information on its service.

Get the latest hypertension research from Nature Publishing Group

International Journal of Obesity
IJO is the leading obesity journal in the subject category of ‘Nutrition and Dietetics’ and provides a multi-disciplinary forum for research describing basic clinical and applied studies in biochemistry, physiology, genetics and nutrition, molecular psychological and epidemiological aspects of obesity and related disorders. The journal also features a quarterly pediatric highlights issue.

Benefits of publishing your research with IJO
• Average time from submission to first decision = 4 weeks
• Author accepted version of your paper will be available online and citable within 3 days of acceptance
• Option to publish your paper Open Access
• High visibility on the nature.com platform

VISIT WWW.NATURE.COM/IJO FOR MORE INFORMATION.

Journal of Human Hypertension
JHH publishes the most up-to-date research regarding all clinical aspects of hypertension, including epidemiology. JHH aims to perform the dual role of increasing knowledge in the field of high blood pressure as well as improving the standard of care of patients.

Benefits of publishing your research with JHH
• Rising Impact Factor: 2.818*
• Average time from submission to first decision = 27 days
• Author accepted version of your paper will be available online and citable within 3 days of acceptance
• Option to publish your paper Open Access
• High visibility on the nature.com platform

VISIT WWW.NATURE.COM/JHH FOR MORE INFORMATION.

*2012 Journal Citation Reports® (Thomson Reuters, 2013)
Registration Information

**REGISTRATION OPENING HOURS**
The pre-registration and on-site registration desks are at disposal of participants during the following hours:

<table>
<thead>
<tr>
<th>Groups</th>
<th>Individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, June 11</td>
<td>14.00 – 19.00</td>
</tr>
<tr>
<td>Thursday, June 12</td>
<td>09.00 – 19.00</td>
</tr>
<tr>
<td>Friday, June 13</td>
<td>08.30 – 19.00</td>
</tr>
<tr>
<td>Saturday, June 14</td>
<td>07.00 – 18.30</td>
</tr>
<tr>
<td>Sunday, June 15</td>
<td>07.00 – 18.30</td>
</tr>
<tr>
<td>Monday, June 16</td>
<td>07.30 – 18.30</td>
</tr>
</tbody>
</table>

**ADMISSION**
Participantes are kindly requested to always wear their name badge during the Meeting activities.
The badge allows the entrance to the scientific sessions and the exhibition.
The badge holder also contains coupons for box lunches.
Lunch is not included in the reduced registration fee reserved to Greek doctors.
Lost badges are replaced against the payment of a handling fee of € 60,00 (LOCAL VAT included) and upon proof of original registration.

**CONGRESS BADGES ARE DISTINGUISHED AS FOLLOWS:**
- Participants: transparent
- Faculty: red
- Exhibition: blue
- Press: green
- Greek Doctors: yellow

Please note that offering your badge to be scanned on exhibition stands or during satellite symposia implies your acceptance that exhibiting/organising companies may contact you, using your contact details.

**ON-SITE REGISTRATION FEES (LOCAL VAT INCLUDED)**
All fees are requested in EURO.

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESH MEMBER*</td>
<td>€ 725,00</td>
</tr>
<tr>
<td>NON MEMBER</td>
<td>€ 885,00</td>
</tr>
<tr>
<td>PARTICIPANT YOUNGER THAN 35**</td>
<td>€ 430,00</td>
</tr>
<tr>
<td>GREEK DOCTORS***</td>
<td>€ 246,00</td>
</tr>
</tbody>
</table>

*Reduced fee is only for European Hypertension Society (ESH) and International Society of Hypertension (ISH) members. It is not applied to members of other Hypertension Associations and to Members of Hypertension National Societies.
**Born after April 1st, 1979; please show photocopy of an identity document.
***Lunches and transportation tickets are not included in the fee for Greek doctors.

**PAYMENT**
Onsite payments are accepted by credit cards only. Cash payments are accepted only for exceptional reasons and only for amount not exceeding € 999,99, as – due to Italian Law, Decree 6.12.2011 No. 201 – it is forbidden to transfer cash between different subjects for greater amounts.

**NAME CHANGES**
Name changes on site are charged a handling fee of € 150,00 (local VAT included).

**CERTIFICATES OF ATTENDANCE**
Certificates of attendance are handed out upon request to all regularly registered participants at the end of the Meeting.

**What is covered by the registration fee?**

**DELEGATE’S FEE**
The registration fee includes admission to the Opening Ceremony, unlimited access to all scientific sessions, access to the exhibition, complete Meeting materials, box lunches on June 14, 15 and 16, 2014 and public transportation tickets.

**GREEK DOCTORS’ FEE**
The registration fee includes admission to the Opening Ceremony, unlimited access to all scientific sessions, access to the exhibition and final programme. Lunch and transportation tickets are not included.

**PRESS REGISTRATION**
A press representative is registered to the Meeting free of charge if he/she fills in the registration form and shows his/her Press Code or similar document confirming the status of press representative. Press registration includes a full set of Congress material and free entrance to all Meeting activities including scientific sessions.
Opening Ceremony and Reception

Friday, June 13

The official Opening Ceremony of the Meeting takes place on Friday, June 13 at 17.30 hrs in the Auditorium Christos Lambrakis Hall, of the Congress Venue.

The Opening Ceremony will be followed by a Concert and a Reception. Access to the Opening Ceremony and Reception is included in the registration fee.
Hypertension 2014 Credits

EBAC – ACCREDITED EDUCATIONAL PROGRAMME

The “JOINT MEETING ESH-ISH - HYPERTENSION, ATHENS 2014” is accredited by the European Board for Accreditation in Cardiology (EBAC) for 17 hours of External CME credits as follows:
- June 15, 2013 = 5 CME credits
- June 16, 2013 = 6 CME credits
- June 17, 2013 = 6 CME credits

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACME), which is an institution of the European Union of Medical Specialists (UEMS). Those who are interested in EBAC Credits should ask for the EBAC Evaluation form at the moment of badge collection at the Secretariat Desk.

CME UEMS CREDITS

The Joint Meeting ESH–ISH Hypertension, Athens 2014 is accredited by the European Accreditation Council for Continuing Medical Education (EACME) to provide the following CME activity for medical specialists. The EACME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The Joint Meeting ESH–ISH Hypertension, Athens 2014 is designated for a maximum of 18 hours of European external CME credits.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits℠. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

ESH CREDITS

Attendance at this Meeting provides 3 credits for application as Hypertension Specialist of the European Society of Hypertension.

Guidelines for Chairpersons and Speakers

GUIDELINES FOR CHAIRPERSONS

- Locate your session room in due time
- Find yourself in the room assigned for presentation at least 10 minutes before the beginning of the session
- Respect the timing allowed to the session and to each presentation
- All presentations, discussions and questions (except for meetings of the HSH for the Greek Doctors held in Greek language) must be in English

GUIDELINES FOR SPEAKERS

- Follow the instructions indicated at the paragraph “Audiovisual Instructions”
- Locate your session room in due time
- Find yourself in the room assigned for presentation at least 10 minutes before the beginning of the session to meet the Chairpersons
- Respect the timing allowed for your presentation
- All presentations, discussions and questions (except for meetings of the HSH for the Greek Doctors held in Greek language) must be in English

AUDIOVISUAL INSTRUCTIONS

Presentations can be downloaded from one's notebook at the slide centre, provided that the speakers come there at least 3 hours before the presentation. Presentations received after this term cannot be guaranteed audiovisual support. Personal computers cannot be connected to the projectors in sessions' rooms and presentations cannot be loaded directly on the computer of the sessions’ rooms. Peak hours of operation in the slide centre are during lunchtime and breaks. We highly recommend Speakers to preferably visit the slide centre early in the morning or during the Sessions. If Speakers created their presentation using a system different from MS Windows (such OS MAC or Linux), they are kindly requested to provide presentations in a Windows compatible format and to come earlier at the slide centre, in order to have enough time to solve possible compatibility issue.

Hypertension 2014 Credits

EBAC – ACCREDITED EDUCATIONAL PROGRAMME

The “JOINT MEETING ESH-ISH - HYPERTENSION, ATHENS 2014” is accredited by the European Board for Accreditation in Cardiology (EBAC) for 17 hours of External CME credits as follows:
- June 15, 2013 = 5 CME credits
- June 16, 2013 = 6 CME credits
- June 17, 2013 = 6 CME credits

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACME), which is an institution of the European Union of Medical Specialists (UEMS). Those who are interested in EBAC Credits should ask for the EBAC Evaluation form at the moment of badge collection at the Secretariat Desk.

CME UEMS CREDITS

The Joint Meeting ESH–ISH Hypertension, Athens 2014 is accredited by the European Accreditation Council for Continuing Medical Education (EACME) to provide the following CME activity for medical specialists. The EACME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The Joint Meeting ESH–ISH Hypertension, Athens 2014 is designated for a maximum of 18 hours of European external CME credits.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits℠. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

ESH CREDITS

Attendance at this Meeting provides 3 credits for application as Hypertension Specialist of the European Society of Hypertension.

Guidelines for Chairpersons and Speakers

GUIDELINES FOR CHAIRPERSONS

- Locate your session room in due time
- Find yourself in the room assigned for presentation at least 10 minutes before the beginning of the session
- Respect the timing allowed to the session and to each presentation
- All presentations, discussions and questions (except for meetings of the HSH for the Greek Doctors held in Greek language) must be in English

GUIDELINES FOR SPEAKERS

- Follow the instructions indicated at the paragraph “Audiovisual Instructions”
- Locate your session room in due time
- Find yourself in the room assigned for presentation at least 10 minutes before the beginning of the session to meet the Chairpersons
- Respect the timing allowed for your presentation
- All presentations, discussions and questions (except for meetings of the HSH for the Greek Doctors held in Greek language) must be in English

AUDIOVISUAL INSTRUCTIONS

Presentations can be downloaded from one's notebook at the slide centre, provided that the speakers come there at least 3 hours before the presentation. Presentations received after this term cannot be guaranteed audiovisual support. Personal computers cannot be connected to the projectors in sessions' rooms and presentations cannot be loaded directly on the computer of the sessions’ rooms. Peak hours of operation in the slide centre are during lunchtime and breaks. We highly recommend Speakers to preferably visit the slide centre early in the morning or during the Sessions. If Speakers created their presentation using a system different from MS Windows (such OS MAC or Linux), they are kindly requested to provide presentations in a Windows compatible format and to come earlier at the slide centre, in order to have enough time to solve possible compatibility issue.
Guidelines for Chairpersons and Speakers

In the slide centre our hostess will be happy to welcome and help Speakers. Experienced technicians will assist Speakers in transferring slides and make changes if needed. Slide presentations will then be uploaded to the respective sessions' room.

In the sessions' rooms Speakers will be able to follow their presentations on a monitor at the lectern.

Speakers are asked to use the mouse pointer, instead of any laser pointer.

SLIDE CENTRE
The slide centre is at Speakers' disposal during the following hours:

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, June 13</td>
<td>08.30/19.00 hrs</td>
</tr>
<tr>
<td>Saturday, June 14</td>
<td>07.00/20.30 hrs</td>
</tr>
<tr>
<td>Sunday, June 15</td>
<td>07.00/20.30 hrs</td>
</tr>
<tr>
<td>Monday, June 16</td>
<td>07.00/18.30 hrs</td>
</tr>
</tbody>
</table>

Poster Sessions

Abstracts accepted as posters are displayed in the Congress Centre, on June 14, 15 and 16, 2014 from 14.00 to 15.30 hrs. Poster sessions will be guided and moderated by a chairperson.

Posters must be hanged on and removed according to the following schedule:

SATURDAY, JUNE 14
Sessions 1–15, ISH New Investigator Committee and Late-Breakers (Session 1): post up on June 13, 18.00 – 19.30 hrs and remove on June 14, 16.00 – 16.30 hrs

SUNDAY, JUNE 15
Sessions 16–30 and Late-Breakers (Session 2): post up on June 14, 18.00 – 19.30 hrs and remove on June 15, 16.00 – 16.30 hrs

MONDAY, JUNE 16
Sessions 31–45 and Late-Breakers (Session 3): post up on June 15, 18.00 – 19.30 hrs and remove on June 16, 16.00 – 16.30 hrs

Note: Authors must strictly respect the above mentioned timing for hanging and removing posters. If they have not been removed by the scheduled time, they will be thrown away. The Organising Secretariat cannot be addressed for any responsibility in posters' loss.

GUIDELINES FOR POSTER DISPLAY:

* Poster size must be: 90 x 150 cm (width x height)
* Each poster has been given a number and should be fixed on the board marked with the same number. Please go to the Posters' Secretariat Desk to check your number
* Authors are kindly requested to stand by their poster from 14.00 – 15.30 hrs for possible questions by the Congress delegates
* All presentations, discussions and questions must be in English
* Poster discussion should start with 1 to maximum 2 minutes presentation of the highlights of the work
* Absence from the poster presentation will exclude the poster from competition for the "Alberto Ferrari" prize, may also have implications for acceptance of abstracts at future meetings and receiving investigators' grants in the future
Posters Session

REGISTRATION

- Each presenting author is allowed to present up to 3 abstracts with one paid registration.
- A special registration fee of €150,00 (local VAT included) has been introduced, for those authors of accepted abstracts who are younger than 30 years old.

POSTER AREA

The area is open for poster viewing during the following hours:

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, June 13</td>
<td>17.00/19.30 hrs</td>
</tr>
<tr>
<td>Saturday, June 14</td>
<td>09.00/19.30 hrs</td>
</tr>
<tr>
<td>Sunday, June 15</td>
<td>09.00/19.30 hrs</td>
</tr>
<tr>
<td>Monday, June 16</td>
<td>09.00/17.00 hrs</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAMME

82  Friday, June 13
87  Saturday, June 14
148 Sunday, June 15
203 Monday, June 16
Friday, June 13

09.45 – 16.30 Dimitris Mitropoulos Hall

MEETINGS OF THE HSH FOR THE GREEK DOCTORS*

09.45 OPENING

ROUND TABLE I
Diagnosis: how to assess in hypertensives
Chairpersons: J. Goudevenos (Ioannina, GREECE)
A. Mela (Athens, GREECE)
10.00 Renal function
R. Kalaizidis (Ioannina, GREECE)
10.15 Cardiac alterations
M. Markatou (Irkillion, GREECE)
10.30 Arterial stiffness
M. Kallistratos (Athens, GREECE)
10.45 Preoperatively a patient
M. Koutsaki (Athens, GREECE)

ROUND TABLE II
Hypertension and organ damage: optimal treatment
Chairpersons: N. Karatzas (Athens, GREECE)
C. Olympios (Athens, GREECE)
11.00 Coronary Heart Disease
T. Makris (Athens, GREECE)
11.15 Stroke
N. Kouremenos (Athens, GREECE)
11.30 Renal Failure
P. Sarafidis (Thessaloniki, GREECE)
11.45 Heart Failure
E. Chamodraka (Athens, GREECE)
12.00 Break

12.30 Diabetes mellitus
T. Loufi (Athens, GREECE)
12.45 Young and adolescents
S. Staboulis (Thessaloniki, GREECE)
13.00 D. ATHANASIADIAD MEMORIAL LECTURE
Chairpersons: A. Tourkantonis (Thessaloniki, GREECE)
P. Toutouzas (Athens, GREECE)
S. Douma (Thessaloniki, GREECE)

INDUSTRY SPONSORED SATELLITE SYMPOSIUM**
Management of thrombosis with rivaroxaban
Chairperson: C. Tsioufis (Athens, GREECE)
13.30 Clinical trials and clinical practice in patients with venous thromboembolic disease
M. Doumas (Thessaloniki, GREECE)
14.00 Clinical trials and clinical practice in patients with atrial fibrillation
C. Tsioufis (Athens, GREECE)
14.30 Break

INDUSTRY SPONSORED SATELLITE SYMPOSIUM**
25 years patient centric innovation in hypertension: from monotherapies to triple combination
Chairperson: A.J. Manolis (Athens, GREECE)
15.30 The evolution of hypertension management: leveraging past learnings to shape current and future approaches
G. Mancia (Milan, Italy)
15.50 From simple blood pressure control to target organ protection
C. Tsioufis (Athens, GREECE)
16.10 Revolutionizing treatment to address current patients' and physicians' needs
G.S. Stergiou (Athens, GREECE)

* MEETINGS OF THE HSH FOR THE GREEK DOCTORS (IN GREEK LANGUAGE ONLY), WITH THE EXCEPTION OF THE 15.30-16.30 SATELLITE SYMPOSIUM THAT IS IN ENGLISH
**please see page: 24
Friday
15.00 – 17.00 Banqueting Hall

Industry Sponsored Satellite Symposium*

EFFECTIVE FIXED SOLUTIONS: ONE, TWO, THREE... GOAL!

Chairpersons:  G.L. Bakris (Chicago, IL, USA)
                J. Redon (Valencia, SPAIN)

15.00  Chairperson’s introduction
        J. Redon (Valencia, SPAIN)

15.15  One, two, three... goal!
        S. Laurent (Paris, FRANCE)

15.40  Patients cases:
       – A patient with apparent compliance
         P. Sarafidis (Thessaloniki, GREECE)
       – A patient with apparent resistant hypertension
         C. Aguiar (Carnaxide, PORTUGAL)

16.20  What if it really doesn’t work
        R.E. Schmieder (Erlangen, GERMANY)

16.40  Discussion and summary
        G.L. Bakris (Chicago, IL, USA)

*please see page: 20

Friday
15.00 – 17.00 Nikos Skalkotas Hall

Industry Sponsored Satellite Symposium*

THE LATEST ARB SATELLITE SYMPOSIUM IN ESH-ISH 2014

Chairpersons:  C.H. Kim (Seoul, SOUTH KOREA)
                B.H. Oh (Seoul, SOUTH KOREA)

15.00  Opening

15.05  Session 1

15.10  Optimal BP reduction of antihypertensive agent
        D.J. Choi (Seoul, SOUTH KOREA)

15.25  Session 2

15.40  Ideal choice of hypertension treatment: beyond BP reduction or strong BP reduction?

15.45  Session 3

16.00  Unmet needs for hypertension treatment

16.45  Panel discussion and closing
        S.H. Kim, S.J. Hong, Y.J. Choi (Seoul, SOUTH KOREA)

*please see page: 20
Saturday, June 14

07.15 – 08.55 Nikos Skalkotas Hall

Joint Session
HBPRCA (High Blood Pressure Research Council of Australia) / ECCR (European Council for Cardiovascular Research)
Workshop 1

NEW VARIATIONS ON THE RAS

Chairpersons: U.M. Steckelings (Odense, DENMARK)
R. Widdop (Melbourne, AUSTRALIA)

07.15 Cardioprotective effects of IRAP inhibition
T. Gaspari (Melbourne, AUSTRALIA)

07.35 Primary Aldosteronism: a leap toward understanding its mechanisms 60 years after Conn’s work
G.P. Rossi (Padua, ITALY)

07.55 Pivotal role of Lipocalin 2/NGAL in cardiovascular remodeling and hypertension induced by aldosterone
A. Tarjus (Paris, FRANCE)

08.10 The anti-inflammatory potential of the angiotensin AT2-receptor
A. Sampson (Melbourne, AUSTRALIA)

08.25 Interleukin 17 production induced by angiotensin II type 2 receptor activation in T cells drives flow-mediated outward remodeling of mouse resistance arteries
A. Caillon (Angers, FRANCE)

08.40 Effects of ACE inhibition on patients with peripheral artery disease
A. Ahimastos (Melbourne, AUSTRALIA)
Breakfast Workshop

**HIGH BLOOD PRESSURE IN STROKE PATIENTS**

**Chairpersons:**  
J. Kallikazaros (Athens, GREECE)  
J.G. Wang (Shanghai, CHINA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45</td>
<td>Acute stroke</td>
<td>C. Sierra (Barcelona, SPAIN)</td>
</tr>
<tr>
<td>08.05</td>
<td>Management according to type of stroke</td>
<td>E. Manios (Athens, GREECE)</td>
</tr>
<tr>
<td>08.25</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>

Breakfast Workshop

**HYPERTENSION AND URIC ACID**

**Chairpersons:**  
A.E. Berbari (Beirut, LEBANON)  
D. Tousoulis (Athens, GREECE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45</td>
<td>UA as a risk factor for hypertension and cardiovascular disease</td>
<td>C. Borghi (Bologna, ITALY)</td>
</tr>
<tr>
<td>08.05</td>
<td>Is there any benefit by treating UA and gout?</td>
<td>J. Dawson (Glasgow, UNITED KINGDOM)</td>
</tr>
<tr>
<td>08.25</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Breakfast Workshop

MANAGEMENT OF HYPERTENSION AND CORONARY HEART DISEASE

Chairpersons:  
S. Foussas (Athens, GREECE)  
F. Wyss (Guatemala City, GUATEMALA)

07.45  Arterial pressure and coronary perfusion pressure  
K.D. Boudoulas (Columbus, OH, USA)

08.05  How far should blood pressure be lowered, and the role of treatment  
Z. Ghazzal (Beirut, LEBANON)

08.25  General Discussion

Breakfast Workshop

GENETIC ARCHITECTURE OF HUMAN HYPERTENSION. WHAT HAVE WE LEARNED AND WHERE ARE WE GOING?

Chairpersons:  
M.J. Caulfield (London, UNITED KINGDOM)  
M. Tomaszewski (Leicester, UNITED KINGDOM)

07.45  Hypertension genetics: from experimental models to genome-wide association studies  
M. McBride (Glasgow, UNITED KINGDOM)

08.05  Hypertension: the regulatory networks of transcriptome  
F.J. Charchar (Ballarat, AUSTRALIA)

08.25  General Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>ROADMAP OBSERVATIONAL FOLLOW-UP STUDY: BENEFITS OF RAAS BLOCKADE WITH OLMESARTAN TREATMENT ARE SUSTAINED AFTER STUDY DISCONTINUATION</td>
<td>J. Menne, E. Ritz, L.M. Ruilope, C. Chatzikyrkou, G. Viberti, H. Haller</td>
<td>Hannover, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VALIDATION OF A URINARY PROTEOMIC CLASSIFIER FOR DIAGNOSIS OF DIABETIC NEPHROPATHY</td>
<td>G. Currie, J. Siwy, M. Lindhardt, C. Deles, J. Jankowski, H. Mischak, P. Rossing</td>
<td>Glasgow, United Kingdom, Hannover, Berlin, Gentofte, Copenhagen, Denmark</td>
</tr>
<tr>
<td>09.30</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>LECTURE: GUIDELINES POSITION TO REDUCE CARDIOVASCULAR RISK IN TYPE 2 DIABETES</td>
<td>A. Mitrakou</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>10.00</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>PROGNOSTIC INTERACTION BETWEEN CLINIC AND AMBULATORY BLOOD PRESSURES AND GLYCATED HEMOGLOBIN IN PATIENTS WITH TYPE 2 DIABETES</td>
<td>C. Cardoso, N. Leite, G. Salles</td>
<td>Rio de Janeiro, Brazil</td>
</tr>
<tr>
<td>10.10</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>C-PEPTIDE AND A PDE5 INHIBITOR RESTORE THE ABILITY OF ERYTHROCYTES OF HUMANS WITH TYPE 2 DIABETES (DM2) TO RELEASE ATP AND STIMULATE LOCAL VASODILATION WHEN EXPOSED TO LOW OXYGEN</td>
<td>J. Richards, W. Gordon, D. Achilleus, E. Bowles, A. Stephenson, M. Ellsworth, R. Sprague</td>
<td>Saint Louis, USA</td>
</tr>
<tr>
<td>10.20</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>TYPE 2 DIABETIC MICE EXHIBIT AN IMPAIRMENT OF MUSCLE REGENERATION WITH ANINCREASE IN ECTOPIC FAT DEPOSITION</td>
<td>M. Mogi, K. Kohara, H. Nakaoka, K. Tsukuda, X. Wang, K. Ohshima, T. Chisaka, H. Bai, H. Kan-No, L. Min, Iwanami, M. Horiuchi</td>
<td>Toon, Japan</td>
</tr>
<tr>
<td>10.30</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>PIOGLITAZONE INCREASED BRACHIAL ARTERY FLOW-MEDIATED DILATION AND CIRCULATING LEVEL OF MICRORNA-21 IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS</td>
<td>S. Hong, J. Park, C. Yu, D. Lim</td>
<td>Seoul, South Korea</td>
</tr>
<tr>
<td>10.40</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>EFFECTS OF THE DPP-4 INHIBITOR SAXAGLIPTIN ON EARLY VASCULAR CHANGES IN THE RETINAL AND SYSTEMIC CIRCULATION</td>
<td>C. Ott, U. Raff, S. Schmidt, I. Kistner, S. Friedrich, P. Bramlage, J. Harazny, R.E. Schmieder</td>
<td>Erlangen, Germany, Mahlow, Germany</td>
</tr>
<tr>
<td>10.50</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>GENETIC SUSCEPTIBILITY OF THE TYPE 2 DIABETES IN A PORTUGUESE POPULATION</td>
<td>A. Pereira, M. Mendonca, S. Gomes, R. Rodrigues, A. Sousa, G. Guerra, M. Rodrigues, E. Henriques, D. Pereira, R. Palma Reis</td>
<td>Funchal, Portugal</td>
</tr>
<tr>
<td>11.00</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>ROADMAP OBSERVATIONAL FOLLOW-UP STUDY: BENEFITS OF RAAS BLOCKADE WITH OLMESARTAN TREATMENT ARE SUSTAINED AFTER STUDY DISCONTINUATION</td>
<td>J. Menne, E. Ritz, L.M. Ruilope, C. Chatzikyrkou, G. Viberti, H. Haller</td>
<td>Hannover, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VALIDATION OF A URINARY PROTEOMIC CLASSIFIER FOR DIAGNOSIS OF DIABETIC NEPHROPATHY</td>
<td>G. Currie, J. Siwy, M. Lindhardt, C. Deles, J. Jankowski, H. Mischak, P. Rossing</td>
<td>Glasgow, United Kingdom, Hannover, Berlin, Gentofte, Copenhagen, Denmark</td>
</tr>
<tr>
<td>11.30</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>LECTURE: GUIDELINES POSITION TO REDUCE CARDIOVASCULAR RISK IN TYPE 2 DIABETES</td>
<td>A. Mitrakou</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>12.00</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>PROGNOSTIC INTERACTION BETWEEN CLINIC AND AMBULATORY BLOOD PRESSURES AND GLYCATED HEMOGLOBIN IN PATIENTS WITH TYPE 2 DIABETES</td>
<td>C. Cardoso, N. Leite, G. Salles</td>
<td>Rio de Janeiro, Brazil</td>
</tr>
<tr>
<td>12.10</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>C-PEPTIDE AND A PDE5 INHIBITOR RESTORE THE ABILITY OF ERYTHROCYTES OF HUMANS WITH TYPE 2 DIABETES (DM2) TO RELEASE ATP AND STIMULATE LOCAL VASODILATION WHEN EXPOSED TO LOW OXYGEN</td>
<td>J. Richards, W. Gordon, D. Achilleus, E. Bowles, A. Stephenson, M. Ellsworth, R. Sprague</td>
<td>Saint Louis, USA</td>
</tr>
<tr>
<td>12.20</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>TYPE 2 DIABETIC MICE EXHIBIT AN IMPAIRMENT OF MUSCLE REGENERATION WITH ANINCREASE IN ECTOPIC FAT DEPOSITION</td>
<td>M. Mogi, K. Kohara, H. Nakaoka, K. Tsukuda, X. Wang, K. Ohshima, T. Chisaka, H. Bai, H. Kan-No, L. Min, Iwanami, M. Horiuchi</td>
<td>Toon, Japan</td>
</tr>
<tr>
<td>12.30</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>PIOGLITAZONE INCREASED BRACHIAL ARTERY FLOW-MEDIATED DILATION AND CIRCULATING LEVEL OF MICRORNA-21 IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS</td>
<td>S. Hong, J. Park, C. Yu, D. Lim</td>
<td>Seoul, South Korea</td>
</tr>
<tr>
<td>12.40</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>EFFECTS OF THE DPP-4 INHIBITOR SAXAGLIPTIN ON EARLY VASCULAR CHANGES IN THE RETINAL AND SYSTEMIC CIRCULATION</td>
<td>C. Ott, U. Raff, S. Schmidt, I. Kistner, S. Friedrich, P. Bramlage, J. Harazny, R.E. Schmieder</td>
<td>Erlangen, Germany, Mahlow, Germany</td>
</tr>
<tr>
<td>12.50</td>
<td><strong>DIABETES</strong> Parallel Oral Session 1A</td>
<td>GENETIC SUSCEPTIBILITY OF THE TYPE 2 DIABETES IN A PORTUGUESE POPULATION</td>
<td>A. Pereira, M. Mendonca, S. Gomes, R. Rodrigues, A. Sousa, G. Guerra, M. Rodrigues, E. Henriques, D. Pereira, R. Palma Reis</td>
<td>Funchal, Portugal</td>
</tr>
</tbody>
</table>
09.00 – 11.00  Alexandra Trianti Hall

Parallel Oral Session 1B

ATRIAL FIBRILLATION

Chairpersons:  K. Narkiewicz (Gdansk, POLAND)
J.G. Wang (Shanghai, CHINA)

09.00 • INCREASE EXERCISE CAPACITY LOWERS THE RISK FOR ATRIAL FIBRILLATION IN MEN WITH TYPE 2 DIABETES MELLITUS
A. Pittaras 1, C. Faselis 2, M. Doumas 2, A.J. Manolis 1, J. Kokkinos 1, H. Grassos 1, M. Papavasiiliou 2, M. Kallistratos 1, K. Kyfrinis 1, N. Kourmenos 1, P. Kokkinos 2
1 Athens, GREECE, 2 Washington, DC, USA

09.10 • SEVERITY OF HYPERTENSION CORRELATES WITH CHA2DS2-VASC SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: IMPLICATIONS OF RELAXED HYPERTENSION TREATMENT TARGETS FOR STROKE PREVENTION
A. Mondry 1, Z. Ng 1, Y. Li 1, Z. Low 1, D. Huang 1, M. Loh 2, 3
1 Singapore, SINGAPORE, 2 London, UNITED KINGDOM, 3 Oulu, FINLAND

09.20 • ASSOCIATION BETWEEN LEFT ATRIAL VOLUME INDEX AND HEART RATE VARIABILITY IN ATRIAL FIBRILLATION PATIENTS WITH ARTERIAL HYPERTENSION AND CORONARY ARTERY DISEASE
A. Shavarov, A. Yusupov, G. Kiyakbaev, V. Moiseev
Moscow, RUSSIA

09.30 • CRP AND PTX3 REFLECT DIFFERENT ASPECTS OF HEMODYNAMIC STATUS AND RISK IN HYPERTENSIVE PATIENTS WITH ACUTE ATRIAL FIBRILLATION
K. Rewiuk, T. Grodzicki
Kraków, POLAND

09.40 • HYPERTENSION AND ATRIAL FIBRILLATION: PROGNOSTIC ASPECTS OF TROPONIN ELEVATIONS IN CLINICAL PRACTICE
A. Conti, A. Alesi, E. Angelì, M. Scopinetti, F. Trausi, C. Donnini, C. Grifoni, D. Lazzeretti, S. Bigiarini, S. Bianchi, A. Coppa, S. Guatieri
Florence, ITALY

09.50 • ARTERIAL HYPERTENSION: MAIN ETIOLOGIC FACTOR OF ATRIAL FIBRILLATION IN PATIENTS HOSPITALIZED TO THERAPEUTIC CLINIC
E. Baranova, O. Listopad, D. Jatsuk, A. Soboleva, E. Shlyakhto
Saint-Petersburg, RUSSIA

10.00 • THE PREVALENCE, INCIDENCE, MANAGEMENT AND RISKS OF ATRIAL FIBRILLATION IN AN ELDERLY CHINESE POPULATION
Shanghai, CHINA

10.10 • COMBINED EFFECT OF SYSTOLIC BLOOD PRESSURE AND PROTEINURIA ON THE RISK OF INCIDENT ATRIAL FIBRILLATION IN AN URBAN JAPANESE COHORT: THE SUITA STUDY
Y. Kokubo, M. Watanabe, T. Kobayashi, K. Kusano, S. Kamakura, K. Kawanishi, Y. Miyamoto
Suita, JAPAN

10.20 • VARIABILITY OF A.B.P.M. IN PATIENTS WITH ATRIAL FIBRILLATION
M. D’Avino 1, G. Caruso 1, R. Muscherà 1, A. Ilardi 1, F. Capasso 1, G. Buonomo 1, C. Simone 2
1 Naples, 2 Benevento, ITALY

10.30 • CHARACTERISTICS OF AN ASYMPTOMATIC ATRIAL FIBRILLATION DETECTED WITH AFIB-TECHNOLOGY DEVICE FOR BLOOD PRESSURE MEASUREMENT IN BULGARIAN URBAN POPULATION
S. Torbova 1, A. Postadjian 1, Y. Yotov 1, S. Tisheva 1, S. Georgiev 1, S. Tsonov 1, S. Naidenov 1, V. Ivanova 1, A. Nikolova 1, E. Anev 3
1 Sofia, 2 Varna, 3 Plovdiv, BULGARIA

10.40 • LECTURE: NEW ANTITHROMBOTICS IN ATRIAL FIBRILLATION
A.J. Manolis
Athens, GREECE
### Parallel Oral Session 1C

**GENETICS, GENOMICS, PROTEOMICS, METABOLOMICS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.40</td>
<td>PREVALENCE OF KELCH-LIKE 3 AND CULLIN 3 MUTATIONS IN FAMILIAL HYPERKALEMIC HYPERTENSION</td>
<td>M. Wolley, M. Glover, J. Ware, A. Henry, R. Walsh, L. Wain, S. Xu, W. Van't Hoff, M. Tobin, I. Hall, S. Cook, R. Gordon, K. O'Shaughnessy, M. Stowasser, Brisbane, Australia, Nottingham, London, Leicester, United Kingdom, Singapore, Cambridgeshire, United Kingdom</td>
</tr>
</tbody>
</table>

**Parallel Oral Session 1D**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>A NOVEL P.Y152C KCNJ5 MUTATION IS RESPONSIBLE FOR FAMILIAL HYPERALDOSTERONISM TYPE III</td>
<td>S. Monticone, N. Hattangady, D. Penton, C. Isales, M. Edwards, T. Williams, C. Sterner, R. Warth, F. Buffolo, F. Mulatero, W. Rainey, Turin, Italy, Ann Arbor, MI, USA, Regensburg, Germany, Augusta, GA, USA</td>
</tr>
<tr>
<td>10.00</td>
<td>LECTURE: BEDSIDE APPLICATION OF GENETIC DATA</td>
<td>M.J. Caulfield, London, United Kingdom</td>
</tr>
<tr>
<td>10.00</td>
<td>A NOVEL LONG NONCODING RNA TARGETING RIFIFYLIN IS MECHANISTICALLY LINKED TO THE REGULATION OF BLOOD PRESSURE, CARDIAC FUNCTION AND SURVIVAL IN A RAT GENETIC MODEL OF HYPERTENSION</td>
<td>B. Joe, K. Gopalakrishnan, S. Kumaramassty, B. Mell, Toledo, OH, USA</td>
</tr>
<tr>
<td>10.30</td>
<td>THE FUNCTIONAL CONSEQUENCES OF UMOD PROMOTER VARIANTS ON SODIUM TRANSPORTERS AND BLOOD PRESSURE CONTROL IN HUMANS</td>
<td>L. Graham, D. Graham, M. Denniff, M. Tomaszewski, A.F. Dominiczak, S. Padmanabhan, M. McInerney, Glasgow, Leicester, United Kingdom</td>
</tr>
<tr>
<td>10.50</td>
<td>MAPPING OF CHROMOSOME 2 REGIONS LINKED TO VASCULAR INJURY AND INFLAMMATION USING CONGENIC RATS</td>
<td>P. Paradis, A. Rehman, I. Idris-Khodja, M. Mian, T. Barhoumi, N. Yamamoto, A. Kwitek, J.L. Schifffrin, Montreal, Canada, Iowa City, IA, USA</td>
</tr>
</tbody>
</table>

---

**Chairpersons:** R. Kreutz (Berlin, Germany) G.P. Rossi (Padua, Italy)
Laté-Breakers

SESSION 1

Chairpersons: L. Landsberg (Chicago, IL, USA) M.A. Weber (New York, NY, USA)

09.00 • MICROALBUMINURIA IN PREHYPERTENSION

09.10 • LERCANIDIPINE CONTRIBUTES TO INCREASE REENDOTHELIALIZATION CAPACITY OF EARLY ENDOTHELIAL PROGENITOR CELLS FROM PATIENTS WITH ESSENTIAL HYPERTENSION

09.20 • ALDOSTERONE–RENIN RATIO AND RENAL HEMODYNAMICS IN ESSENTIAL HYPERTENSION

09.30 • A CARDIOMYOCYTE TARGETED DELIVERY SYSTEM OF THERAPEUTIC REGIMENS FOR THE EFFICIENT REGRESSION OF CARDIAC HYPERTROPHY IN RAT MODEL
S. Rana, S. Sarkar Calcutta, INDIA

09.40 • IN VITRO EMBRYO CULTURE: A PERCONCEPTIONAL MANIPULATION THAT LEADS TO ALTERED BAROREFLEX SENSITIVITY IN EARLY POSTNATAL LIFE
M. Padhe 1, C. McMillen 1, S. MacLaughlin 1, S. Zhang 1, J. Armitage 1, D. Kleemann 1, S. Walker 1, J. Morrisson 1
1 Adelaide, 2 Geelong, AUSTRALIA

09.50 • BLOOD PRESSURE AND MORTALITY RISK IN AN OLDER POPULATION: THE CRITICAL ROLE OF BIOLOGICAL AGE?
M. Muller 1, G. Post Hospel 1, A.B. Maier 1, D.J. Deeg 1, Y.M. Smulders 2
1 Leiden, 2 Amsterdam, NETHERLANDS

10.00 • VASODILATOR PROSTANOIDS INFLUENCE INTERACTIONS OF LOCAL HYPERINSULINEMIA WITH ENDOTHELIN-B–RECEPTORS IN THE HUMAN MICROCIRCULATION
A. Mitchell 1, U. Rushentsova 1, S. Becker 1, S. Dolff 1, N. Unger 1, H. Guberina 1
1 Essen, 2 Herne, GERMANY

10.10 • CARDIORESPIRATORY FITNESS ATTENUATES THE PROGRESSION TO CHRONIC KIDNEY DISEASE IN HYPERTENSIVES
P. Kokkinos 1, M. Dounas 1, A. Pittaras 1, A. Tsimploulis, 1, H. Grassos 2, A.J. Manolis 2, C. Faselis 1
1 Washington, DC, USA, 2 Athens, GREECE

10.20 • ANGIOTENSIN 1–7 SIGNIFICANTLY REDUCES DIABETES-INDUCED LEUCOCYTE TRAFFICKING AND VASCULAR INJURY
D. De Nardo, F. Bossi, F. Fischetti, A. Bramante, R. Carretta, S. Bernardi, B. Fabris Trieste, ITALY

10.30 • COSTS OF HYPERTENSION DETECTION WITHIN THE NHS HEALTH CHECK PROGRAMME COMPARED TO OPPORTUNISTIC DETECTION
C. Clark 1, J. Fordham 2, M. Greenwood 2, S. Richards 1, J. Campbell 1
1 Exeter, 2 Witheridge, UNITED KINGDOM

10.40 • AORTIC AND RENAL HAEMODYNAMICS AND BARORECEPTOR FUNCTION DURING UNILATERAL FIELD STIMULATION OF CAROTID BARORECEPTOR NERVES IN SPONTANEOUSLY HYPERTENSIVE RATS
M. Butlin 1, Z. Kouchaki 1, D. Georgakopoulos 2, A. Avalos 1
1 Sydney, AUSTRALIA, 2 Minneapolis, MN, USA

10.50 • LONGER TERM SAFETY AND EFFICACY OF MULTI-ELECTRODE RENAL DENERVATION IN PATIENTS WITH DRUG-RESISTANT HYPERTENSION: TWENTY-FOUR MONTH RESULTS OF A FIRST-IN-HUMAN, MULTICENTER STUDY
J. Tsiouris 1, S.G. Worthley 1, M. Worthley 1, D. Chew 1, A. Sinhal 1, I. Meredith 1, Y. Malaiapan 1, V. Papademetriou 1
1 Athens, GREECE, 2 Adelaide, 3 Melbourne, AUSTRALIA, 4 Washington, DC, USA

Saturday 14
Parallel Oral Session 1D

BLOOD PRESSURE MEASUREMENT

Chairpersons:  
A.M. Heagerty (Manchester, UNITED KINGDOM)  
Y. Sirenko (Kiev, UKRAINE)

09.00  • PROGNOSTIC VALUE OF AMBULATORY HEART RATE CIRCADIAN RHYTHM IN HYPERTENSIVES OLDER THAN 60 YEARS  
P. Cuffaro, J. Barochiner, M. Morales, M. Marin, L. Aparicio, M. Rada, C. Galarza, G. Waisman  
Buenos Aires, ARGENTINA

09.10  • PROGNOSTIC IMPACT OF CLINIC, DAYTIME, AND NIGHTTIME SYSTOLIC BLOOD PRESSURE IN 9 COHORTS OF 13,844 PATIENTS WITH HYPERTENSION: SYSTEMATIC REVIEW AND META-ANALYSIS  
G. Roush 1, R.H. Fagard 2, G. Salles 1, S. Pierdomenico 3, G. Reboldi 3, P. Verdecchia 6, K. Eguchi 7, K. Kario 7, J. Polonia 8, A. De La Sierra 9, R. Hermida 10  
1 Farmington, CT, USA, 2 Leuven, BELGIUM, 3 Rio de Janeiro, BRAZIL, 4 Chieti, 5 Perugia, 6 Assisi, ITALY, 7 Tochigi, 8 Porto, PORTUGAL, 9 Terrassa, 10 Vigo, SPAIN

09.20  • OFFICE, HOME, AND AMBULATORY BLOOD PRESSURE AS PREDICTORS OF CARDIOVASCULAR RISK  
T. Niiranen, J. Maki, P. Puukka, H. Karanko, A. Jula  
Turku, FINLAND

09.30  • TELEMONITORING OF 24-H BLOOD PRESSURE IN LOCAL PHARMACIES AND BLOOD PRESSURE CONTROL IN THE COMMUNITY: RESULTS FROM THE TEMPLAR PROJECT  
S. Omboni, M. Caserini  
Varese, ITALY, on behalf of the TEMPLAR Project Group

09.40  • ATRIAL FIBRILLATION DETECTION USING OSCILLOMETRIC 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING VERSUS 24-HOUR HOLTER ELECTROCARDIOGRAPHY  
A. Kolias, P. Kalogeropoulos, A. Nimeri, K. Dimitriadis, M. Zeniodi, G.S. Stergiou  
Athens, GREECE

09.50  • PREDICTIVE CAPACITY OF AMBULATORY VERSUS CLINIC BLOOD PRESSURE IN THE OBESE AND NON-OBESE PARTICIPANTS OF THE ABP-INTERNATIONAL STUDY  
P. Palatini 1, G. Reboldi 2, L. Bellin 3, K. Eguchi 4, Y. Imai 5, K. Kario 7, T. Ohkubo 5, S. Pierdomenico 3, J. Schwartz 7, L. Wing 7, P. Verdecchia 6  
1 Padua, 2 Perugia, ITALY, 3 Perth, AUSTRALIA, 4 Tochigi, 5 Sendai, JAPAN, 6 Chieti, ITALY, 7 New York, NY, USA, 8 Adelaide, AUSTRALIA, 9 Assisi, ITALY

10.00  • IN-CLINIC BLOOD PRESSURE REACTIVITY IS ASSOCIATED WITH PRESERVED ENDOTHELIAL FUNCTION AMONG PATIENTS WITH DIABETES  
P. Veloudi 1, L. Blizzard 1, V. Srikanth 2, J. Sharman 1  
1 Hobart, 2 Melbourne, AUSTRALIA

10.10  • COMPARISON OF WRIST-TYPE AND ARM-TYPE AMBULATORY BLOOD PRESSURE MONITORING DEVICES  
W. Zeng, T. Chu, B. Fox, M. Hu, B. Tomlinson  
Shatin, HONG KONG

10.20  • NOT CASUAL BLOOD PRESSURE BUT AMBULATORY BLOOD PRESSURE IS CORRELATED WITH 24 HOUR URINARY SODIUM EXCRETION  
J. Shin 1, Y. Yamori 2, B. Choi 1, M. Kim 1, B. Kim 1, Y. Lee 1  
1 Seoul, SOUTH KOREA, 2 Hyogo, JAPAN

10.30  • INVASIVE VALIDATION OF THE COMPLIOR® ANALYSE IN THE ASSESSMENT OF CENTRAL ARTERY PRESSURE CURVES: A METHODOLOGICAL STUDY  
T. Pereira, J. Maldonado  
Coimbra, PORTUGAL

10.40  • CHARACTERISTICS OF SELF-MEASURED HOME AND OFFICE-MEASURED BLOOD PRESSURE AMONG BLACK AFRICANS: A PILOT STUDY IN A NIGERIAN URBAN COMMUNITY  
A. Okoli 1, V. Ameh 1, K. Asayama 2, L. Thijs 1, J.A. Staessen 1  
1 Abuja, NIGERIA, 2 Leuven, BELGIUM, 3 Maastricht, NETHERLANDS

10.50  • THE MORNING BLOOD PRESSURE SURGE VELOCITY AND SALT-SENSITIVITY IN PATIENTS WITH ESSENTIAL HYPERTENSION  
G. Abdullaeva, R. Kurtbarov, S. Khamidullayeva  
Tashkent, UZBEKISTAN
### Joint Session

**ESH (European Society of Hypertension) / ISH (International Society of Hypertension) / CHL (Chinese Hypertension League)**

**CARDIOVASCULAR RISK ASSOCIATED WITH AMBULATORY SYSTOLIC AND DIASTOLIC BLOOD PRESSURE AND HYPERTENSION SUBTYPES**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Hypertension and atrial fibrillation: diagnostic approach and treatment</td>
<td>A.J. Manolis (Athens, GREECE)</td>
</tr>
<tr>
<td>09.15</td>
<td>Strategies and actions to improve BP control rate: experiences from China</td>
<td>W. Wang (Beijing, CHINA)</td>
</tr>
<tr>
<td>09.30</td>
<td>Blood pressure target: should it be the same in Asian and in European populations?</td>
<td>Y. Zhang (Beijing, CHINA)</td>
</tr>
<tr>
<td>09.45</td>
<td>Adherence to antihypertensive treatment. Information from population data–bases</td>
<td>G. Mancia (Milan, ITALY)</td>
</tr>
<tr>
<td>10.00</td>
<td>Cardiovascular risk associated with ambulatory systolic and diastolic blood pressure and hypertension subtypes</td>
<td>L. Yan (Shanghai, CHINA)</td>
</tr>
</tbody>
</table>

### Parallel Oral Session

**ISH NEW INVESTIGATOR COMMITTEE AWARDS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairpersons/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Blood Pressure Research – Looking Back, Looking Forward</td>
<td>S.B. Harrap, Melbourne, AUSTRALIA</td>
</tr>
<tr>
<td>09.20</td>
<td>Both Isoforms of the Nitric Oxide–Receptor Guanylyl Cyclase Play an Important Role in the Regulation of Blood Pressure and Renal Perfusion</td>
<td>M. Thiemer, L. Rump, E. Mergia, D. Vonend, S. Potthoff, J. Stegbauer, Düsseldorf, Bochum, GERMANY</td>
</tr>
<tr>
<td>09.30</td>
<td>Putative Calcium-Sensitive Genes, VSIN1 and ANO4, Are Upregulated in Human Zona Glomerulosa Cells and May Play a Role in Regulation of Aldosterone Production</td>
<td>C. Maniero, J. Zhou, E. Azizan, I. McFarlane, S. Neogi, C. Brighton, P. Scudieri, L. Galletta, M. Brown, Cambridge, UNITED KINGDOM, Genoa, ITALY</td>
</tr>
<tr>
<td>09.45</td>
<td>Pharmacological Angiotensin Type 2 Receptor Stimulation Modulates Acute Renal Function in Female But Not Male Spontaneously Hypertensive Rats</td>
<td>L. Hillard, C. Chow, U. Steckelings, R. Widdop, K. Denton, Melbourne, AUSTRALIA, Odense, DENMARK</td>
</tr>
<tr>
<td>10.00</td>
<td>DACH1, A Zona Glomerulosa Selective Gene in the Human Adrenal, Plays an Important Role in Aldosterone Production and Regulates Wnt Activity</td>
<td>J. Zhou, E. Azizan, S. Neogi, I. McFarlane, C. Brighton, C. Maniero, A. Teo, L. Shaikh, M. Brandorff, M. Brown, Cambridge, UNITED KINGDOM</td>
</tr>
</tbody>
</table>
Joint Session
ESH (European Society of Hypertension) / LASH (Latin American Society of Hypertension)

THE BURDEN OF CARDIOVASCULAR RISK FACTORS IN LATIN AMERICA

Chairpersons: A. Coca (Barcelona, SPAIN)  
R. Sánchez (Buenos Aires, ARGENTINA)

09.30 Evaluating the risk factors in Latin America: the case of sodium intake  
J.P. Lopez-Jaramillo (Santander, COLOMBIA)

09.50 The role of comorbidities in the global risk of hypertensive patients  
J. Redon (Valencia, SPAIN)

10.10 Management of hypertension in diabetes mellitus and the metabolic syndrome  
A. Zanchetti (Milan, ITALY)

10.30 Lights and darkness in the treatment of hypertension in Latin America  
A.J. Ramirez (Buenos Aires, ARGENTINA)

10.50 General Discussion
Parallel Oral Session 2A

INFLAMMATION AND URIC ACID

Chairpersons: J.M. Halimi (Tours, FRANCE)  
G.F. Salles (Rio de Janeiro, BRAZIL)

11.00 • MATRIX METALLOPROTEINASE-2 IS ESSENTIAL FOR ANGIOTENSIN II TO INDUCE ENDOTHELIAL DYSFUNCTION AND VASCULAR REMODELING, OXIDATIVE STRESS AND INFLAMMATION  
M. Mian, T. Barhoumi, A. Rehman, N. Idris-Khoja, Y. Rautureau, P. Paradis, E.L. Schiffri  
Montreal, CANADA

11.10 • COMPLEMENTS REGULATE PERIVASCULAR ADIPOSE TISSUE MACROPHAGE POLARIZATION IN DEOXYCORTICOSTERONE ACETATE-SALT HYPERTENSIVE MICE  
P. Gao, C. Ruan  
Shanghai, CHINA

11.20 • ATTENUATION OF HYPERTENSION IN THE SPONTANEOUSLY HYPERTENSIVE RAT BY BONE MARROW RECONSTITUTION WITH NORMOTENSIVE WKY CELLS  
M. Santisteban, J. Zhu, Y. Qi, J. Marulanda Carvajal, M. Zingler  
Gainesville, FL, USA

11.30 • INFLAMMATORY CHANGES AND COAGULATION IN CORONARY HEART DISEASE ASSOCIATED WITH SUBCLINICAL HYPOTHYROIDISM  
I. Shatynska-Mytsyk, Y. Mytsyk, O. Makar  
Lviv, UKRAINE

11.40 • LECTURE: IMMUNE MECHANISMS IN HYPERTENSION AND CARDIOVASCULAR DISEASE  
B.M. Mitchell  
Temple, TX, USA

12.00 • ASSOCIATION OF URIC ACID GENETIC RISK SCORE WITH SYSTOLIC AND DIASTOLIC BLOOD PRESSURE: THE ROTTERDAM STUDY  
S. Seresha, R. Prazak, A. Uitterlinden, A. Hofman, M. Ikrham, O. Franco, A. Dehghan  
Rotterdam, NETHERLANDS

12.10 • PERIVASCULAR INFLAMMATION IN AGEING SPONTANEOUSLY HYPERTENSIVE RATS  
R. Nosalski, T. Mikołajczyk, J. Maciag, T. Guzik  
Kraków, POLAND, 2 Glasgow, UNITED KINGDOM

12.20 • RENAL SYMPATHETIC DENERVATION AND INFLAMMATORY PARAMETERS  
B. Lang, C. Primus, T. Lambert, C. Steinwender, R. Berent, I. Auer  
1 Graz, 2 Braunau, 3 Linz, 4 Bad Schallerbach, AUSTRIA
**Industry Sponsored Minisymposium**

**THE PATH FORWARD WITH RENAL DENERVATION**

Chairperson: C. Tsioufis (Athens, GREECE)

11.00  Introduction and program overview  
C. Tsioufis (Athens, GREECE)

11.05  ESH position statement on renal denervation therapy  
M. Burnier (Lausanne, SWITZERLAND)

11.10  What are the treatment options for uncontrolled hypertensive patients?  
L.M. Ruilope (Madrid, SPAIN)

11.20  Overview and key learnings from the RDN trials and real world experience  
R.E. Schmieder (Erlangen, GERMANY)

11.35  Discussion and highlights on recent recommendations of RDN therapy  
- Recent publication review  
- Recent clinical data review and key learnings

11.55  Concluding remarks  
C. Tsioufis (Athens, GREECE)

*please see page: 21

**Industry Sponsored Minisymposium**

**EPIDEMIOLOGICAL, CLINICAL AND BIOCHEMICAL ADVANCES IN THE DIAGNOSIS OF PRIMARY HYPERALDOSTERONISM**

Chairperson: A. Morganti (Milan, ITALY)

11.30  Primary aldosteronism: clinical features and diagnostic algorithm  
A. Morganti (Milan, ITALY)

11.50  Prevalence of primary aldosteronism in resistant hypertension  
M. Doumas (Thessaloniki, GREECE)

12.10  Diagnostic cut-offs for the ARR and saline infusion test using automated chemiluminescence immunoassays for Aldosterone and Direct Renin  
J. Manolopoulou (Boldon, UNITED KINGDOM)

*please see page: 21
Parallel Oral Session 2B

AGEING

Chairpersons: J.B. Park (Seoul, SOUTH KOREA)
B.H. Watschinger (Vienna, AUSTRIA)

11.00 • LECTURE:
IMPACT OF SODIUM PUMP INHIBITORS IN AGING OF HEART AND VESSELS
O. Fedorova
Baltimore, MD, USA

11.20 • ASSOCIATION BETWEEN MORTALITY AND BLOOD PRESSURE LEVELS IN ELDERLY LIVING NURSING HOME SUBJECTS. ARE FRAIL SUBJECTS OVERTREATED (PARTAGE STUDY)?
A. Benetos 1, S. Gautier 1, P. Salvi 2, F. Valibus 3, O. Toulza 3, D. Agnoletti 3, M. Zamboni 3, P. Mannikou 1, O. Hanon 1, C. Labat 1
1 Vandoeuvre-lès-Nancy, FRANCE, 2 Milan, 3 Verona, ITALY

11.30 • EXERCISE CAPACITY AND MORTALITY IN HYPERTENSIVE MEN 70 YEARS AND OLDER
A. Pittaras 1, C. Faselis 2, M. Doumas 2, A.J. Manolis 1, A. Owen 2, H. Krum 1, L.M. Wing 2, M.R. Nelson 2, C.M. Reid 1
1 Athens, GREECE, 2 Washington, DC, USA

11.40 • PROGRESSION OF RENAL FUNCTION IN ELDERLY TREATED HYPERTENSIVE PATIENTS: FINDINGS FROM SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY
E. Chowdhury 1, R. Langham 2, Z. Ademi 1, A. Owen 2, H. Krum 1, L.M. Wing 1, M.R. Nelson 2, C.M. Reid 1
1 Melbourne, 2 Adelaide, 3 Hobart, AUSTRALIA

11.50 • IMPAIRED BASELINE AORTIC STIFFNESS PREDICTS PULSE WAVE VELOCITY IMPROVEMENT IN RECENTLY DIAGNOSED PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: A 3-YEAR FOLLOW-UP STUDY
H. Triantafyllidis 1, P. Trivilou 1, I. Ikonomidis 1, K. Kontsas 1, S. Tzortzis 1, G. Pavlidis 1, A. Saxinas 1, D. Kremastinos 1, M. Anastasolou-Nana 1, J. Lekakis 1

12.00 • EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND ESTROGEN SUPPLEMENTATION ON CONTRACTIONS TO THROMBOXANE A2 IN AORTA FROM SENESCENCE ACCELERATED MICE
G. Segarra 1, X. Vidal-Gomez 1, D. Perez-Cremades 1, C. Alite 1, A. Dantas 1, C. Hermenegildo 1, P. Medina 1, S. Novella 1
1 Valencia, 2 Barcelona, SPAIN

12.10 • ASSESSMENT OF SUDDEN CARDIAC DEATH RISK IN ELDERLY HYPERTENSIVE PATIENTS USING BAYESIAN NETWORK MODELISATION
C. Loup 1, L. Boursignou 1, F. Gueyffier 1, J. Fauvel 1, M. Ducher 1
1 Francheville, Lyon, FRANCE

12.20 • ACTIVATION OF HYPOXIC CARDIAC STEM CELLS REVERSING MYOCARDIAL AGING
F. Sanada 1, Y. Taniyama 1, Y. Ikeda-Iwabe 1, J. Azuma 1, M. Iwabayashi 1, R. Rakugi 1, R. Morishita 1

11.00 – 12.30  Dimitris Mitropoulos Hall
Parallel Oral Session 2C

CEREBROVASCULAR DISEASES AND COGNITIVE DYSFUNCTION

Chairpersons: K. Kario (Tochigi, JAPAN) A.O. Konradi (Saint-Petersburg, RUSSIA)

11.00 • SYSTEMIC CIRCULATION AND CEREBRAL BLOOD FLOW: THE ROTTERDAM STUDY
Rotterdam, NETHERLANDS

11.10 • HIGH BODY MASS INDEX IS ASSOCIATE TO BETTER COGNITIVE FUNCTION AT A POPULATION LEVEL
V. Tikhonoff 1, N. Giordano 1, F. Guidotti 1, A. Bascelli 1, G. Boschetti 1, S. Crociani 1, A. Mazza 2,
P. Palatini 1, E. Casiglia 1
1 Padua, 2 Vicenza, 3 Rovigo, ITALY

11.20 • PULSE PRESSURE AS PREDICTOR OF OUTCOME IN ISCHEMIC STROKE PATIENTS
L. Brescacin, C. Alonzo, M. Zurru, S. Pigretti, L. Camera, E. Cristiano, G. Waisman
Buenos Aires, ARGENTINA

11.30 • BIPHASIC PIAL ARTERY AND SUBARACHNOID WIDTH RESPONSE TO SHORT APNEA IN NORMOTENSIVE SUBJECTS
M. Wszydyl-Winklewskas 1, J. Wolf 1,2, E. Swierbelska 1, K. Kunicka 1, P. Winklewski 1,
A. Frydrychowski 1, L. Bieniaszewski 1, K. Narkiewicz 1,2
1 Gdansk, 2 Brno, CZECH REPUBLIC

11.40 • ELEVATED CENTRAL PULSE PRESSURE AND MILD COGNITIVE IMPAIRMENT INCIDENCE IN HYPERTENSIVE PATIENTS
T. Yaneva-Sirakova, R. Tarnovska-Kadreva, L. Traykov
Sofia, BULGARIA

11.50 • ACUTE-PHASE BLOOD PRESSURE VARIABILITY AND SHORT-TERM OUTCOME IN PATIENTS HOSPITALIZED FOR ISCHEMIC STROKE
K. Tsizanakis, S. Bouziana, M. Spanou, M. Papadopoulou, V. Glampatzis, V. Dourilou, P. Kazantzidou,
S. Kostaki, C. Savopoulos, A. Hatzitolios
Thessaloniki, GREECE

12.00 • INCREASED PULSE PRESSURE IS RELATED TO HIGHER BURDEN OF MICROVASCULAR BRAIN DAMAGE IN ISCHEMIC STROKE PATIENTS
C. Alonzo, L. Brescacin, M. Zurru, A. Luzzi, L. Camera, E. Cristiano, G. Waisma
Buenos Aires, ARGENTINA

12.10 • ENHANCED CAROTID PLAQUE ECHOLUCENCY IS ASSOCIATED WITH WORSE COGNITIVE PERFORMANCE IN ELDERLY PATIENTS WITH ATHEROSCLEROTIC DISEASE
D. Mastroiacovo 1, D. Grassi 2, M. Pinelli 2, G. De Blasis 1, G. Turco 1, A. Camerota 1,2, M. Andriulli 1,
F. Cipollone 1, C. Marini 1, C. Ferri 1, G. Desideri 1,2
1 Avezzano, 2 L’Aquila, 3 Chieti, ITALY

12.20 • LOW MEAN BLOOD PRESSURE DURING THE ACUTE PERIOD OF ISCHEMIC STROKE IS ASSOCIATED WITH DECREASED SURVIVAL
P. Wohlfahrt 1, A. Krajcoviechova 1, M. Jozifova 1, O. Mayer 2, J. Vanek 1, J. Filipovsky 2, R. Cifkovà 1,
1 Prague, 2 Pilsen, CZECH REPUBLIC
Parallel Oral Session 2D

CLINICAL TRIALS

Chairpersons: J. Chalmers (Sydney, AUSTRALIA)  
P. Zebekakis (Thessaloniki, GREECE)

11.10 • LECTURE: META-ANALYSES OF BLOOD PRESSURE LOWERING TRIALS: SHOULD THEY ADDRESS CLINICALLY ORIENTED QUESTIONS?  
A. Zanchetti  
Milan, ITALY

11.20 • ORTHOSTATIC HYPERTENSION IS ASSOCIATED WITH INCREASED CARDIOVASCULAR AND ALL CAUSE MORTALITY IN PATIENTS WITH ISOLATED SYSTOLIC HYPERTENSION  
J.B. Kostis 1, J. Sedjo 2, W. Kostis 3, J. Cabrera 4, S. Pressel 5, N. Cosgrove 6, B. Davis 7  
1 New Brunswick, NJ, 2 Boston, MA, 3 Piscataway, NJ, 4 Houston, TX, USA

11.30 • COMBINATION THERAPY FOR ELDERLY HYPERTENSION: A SUB-ANALYSIS OF COMBINATION OF OLMESARTAN AND CALCIUM CHANNEL BLOCKER OR DIURETIC IN THE ELDERLY HYPERTENSION (COLEM) TRIAL  
T. Ogihara 1, T. Saruta 2, H. Rakugi 2, I. Saito 2, K. Shimamoto 3, H. Matsuoka 4, S. Tanamukai 5, J. Hijaki 6, S. Ito 7, K. Shimada 8, for the Colm Investigators  
1 Osaka, 2 Tokyo, 3 Sapporo, 4 Tochigi, 5 Ube, 6 Osaka, 7 Suito, 8 Tokyo, JAPAN

11.40 • DIFFERENTIAL EFFECTS OF ANTIHYPERTENSIVE DRUGS ON CENTRAL BLOOD PRESSURES IN BLACK HYPERTENSIVE PATIENTS LIVING IN SUB-SAHARAN AFRICA: INSIGHT FROM NOAOH STUDY  
D. Lemogoum 1, L. Jacobs 2, B. Anisiuba 3, M. Kamdem 1, J. Kaptue 1, B. Ezeala-Adikie 1, L. Thijs 2, I. Ulasses 1, J.A. Staessen 3, J.M. Buyamba-Kabangu 4  
1 Douala, CAMEROON, 2 Leuven, BELGIUM, 3 Enugu, NIGERIA, 4 Kinshasa, CONGO (DRC)

11.50 • RANDOMISED EVALUATION OF A NOVEL, FIXED-DOSE COMBINATION OF PERINDOPRIL 3.5 MG/AMLODIPINE 2.5 MG AS A FIRST-STEP TREATMENT IN HYPERTENSION  
S. Laurent 1, I. Chazova 2, Y. Sirenko 3, A. Erglis 4, A. Laucevicius 5, C. Farsang 6  
1 Paris, FRANCE, 2 Moscow, RUSSIA, 3 Kiev, UKRAINE, 4 Riga, LATVIA, 5 Vilnius, LITHUANIA, 6 Budapest, HUNGARY

12.00 • EFFECTS OF FIXED COMBINATION OF PERINDOPRIL 10 MG/INDAPAMIDE 2.5 MG IN HYPERTENSIVE PATIENTS POST STROKE/TIA: A PICASSO SUB-STUDY  
C. Farsang  
Budapest, HUNGARY

12.10 • EFFECTS OF SODIUM AND POTASSIUM SUPPLEMENTATION ON BLOOD PRESSURE, ARTERIAL STIFFNESS AND RENAL FUNCTION IN UNTREATED (PRE) HYPERTENSIVES ON A FULLY CONTROLLED DIET  
L. Gijsbers 1, J. Dower 1, M. Mensink 1, S. Bakker 12, J. Geleijnse 1  
1 Wageningen, 2 Groningen, NETHERLANDS

12.20 • EFFECTS OF CALCIUM CHANNEL BLOCKER BENIDIPINE-BASED COMBINATION THERAPY ON TARGET BLOOD PRESSURE CONTROL RATE AND CARDIOVASCULAR OUTCOME: A SUB-ANALYSIS OF THE COPE TRIAL  
S. Unemoto 1, T. Ogihara 1, H. Rakugi 2, M. Matsuzaki 1, Y. Ohashi 1, T. Saruta 1, the Cope Trial Group  
1 Ube, 2 Osaka, 3 Suito, 4 Tokyo, JAPAN
**Teaching Seminar - Session 1**

**INTERVENTIONS IN HYPERTENSION**

Chairpersons:  
A. Avolio (Sydney, AUSTRALIA)  
T.E. Lohmeier (Jackson, MS, USA)

**12.45** Baroreflex stimulation in resistant hypertension  
P.W. de Leeuw (Maastricht, NETHERLANDS)

**13.00** Renal nerve ablation  
R.E. Schmieder (Erlangen, GERMANY)

**13.15** Is PTA stenting better than medical treatment in renal artery stenosis?  
P.F. Plouin (Paris, FRANCE)

**13.30** Is there a need for special blood pressure management before interventions?  
C. Tsioufis (Athens, GREECE)

**13.45** General Discussion

---

**Industry Sponsored Satellite Symposium**

**TRIPLE COMBINATION IN HYPERTENSION: REACHING NEW GOALS**

Chairpersons:  
J. Chalmers (Sydney, AUSTRALIA)  
R. Čifková (Prague, CZECH REPUBLIC)

**12.45** Introduction  
J. Chalmers (Sydney, AUSTRALIA)

**13.00** Resistant or suboptimally treated hypertension: where is the truth?  
B. Williams (London, UNITED KINGDOM)

**13.20** Triple combination in hypertension: what does theory suggest?  
S. Taddei (Pisa, ITALY)

**13.40** Triple combination in hypertension: from theory to clinical evidence  
J. Chalmers (Sydney, AUSTRALIA)

**14.00** Conclusion  
R. Čifková (Prague, CZECH REPUBLIC)

*please see page: 20*
14.00 – 15.30

Attended Poster Sessions

**PS 01. CARDIOVASCULAR RISK FACTORS**
- **ROOM 1** POSTERS FROM 1 TO 43
- Chairperson: D. Prabhakaran (New Delhi, INDIA)

**PS 02. BLOOD PRESSURE MEASUREMENT**
- **ROOM 2** POSTERS FROM 1 TO 44
- Chairperson: M. Ruzicka (Ottawa, CANADA)

**PS 03. OBESITY**
- **ROOM 3** POSTERS FROM 1 TO 46
- Chairperson: C. Grassos (Athens, GREECE)

**PS 04. ATRIAL FIBRILLATION - ORGAN DAMAGE**
- **ROOM 4** POSTERS FROM 1 TO 46
- Chairperson: J.G. Wang (Shanghai, CHINA)

**PS 05. EXPERIMENTAL HYPERTENSION**
- **ROOM 5** POSTERS FROM 1 TO 41
- Chairperson: E. Baranova (Saint-Petersburg, RUSSIA)

**PS 06. HEART**
- **ROOM 6** POSTERS FROM 1 TO 45
- Chairperson: D. Papadopoulos (Athens, GREECE)

**PS 07. ENDOTHELIUM**
- **ROOM 7** POSTERS FROM 1 TO 29
- Chairperson: T. Ogihara (Osaka, JAPAN)

**PS 08. LARGE ARTERIES**
- **ROOM 8** POSTERS FROM 1 TO 43
- Chairperson: F. Martinez Garcia (Valencia, SPAIN)
PS 09. MOLECULAR BIOLOGY – NEURAL AND MEMBRANE MECHANISMS
ROOM 9 POSTERS FROM 1 TO 27
Chairperson: M. Correia (Iowa City, IA, USA)

PS 10. EPIDEMIOLOGY
ROOM 10 POSTERS FROM 1 TO 40
Chairperson: D.T. Lackland (Charleston, SC, USA)

PS 11. SLEEP APNOEA
ROOM 11 POSTERS FROM 1 TO 25
Chairperson: E. Gianakopoulos (Athens, GREECE)

PS 12. KIDNEY
ROOM 12 POSTERS FROM 1 TO 40
Chairperson: L.G. Navar (New Orleans, LA, USA)

PS 13. MICROCIRCULATION
ROOM 13 POSTERS FROM 1 TO 26
Chairperson: A. Montezano (Glasgow, UNITED KINGDOM)

PS 14. RESISTANT HYPERTENSION
ROOM 14 POSTERS FROM 1 TO 37
Chairperson: V. Stojanov (Belgrade, SERBIA)

PS 15. AGEING
ROOM 15 POSTERS FROM 1 TO 36
Chairperson: A. Avolio (Sydney, AUSTRALIA)

LATE-BREAKER POSTERS’ SESSION 1
ROOM 16 POSTERS FROM 1 TO 36
Chairperson: A. Nedoshivin (Saint-Petersburg, RUSSIA)

ISH NEW INVESTIGATOR COMMITTEE
Section 1: Basic Science
ROOM 17 POSTERS FROM 1 TO 10
Chairperson: F.J. Charchar (Ballarat, AUSTRALIA)
Judges: D. Burger (Ottawa, CANADA)
R.M. Touyz (Glasgow, UNITED KINGDOM)

Section 2: Clinical Science
ROOM 17 POSTERS FROM 1 TO 10
Chairperson: P. Veerabhadrappa (Philadelphia, PA, USA)
Judges: L.M. Burrell (Melbourne, AUSTRALIA)
L.H. Lindholm (Umeå, SWEDEN)

Section 3: Population Science
ROOM 17 POSTERS FROM 1 TO 9
Chairperson: A.E. Schutte (Potchefstroom, SOUTH AFRICA)
Judges: E.L. Schiffrin (Montreal, CANADA)
M. Tomaszewski (Leicester, UNITED KINGDOM)
Industry Sponsored Minisymposium*

**CLINICAL IMPLICATION OF PULSE WAVE ANALYSIS: PWV, AI AND CENTRAL BLOOD PRESSURE**

**Chairperson:** S. Laurent (Paris, FRANCE)

**14.30** Brachial-Ankle PWV, AI, and central BP measurement by modern device developed in Japan. Their clinical applicability as biomarker
A. Yamashina (Tokyo, JAPAN)

**15.00** Destiffening of arteries: recent evidences issued from central blood pressure measurements
P. Boutouyrie (Paris, FRANCE)

**14.30 – 15.30 Nikos Skalkotas Hall**

**Industry Sponsored Minisymposium**

**ARTERIAL STIFFNESS FROM RESEARCH TO CLINICAL APPLICATION**

**Chairperson:** R. Asmar (Paris, FRANCE)
**Co-Chairperson:** C. Giannattasio (Milan, ITALY)

**14.30** Triple A Study
A. Benetos (Nancy, FRANCE)

**14.45** Pregnancy complications and risk of cardiovascular disease for mother and offspring: mechanistic insights from CAVI (Cardio-Ankle Vascular Index)
P. Leeson (Oxford, UNITED KINGDOM)

**15.00** Arterial stiffness and BP variability. Pathophysiological and clinical implications
G. Parati (Milan, ITALY)

**15.20** General Discussion

*please see page: 21
14.30 – 15.30 Dimitris Mitropoulos Hall

Industry Sponsored Minisymposium*

MANAGING THE AF PATIENT WITH HYPERTENSION – IMPLICATIONS FOR CLINICAL PRACTICE

Chairperson: G. Mancia (Milan, ITALY)

14.30 Welcome and introduction
G. Mancia (Milan, ITALY)

14.35 The burden of atrial fibrillation and hypertension co-morbidity
F. Andreotti (Rome, ITALY)

14.50 Novel oral anticoagulants in patients with AF: interpretation of the latest findings
R. Cappato (Milan, ITALY)

15.05 Practical Management with novel oral anticoagulants
A. Zirlik (Freiburg, GERMANY)

15.20 Q&A and summary
G. Mancia (Milan, ITALY)

*please see page: 21

14.30 – 15.30 Conference Suite I – Room 1

How-To Session

HOW TO ASSESS ARTERIAL DAMAGE

Chairperson: C. Vlachopoulos (Athens, GREECE)
## Saturday

### Meet-The-Expert Session

#### RENOVASCULAR HYPERTENSION

The Expert:  
P.F. Plouin (Paris, FRANCE)

### Clinical Case

#### SESSION 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Clinical Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>Sclerodermal renal crises</td>
</tr>
<tr>
<td></td>
<td>P. Sarafidis (Thessaloniki, GREECE)</td>
</tr>
<tr>
<td>15.00</td>
<td>Severe hypertension and proteinuria in a young man</td>
</tr>
<tr>
<td></td>
<td>M. Bursztyn (Jerusalem, ISRAEL)</td>
</tr>
</tbody>
</table>
Parallel Oral Session 3A

RESISTANT HYPERTENSION

Chairpersons: A. Morganti (Milan, ITALY)
C. Ott (Erlangen, GERMANY)

15.30 • LECTURE:
SHOULD LOW DIASTOLIC BLOOD PRESSURE BE CONSIDERED IN THE TREATMENT OF SYSTOLIC HYPERTENSION?
A.M. Heagerty
Manchester, UNITED KINGDOM

15.50 • ADJUSTED DRUG TREATMENT IS SUPERIOR TO RENAL SYMPATHETIC DENERVATION IN PATIENTS WITH TRUE TREATMENT RESISTANT HYPERTENSION
F. Fadl Elmula, P. Hoffmann, A. Larstorp, M. Brekke, E. Fossum, E. Gjønnæss, H. Haller, E. Lovett, I. Bissognano
Oslo, NORWAY

16.00 • VALIDATION OF LONG-TERM BLOOD PRESSURE CONTROL WITH BAROREFLEX ACTIVATION THERAPY IN A LARGE COHORT OF RESISTANT HYPERTENSION PATIENTS
1 Maastricht, THE NETHERLANDS, 2 Chicago, IL, 3 Los Angeles, CA, USA, 4 Hannover, GERMANY, 5 Minneapolis, MN, 6 Rochester, NY, USA

16.10 • TREATMENT RESISTANT HYPERTENSION: RESULTS OF A 2-YEAR FOLLOW-UP IN REAL WORLD
1 Erlangen, 2 Berlin, 3 Ludwigshafen, 4 Nürnberg, GERMANY

16.20 • THE PREVALENCE AND FACTORS ASSOCIATED WITH RESISTANT HYPERTENSION IN A LARGE HEALTH MAINTENANCE ORGANIZATION IN ISRAEL
1 Tel-Aviv, 2 Tel Hashomer, 3 Israel

16.30 • ENDOCARDIAL ABLATION SYSTEM FOR RENAL DENERVATION: LESS DEMAND TO ANATOMY OF RENAL ARTERIES
S. Petkarsky, A. Baev, V. Mordovin, T. Ripp, G. Semke, E. Sitkova, V. Lichikati, A. Krylov, S. Popov, R. Karpov
Tomsk, RUSSIA

16.40 • SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR IS REDUCED IN PATIENTS WITH RESISTANT HYPERTENSION AFTER RENAL DENERVATION
N. Eikelis, D. Hering, P. Marusic, A. Walton, G. Lambert, M.D. Esler, M.P. Schlaich
1 Melbourne, AUSTRALIA, 2 Gdansk, POLAND

16.50 • AMBULATORY BLOOD PRESSURE CHANGES AFTER RENAL DENERVATION IN SUBJECTS WITH RESISTANT HYPERTENSION: EARLY OUTCOMES FROM THE GLOBAL SYMPLICITY REGISTRY
G. Mancia, M.P. Schlaich, K. Narkiewicz, L.M. Ruilope, B. Williams, R.E. Schmieder, F. Mahfoud, M. Böhm
1 Milan, ITALY, 2 Melbourne, AUSTRALIA, 3 Gdansk, POLAND, 4 Madrid, SPAIN, 5 Leicester, UNITED KINGDOM, 6 Erlangen, 7 Homburg/Saar, GERMANY
**Parallel Oral Session 3B**

**LARGE ARTERIES**

**Chairpersons:** J. Filipovsky (Pilsen, CZECH REPUBLIC)  
G.F. Mitchell (Waltham, MA, USA)

**15.30 • INTER-ARM BLOOD PRESSURE DIFFERENCE AND ARTERIAL STIFFNESS**  
C. Clark, F. Casanova, K. Gooding, N. Pamphilon, K. Alzawa, D. Mawson, D. Adingupu, C. Ball,  
F. Worthington, S. Elyas, D. Strain, P. Gates, A. Shore, J. Campbell  
*Exeter, UNITED KINGDOM*

**15.40 • AORTIC STIFFNESS FOR CARDIOVASCULAR RISK PREDICTION: AN UPDATED SUMMARY DATA META-ANALYSIS**  
C. Vlachopoulos, K. Aznaouridis, C. Stefanadis  
*Athens, GREECE*

**15.50 • LONG TERM CHANGES IN CAROTID INTIMA–MEDIA THICKNESS AND ARTERIAL REMODELING ARE ASSOCIATED WITH ANTIHYPERTENSIVE TREATMENT STATUS**  
*Maastricht, NETHERLANDS*

**16.00 • PROXIMAL AORTIC REMODELING IN ESSENTIAL HYPERTENSION IS ASSOCIATED TO LEFT VENTRICULAR MASS AND PULSE WAVE VELOCITY**  
*Turin, ITALY*

**16.10 • BRACHIAL-ANKLE PULSE WAVE VELOCITY AS A PREDICTOR OF MORTALITY IN ELDERLY CHINESE**  
C. Sheng, Y. Li, L. Li, J. Wang  
*Shanghai, CHINA*

**16.20 • FUNCTIONAL AND STRUCTURAL ARTERIAL CHANGES AND ITS DETERMINANTS IN PATIENTS WITH ACROMEGALY**  
L. Bortolotto, V. Costa-Hong, A. Amaro, M. Bronstein, F. Gaia, R. Soares, G. Lorenzi Filho, R. Pedrosa,  
L. Drager  
*São Paulo, BRAZIL*

**16.30 • DEBATE:**  
**EVALUATION OF SUBCLINICAL ORGAN DAMAGE: DOES IT REALLY MATTER?**

- **YES**  
  T. Weber  
  *Wels, AUSTRIA*

- **NO**  
  J.B. Kostis  
  *New Brunswick, NJ, USA*
**Saturday**

**15.30 – 16.30**  
**Dimitris Mitropoulos Hall**  
**Parallel Oral Session 3C**

**CARDIOVASCULAR RISK FACTORS**

**Chairpersons:**  
M. Diaz (Montevideo, URUGUAY)  
G.A. Head (Melbourne, AUSTRALIA)

---

**15.30**  
**GENETIC FACTORS AS PREDICTORS OF LATE CARDIOVASCULAR MORTALITY IN CORONARY PATIENTS**  
A. Pereira ¹, M. Mendonca ¹, S. Gomes ¹, R. Rodrigues ¹, A. Sousa ¹, A. Freitas ¹, S. Borges ¹, M. Rodrigues ¹, D. Pereira ¹, R. Palma Reis ²  
¹ Funchal, ² Lisbon, PORTUGAL

**15.40**  
**ARTERIAL HYPERTENSION PREVALENCE AND RISK FACTORS OF THIS DISEASE IN THE POPULATION LIVING IN THE RADIOACTIVE CONTAMINATED TERRITORY**  
A. Schastlivenko ¹, V. Podpalov ¹, A. Deev ², I. Stchastlivenka ¹, N. Prakoshyna ¹  
¹ Vitebsk, BELARUS, ² Moscow, RUSSIA

**15.50**  
**CLINICAL IMPACT OF LEFT AXIS DEVIATION ON THE RISK OF CARDIOVASCULAR DISEASE IN JAPANESE SUBJECTS FROM A BLOOD PRESSURE POINT OF VIEW: THE SUITA STUDY**  
T. Kobayashi, M. Watanabe, Y. Kokubo, S. Kamakura, K. Kusano, Y. Miyamoto  
Suita, JAPAN

**16.00**  
**Lecture:**  
HEART RATE, LIFE EXPECTANCY AND THE CARDIOVASCULAR SYSTEM  
H. Boudoulas  
Columbus, OH, USA

**16.30**  
**BASELINE MEAN PLATELET VOLUME IS ASSOCIATED WITH RESIDUAL PLATELET REACTIVITY IN PATIENTS WITH UNSTABLE ANGINA AND ARTERIAL HYPERTENSION**  
I. Martava, A. Miatzvedzeva, L. Helis, I. Lazareva  
Minsk, BELARUS

**16.30**  
**COST-EFFECTIVENESS OF CARDIOVASCULAR RISK MANAGEMENT BY PRACTICE NURSES, WITH AND WITHOUT SELF-MONITORING, IN PRIMARY CARE**  
A. Smit, A. Tiessen, K. Vermeulen, J. Broer, K. Van Der Meer  
Groningen, NETHERLANDS

---

**15.30 – 17.00**  
**Banqueting Hall**  
**Industry Sponsored Minisymposium*”**

**UNLOCKING THE POTENTIAL OF HOME BLOOD PRESSURE MONITORING**

**Chairperson:**  
P.L. Padfield (Edinburgh, UNITED KINGDOM)

**15.30**  
Home monitoring of blood pressure. From research to clinical practice, give us the evidence!  
G.S. Stergiou (Athens, GREECE)

**15.50**  
Home monitoring in the real world. What are the barriers to more widespread use?  
P.L. Padfield (Edinburgh, UNITED KINGDOM)

**16.10**  
Panel Discussion  
P.L. Padfield (Edinburgh, UNITED KINGDOM)  
G.S. Stergiou (Athens, GREECE)  
N. Stetson (London, UNITED KINGDOM)

---

*please see page: 21
16.40 • DEVELOPMENT OF A CARDIOVASCULAR MORTALITY RISK PREDICTION MODEL FOR PARTICIPANTS IN THE OHASAMA STUDY
C. Reid 1, M. Huq 1, A. Owen 1, Z. Ademi 1, T. Ohkubo 1, Y. Imai 1, G.A. Head 1
1Melbourne, AUSTRALIA, 2Tokyo, JAPAN

16.50 • TEN-YEAR CORONARY ARTERY DISEASE RISK ASSESSMENT IN NIGERIAN HYPERTENSIVE SUBJECTS
D. Ojji 1, A. Falase 1, S. Ajayi 2, M. Mamven 1, M. Ngabea 1, K. Sliwa 3
1 Abuja, 2Ibadan, NIGERIA, 3Cape Town, SOUTH AFRICA

15.30 – 17.00  Conference Suite II - MC2

Parallel Oral Session 3D

EXPERIMENTAL HYPERTENSION

Chairpersons: T. Fujita (Tokyo, JAPAN) G. London (Paris, FRANCE)

15.30 • THE KIDNEY CYP2C44 EPOXYGENASE REGULATES EPITHELIAL SODIUM CHANNEL (ENAC) ACTIVITY AND THE BLOOD PRESSURE RESPONSES TO INCREASED DIETARY SALT
J. Capdevila 1, W. Wang 2
1 Nashville, TN, 2Valhalla, NY, USA

15.40 • EFFECTIVENESS OF INTRATRACHEAL DELIVERY OF AUTOLOGOUS BONE MARROW-DERIVED CELLS INTO THE LUNGS OF MONOROTALINE-INDUCED PULMONARY HYPERTENSION MODEL RATS
Y. Yamazato, M. Yamazato, A. Ishida, J. Fujita, Y. Ohya
Okinawa, JAPAN

15.50 • ALTERATIONS IN RENAL FUNCTION OCCUR PRIOR TO THE INCREASE IN ARTERIAL PRESSURE IN RAT OFFSPRING FOLLOWING SHORT-TERM EXPOSURE TO MATERNAL GLUCOCORTICOIDS
K. Denton 1, D. Fong 1, R. Brown 1, R. Singh 1, R. Evans 1, K. Moritz 2
1Melbourne, 2Brisbane, AUSTRALIA

16.00 • ANGIOGENESIS INHIBITION-INDUCED BLOOD PRESSURE RISE AND RENAL TOXICITY ARE DOSE-RELATED
S. Lankhorst 1, M. Kappers 1, J. Van Esch 1, F. Smedts 1, S. Steijler 1, A.H.J. Danser 1, A. Van Den Meiracker 1
1Rotterdam, 2Breda, 3Delft, NETHERLANDS

16.10 • INCREASED URINARY ANGIOTENSINOGEN IN THE NON-CLIPPED KIDNEYS OF 2-KIDNEY 1-CLIP HYPERTENSIVE RATS
L.G. Navar, W. Shao, M. Prieto, A. Katsurada, K. Mitchell
New Orleans, LA, USA

16.20 • INTRACEREBROVENTRICULAR ADMINISTRATION OF AUTOLOGOUS BONE MARROW-DERIVED CELLS ATTENUATES CARDIAC PERIVASCULAR FIBROSIS IN DEOXYCORTICOSTERONE ACETATE–SALT HYPERTENSIVE RATS
T. Nakamura, M. Yamazato, A. Ishida, Y. Yamazato, Y. Ohya
Okinawa, JAPAN
Joint Session
ESH (European Society of Hypertension) / ERA (European Renal Association) – EDTA (European Dialysis and Transplant Association)

HYPERTENSION IN CHRONIC KIDNEY DISEASE

Chairpersons:  
L.M. Ruilope (Madrid, SPAIN)  
C. Zoccali (Reggio Calabria, ITALY)

15.30 The changing epidemiology of CKD in the general population  
R.E. Schmieder (Erlangen, GERMANY)

15.50 Appropriate blood pressure targets in patients with CKD  
G. London (Paris, FRANCE)

16.10 Degree of RAS blockade in hypertensive patients with CKD  
P. Sarafidis (Thessaloniki, GREECE)

16.30 Diagnosis and management of hypertension in ESRD patients  
C. Zoccali (Reggio Calabria, ITALY)

16.50 General Discussion

16.30 - 17.00  Conference Suite II - MC3

Differential Effects of Aerobic Training on Plasma and Heart Renin-Angiotensin System in Spontaneously Hypertensive Rats  
S. Silva Junior, D.E. Casarini, L.C. Michelini  
São Paulo, BRAZIL

Effect of a High Salt Diet on Endothelial Function and Blood Pressure in a Genetic Model of Hypertension  
S. Didion, E. Mezzetti, M. Garrett  
Jackson, MS, USA

The Role of Macrophage-Derived Exosomes in Hypertension  
Osaka, JAPAN
**Plenary Session**

**ESH PRESENTATION OF AWARDS**

**BJÖRN FOLKOW AWARD LECTURE**

**PRESIDENTIAL LECTURE**

**Chairpersons:**
- A.F. Dominiczak (Glasgow, UNITED KINGDOM)
- R.E. Schmieder (Erlangen, GERMANY)
- C. Tsioufis (Athens, GREECE)

**17.00**  
**Presentation of ESH Awards**

- **Björn Folkow Award**  
  G.L. Jennings (Melbourne, AUSTRALIA)
- **Alberto Zanchetti Life Achievement Award**  
  E. Ritz (Heidelberg, GERMANY)
- **Peter Sleight Award**  
  B. Williams (London, UNITED KINGDOM)
- **ESH Honorary Membership**  
  C. Farsang (Budapest, HUNGARY)
- **Talal Zein Award**  
  A.J. Manolis (Athens, GREECE)
- **Paul Milliez Award**  
  F. Zannad (Nancy, FRANCE)

**17.30**  
**Björn Folkow Award Lecture**

- Hypertension – lost causes and consequences  
  G.L. Jennings (Melbourne, AUSTRALIA)

**18.00**  
**Presidential Lecture**

- Genomics and blood pressure: a long journey to precision medicine  
  A.F. Dominiczak (Glasgow, UNITED KINGDOM)

---

**Industry Sponsored Minisymposium**

**CAN THE ANTIHYPERTENSIVE TREATMENT MODIFY THE MICROVASCULAR DAMAGES AND PROTECT THE TARGET ORGANS IN HYPERTENSION? AN OPEN DISCUSSION**

**Chairperson:**  
S. Laurent (Paris, FRANCE)

**16.00 – 17.00**  
**Nikos Skalkotas Hall**

**16.00**  
**Opening remarks**  
S. Laurent (Paris, FRANCE)

**16.05**  
**Effects of antihypertensive treatment on microvascular structure**  
E. Agabiti Rosei (Brescia, ITALY)

**16.20**  
**Effect of antihypertensive treatment on renal function**  
R.E. Schmieder (Erlangen, GERMANY)

**16.35**  
**Open Discussion**

**16.55**  
**Closing remarks**  
S. Laurent (Paris, FRANCE)

---

*please see page: 22*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.30</td>
<td>ESH Working Group on</td>
<td>Christos Lambrakis Hall</td>
<td>E. Agabiti Rosei (Brescia, ITALY)</td>
</tr>
<tr>
<td></td>
<td><strong>BLOOD PRESSURE MONITORING AND CARDIOVASCULAR VARIABILITY</strong></td>
<td></td>
<td>A.J. Manolis (Athens, GREECE)</td>
</tr>
<tr>
<td>18.30</td>
<td>Is masked hypertension a clinically relevant condition that should be treated?</td>
<td></td>
<td>G. Parati (Milan, ITALY)</td>
</tr>
<tr>
<td></td>
<td>E. O'Brien (Dublin, IRELAND)</td>
<td></td>
<td>G.S. Stergiou (Athens, GREECE)</td>
</tr>
<tr>
<td>18.45</td>
<td>What is 24 hour ambulatory central blood pressure and why should it be measured?</td>
<td></td>
<td>Should blood pressure variability measures be incorporated in guidelines?</td>
</tr>
<tr>
<td></td>
<td>A. Protogerou (Athens, GREECE)</td>
<td></td>
<td>G.A. Head (Melbourne, AUSTRALIA)</td>
</tr>
<tr>
<td>19.00</td>
<td>Should blood pressure variability measures be incorporated in guidelines?</td>
<td></td>
<td>Prognostic value of nighttime blood pressure and heart rate: focus on mean</td>
</tr>
<tr>
<td></td>
<td>G.A. Head (Melbourne, AUSTRALIA)</td>
<td></td>
<td>levels or on dipping?</td>
</tr>
<tr>
<td></td>
<td>P. Palatini (Padua, ITALY)</td>
<td></td>
<td>Should evening drug dosing be used to control nocturnal hypertension?</td>
</tr>
<tr>
<td></td>
<td>J. Redon (Valencia, SPAIN)</td>
<td></td>
<td>Morning blood pressure surge and orthostatic hypertension: different sides of</td>
</tr>
<tr>
<td></td>
<td>K. Kario (Tochigi, JAPAN)</td>
<td></td>
<td>the same coin?</td>
</tr>
<tr>
<td>20.00</td>
<td>Business Meeting</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>ESH Working Group on</th>
<th>Alexandra Trianti Hall</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.30</td>
<td>ESH Working Group on</td>
<td></td>
<td>E. Agabiti Rosei (Brescia, ITALY)</td>
</tr>
<tr>
<td></td>
<td><strong>HYPERTENSION, THROMBOSIS AND ARRHYTHMIAS</strong></td>
<td></td>
<td>A.J. Manolis (Athens, GREECE)</td>
</tr>
<tr>
<td>18.30</td>
<td>Similarities and differences of new antithrombotics</td>
<td></td>
<td>M. Salvetti (Brescia, ITALY)</td>
</tr>
<tr>
<td>19.00</td>
<td>Prevalence, incidence, and management of ventricular arrhythmias in hypertension</td>
<td></td>
<td>A. Pittaras (Athens, GREECE)</td>
</tr>
<tr>
<td>19.30</td>
<td>Antiplatelet drugs in hypertension. Which drug and for whom</td>
<td></td>
<td>B. Jelakovic (Zagreb, CROATIA)</td>
</tr>
<tr>
<td>20.00</td>
<td>General Discussion: ESH Research Project on AF and Hypertension</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ESH Working Group on ENDOCRINE HYPERTENSION

Chairpersons: P. Mulatero (Turin, ITALY)
J. Widimsky (Prague, CZECH REPUBLIC)

18.30 Renin concentration vs. renin activity for assessing the aldosterone to renin ratio in patients at risk of primary aldosteronism
A. Morganti (Milan, ITALY)

18.45 Adrenal venous sampling performance and interpretation: an update
P. Mulatero (Turin, ITALY)

19.00 Recent developments in functional imaging for pheochromocytomas and paragangliomas
L. Amar (Paris, FRANCE)

19.15 Cardiovascular consequences of catecholamine hypersecretion in PPGL
A. Januszewicz (Warsaw, POLAND)

19.30 WG FORUM
Chairperson: P.F. Plouin (Paris, France)

ESH Working Group on HYPERTENSION AND SEXUAL DYSFUNCTION

Chairperson: M. Viigimaa (Tallinn, ESTONIA)

18.30 Sexual history and counseling: listen to what the patient has to say
D. Lovic (Niš, SERBIA)

18.45 Biomarkers that gauge the risk in the ED patient
N. Ioakeimidis (Athens, GREECE)

19.00 Doctor, the drug you gave me caused ED: what should I do?
M. Doumas (Thessaloniki, GREECE)

19.15 To treat low testosterone or not?
C. Vlachopoulos (Athens, GREECE)

19.30 Business Meeting
ESH Working Group on

VASCULAR STRUCTURE AND FUNCTION

Chairpersons:
- P. Chowienzyk (London, UNITED KINGDOM)
- G. Schillaci (Perugia, ITALY)

18.30 Update on European Network
S. Laurent (Paris, FRANCE)

18.40 Update on ARTERY
L.M. Van Bortel (Ghent, BELGIUM)

Assessment of local and regional arterial stiffness

18.50 Carotid-femoral PWV – what is left to know
C. Vlachopoulos (Athens, GREECE)

19.05 Local stiffness – Insights into arterial remodeling
P. Boutouyrie (Paris, FRANCE)

19.20 Stiffness derived from pulse wave measures – theory
J. Alastruey (London, UNITED KINGDOM)

19.35 Pulse wave measures – practice
T. Weber (Wels, AUSTRIA)

19.50 Synthesis
S. Laurent (Paris, FRANCE)
**MEETING OF THE HSH FOR THE GREEK DOCTORS**

**Chairperson:** A. Tselepis (Ioannina, GREECE)

**INDUSTRY SPONSORED SATELLITE SYMPOSIUM**
Stroke prevention in non valvular atrial fibrillation: improving patients outcomes

18.30 Welcome and introduction
A. Tselepis (Ioannina, GREECE)

18.35 The perception and reality of stroke prevention in non valvular atrial fibrillation
K. Vemmos (Athens, GREECE)

18.55 Novel oral anticoagulants: evidence, clinical questions and practical insights
C. Vlachopoulos (Athens, GREECE)

19.15 Q&A panel discussion

**ESH Working Group on INTERVENTIONAL TREATMENT OF HYPERTENSION**

The "do's and the dont's" of "interventions" for the control of hypertension

**Chairpersons:** R.E. Schmieder (Erlangen, GERMANY)
C. Tsioufis (Athens, GREECE)

18.30 Stenting of renal artery stenosis
K. Dimitriadis (Athens, GREECE)

18.45 Bariatric surgery in the obese hypertensive patient
M.P. Schlaich (Melbourne, AUSTRALIA)

19.00 CPAP therapy in the hypertensive patient with obstructive sleep apnea
J. Floras (Toronto, CANADA)

19.15 Renal sympathetic denervation
F. Mahfoud (Homburg, GERMANY)

19.30 Business Meeting
**Sunday, June 15**

**07.15 – 08.55  Nikos Skalkotas Hall**

**Joint Session**
HBPRCA (High Blood Pressure Research Council of Australia) / ECCR (European Council for Cardiovascular Research)
Workshop 2

**CO-MORBIDITIES OF HYPERTENSION**

**Chairpersons:**
- J. Chin-Dusting (Melbourne, AUSTRALIA)
- T. Unger (Maastricht, NETHERLANDS)

**07.15** Obesity, diabetes and endothelial dysfunction: the role of adipokines
C. Peiro (Madrid, SPAIN)

**07.35** Role of ACE2 in cardiovascular disease
L.M. Burrell (Melbourne, AUSTRALIA)

**07.55** Pulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels
C. Wandall-Frostholm (Aarhus, DENMARK)

**08.10** Exercise hypertension: clinical relevance and mechanisms
M. Schultz (Hobart, AUSTRALIA)

**08.25** The role of depression in cardiovascular disease and hypertension
E. Bouzinova (Aarhus, DENMARK)

**08.40** In vitro culture and embryo transfer alters the regulation of blood pressure in early postnatal life
M. Padhee (Adelaide, AUSTRALIA)

---

**07.45 – 08.45  Dimitris Mitropoulos Hall**

**Breakfast Workshop**

**COGNITIVE DYSFUNCTION AND DEMENTIA**

**Chairpersons:**
- D. Lovic (Niš, SERBIA)
- J.B. Park (Seoul, SOUTH KOREA)

**07.45** Roles of activation of angiotensin II type 2 receptor in cognitive function
M. Horiuchi (Ehime, JAPAN)

**08.05** The role of antihypertensive treatment in cognitive dysfunction and dementia
A. Vicario (Buenos Aires, ARGENTINA)

**08.25** General Discussion
Breakfast Workshop

MANAGEMENT OF HYPERTENSION IN OSA

Chairpersons: J. Floras (Toronto, CANADA)
C. Thomopoulos (Athens, GREECE)

07.45  Does OSA increase the risk of hypertension?
   K. Narkiewicz (Gdansk, POLAND)

08.05  Does CPAP treatment reduce blood pressure in patients with OSA and hypertension?
   V.K. Somers (Rochester, MN, USA)

08.25  General Discussion

Breakfast Workshop

HYPERTENSION AND SEXUAL DYSFUNCTION

Chairpersons: M.H. Olsen (Glostrup, DENMARK)
M. Viigimaa (Tallinn, ESTONIA)

07.45  Prevalence and questionnaire
   M. Viigimaa (Tallinn, ESTONIA)

08.05  How drug treatment may improve both
   M. Doumas (Thessaloniki, GREECE)

08.25  General Discussion
**Parallel Oral Session 4A**

**ORGAN DAMAGE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairpersons</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>AORTIC ROOT DIAMETER AND RISK OF CARDIOVASCULAR EVENTS IN A GENERAL POPULATION: DATA FROM THE PAMELA STUDY</td>
<td>C. Cuspidi, R. Facchetti, M. Bombelli, A. Re, C. Sala, G. Seravalle, G. Grassi, G. Mancia</td>
<td>Milan, ITALY</td>
</tr>
<tr>
<td>09.10</td>
<td>ARTERIAL STIFFNESS IS A BETTER PREDICTOR OF LEFT VENTRICULAR HYPERTROPHY THAN THE FRAMINGHAM RISK SCORE AND CENTRAL HEMODYNAMICS: INSIGHTS FROM 1,141 NEVER-TREATED HYPERTENSIVES</td>
<td>P. Xaplanteris, C. Vlachopoulos, N. Ioakeimidis, P. Petrè, M. Abdelrasoul, G. Vyssoulis, C. Stefanadis</td>
<td>Athens, GREECE</td>
</tr>
<tr>
<td>09.20</td>
<td>PROGNOSTIC VALUE OF MICROALBUMINURIA DURING ANTIHYPERTENSIVE TREATMENT IN ESSENTIAL HYPERTENSION</td>
<td>J. Pascual 1,2, E. Rodilla 1, J. Costa 1, J. Martin 1, C. Gonzalez 1, M. Garcia 1, J. Redon 1,2</td>
<td>Valencia, SPAIN, Madrid, SPAIN</td>
</tr>
<tr>
<td>09.30</td>
<td>IMPAIRED DIASTOLIC PARAMETERS IN CARDIOVASCULAR REMODELING OF PSORIASIS</td>
<td>C. Gadaleta Caldarola, C. Mongiardi, A. Maresca, S. Moretti, M. Agostinì, F. Mola, A. Antelmi, A. Motolese, A. Bertolini, L. Guasti, A. Grandi</td>
<td>Varese, ITALY</td>
</tr>
<tr>
<td>09.40</td>
<td>THE EFFECT OF EPLERENONE ON CELL PROLIFERATION IN CONTRALATERAL KIDNEY OF RATS WITH UNILATERAL URETERAL OBSTRUCTION</td>
<td>C. Wang 1, X. Xu 1, X. Wang 1, X. Wang 1, R. Wang 1, L. Liang 1, Z. Wang 1, D. Sun 1, T. Shimosawa 1</td>
<td>Tokyo, JAPAN, Hebei, CHINA</td>
</tr>
<tr>
<td>09.50</td>
<td>ACCUMULATION OF DIFFERENT MICRO- AND MACROVASCULAR TARGET ORGAN DAMAGE IN HYPERTENSIVE PATIENTS. PATHOPHYSIOLOGICAL COMMON PATHWAYS AND CARDIOVASCULAR RISK ASPECTS EXPLORATION</td>
<td>A. Triantafyllou 1, E. Gavriliadou 1, P. Amyfanti 1, X. Zabulis 1, E. Giallagkousi 1, G. Triantafyllou 1, K. Petidis 1, V. Gkios 1, A. Pyprasopoulou 1, F. Dogramatzis 1, S. Aslanidis 1, S. Douma 1</td>
<td>Thessaloniki, Crete, GREECE</td>
</tr>
</tbody>
</table>

---

**Breakfast Workshop**

**HYPERTENSION AND THE KIDNEY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chairpersons</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45</td>
<td>Overview of the new CKD staging system for non-nephrologists</td>
<td>A. Abu-Alfa (Beirut, LEBANON)</td>
<td>Conference Suite II - MC3</td>
</tr>
<tr>
<td>08.05</td>
<td>Understanding KDIGO guidelines in the context of hypertension management</td>
<td>G.L. Bakris (Chicago, IL, USA)</td>
<td>Conference Suite II - MC3</td>
</tr>
<tr>
<td>08.25</td>
<td>General Discussion</td>
<td></td>
<td>Conference Suite II - MC3</td>
</tr>
</tbody>
</table>
Parallel Oral Session 4B

**OBESITY AND OBSTRUCTIVE SLEEP APNOEA**

Chairpersons: B.M. Mitchell (Temple, TX, USA) V.K. Somers (Rochester, MN, USA)

09.00 • EXERCISE CAPACITY AND MORTALITY IN HYPERTENSIVE, OBESE INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS
A. Pittaras 1, M. Doumas 2, C. Faselis 2, A.J. Manolis 1, K. Kyfnidis 1, T. Zamfir 1, E. Hamodraka 1, O. Diakoumakou 1, M. Papavasiliou 1, N. Kouremenos 1, D. Lovic 1, A. Tsimploulis 1, P. Kokkinos 1
1 Athens, GREECE, 2 Washington, DC, USA

09.10 • EFFECTS OF WEIGHT ON BLOOD PRESSURE AT REST AND DURING EXERCISE
R. Schoenenberger-Berzins 1, A. Schoenenberger 2, P. Suter 3, P. Erne 1
1 Luzern, 2 Bern, 3 Zürich, SWITZERLAND

09.20 • PROSPECTIVE STUDY OF TOTAL SLEEP DURATION AND INCIDENT METABOLIC SYNDROME: THE ARIRANG STUDY
Wonju, SOUTH KOREA

09.30 • PREVALENCE OF OBSTRUCTIVE SLEEP APNEA IN PATIENTS WITH RESISTANT HYPERTENSION REFERRED FOR RENAL SYMPATHETIC DENERVATION
T. Kara 1, M. Soucek 1, Z. Starek 1, M. Novak 1, T. Mikusova 1, M. Belehrad 1, J. Vitovec 1, P. Neuzil 2, N. Montano 3, K. Narkiewicz 4, V.K. Somers 5
1 Brno, 2 Prague, CZECH REPUBLIC, 3 Milan, ITALY, 4 Gdansk, POLAND, 5 Rochester, MN, USA

09.40 • LECTURE: RETINAL VASCULAR ALTERATIONS IN HYPERTENSION
A. Hughes
London, UNITED KINGDOM
Parallel Oral Session 4C

CORONARY HEART DISEASE AND HEART FAILURE

Chairpersons: J. Deinum (Nijmegen, NETHERLANDS) C.H. Kim (Seoul, SOUTH KOREA)

09.00 • PREDICTIVE VALUE OF CIRCULATING ENDOTHELIAL-DERIVED APOPTOTIC MICROPARTICLES IN PATIENTS WITH ISCHEMIC SYMPTOMATIC CHRONIC HEART FAILURE
A. Bereez, A. Kremzer, Y. Martovitskaya, T. Samura
Zaporozhye, UKRAINE

09.10 • ASSOCIATIONS OF TRYPTOPHAN METABOLISM WITH SYSTOLIC AND DIASTOLIC LEFT VENTRICULAR FUNCTION IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM
A. Tomaschitz 1, N. Verheyen 2, M. Gaksch 2, M. Grübler 2, J. Wetzel 2, E. Beljavskiy 2, C. Colantonio 2, E. Kraigher-Krainer 2, W. März 2, T. Grammer 2, J. Rus-Machan 1, A. Fahrleitner-Pammer 2, B. Pieske 2, S. Pilz 2
1 Bad Aussee, 2 Graz, AUSTRIA, 3 Manheim, GERMANY, 4 Amsterdam, NETHERLANDS

09.20 • THE RELATIVE CONTRIBUTION OF DIRECT DIFFERENTIATION VERSUS PARACINE EFFECT ON ADIPOSE-DERIVED STEM CELL THERAPY FOR MYOCARDIAL INFARCTION
Chongqing, CHINA

09.30 • LECTURE: TREATMENT OF HYPERTENSION IN PATIENTS WITH CORONARY ARTERY DISEASE AND HEART FAILURE
C. Rosendorff
New York, NY, USA

09.50 • NOT RESTING BUT MAXIMAL EXERCISE BLOOD PRESSURE IS AN INDEPENDENT FACTOR OF LEFT VENTRICULAR MASS IN ELITE PROFESSIONAL MALE ATHLETES
M. Zdravkovic, I. Saedi, M. Djelic, I. Nedeljkovic, M. Kolaric, M. Antic, T. Acimovic
Belgrade, SERBIA

10.00 • RISK FACTORS AND THEIR PREDICTIVE VALUE OF EVENTS IN ACUTE CORONARY SYNDROME
R. Palma Dos Reis 1, R. Rodrigues 2, A. Pereira 3, S. Gomes 2, A. Sousa 2, G. Guerra 2, E. Henriques 2, S. Borges 2, A. Pereira 2, M. Mendonca 2
1 Lisbon, 2 Funchal, PORTUGAL
10.10 • MORBIDITY AND MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE KAZAKHSTAN POPULATION IN THE LATE PERIOD AFTER RADIATION EXPOSURE  
A. Markabayeva, T. Belikhina, L. Pivina, A. Kerimkulova, B. Ashimova, A. Nurzhanova, S. Maukayeva  
Semey, KAZAKHSTAN

10.20 • RENAL DENERVATION ATTENUATES CARDIAC DIASTOLIC DYSFUNCTION THROUGH SPECIFIC RESTORATION OF SERCA2A  
D. Hirohama 1, F. Mori 1, S. Ogura 1, Y. Uetake 1, R. Jimbo 1, L. Reheman 1, C. Wang 1, Y. Yatomi 1, T. Fujita 1, M. Mardini 1, T. Shimosawa 1  
1 Tokyo, JAPAN, 2 Fayetteville, AR, USA

10.30 • ELEVATED ADMISSION SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH ACUTE CORONARY SYNDROME IS ASSOCIATED WITH FAVORABLE SHORT AND LONG TERM OUTCOMES  
E. Grossman, G. Shlomoj, E. Kopel, I. Goldenberg  
Tel-Hashomer, ISRAEL

10.40 • SIGNATURES OF RECESSIVE ALLELES AND SUSCEPTIBILITY TO CORONARY ARTERY DISEASE. GENOME - WIDE HOMOZYGOSITY ANALYSIS  
P. Christofidou 1, C. Nelson 1, M. Nikpay 1, L. Qiu 1, M. Li 1, P. Braund 1, M. Dennyff 1, R. Roberts 1, H. Schunkert 1, M. Reilly 1, J. Erdmann 1, R. McPherson 1, I. König 1, J. Thompson 1, N. Samani 1, M. Tomaszkiewski 1  
1 Leicester, UNITED KINGDOM, 2 Ontario, CANADA, 3 Philadelphia, PA, USA, 4 Lübeck, GERMANY

10.50 • LINK BETWEEN LEVEL OF CIRCULATING GALACTIN-3 AND CONCENTRATION OF PROANGIOGENIC MONONUCLEAR PROGENITOR CELLS IN CHRONIC HEART FAILURE PATIENTS  
A. Berezhn, A. Kremzer, T. Samura, Y. Martovitskaya  
Zaporozhye, UKRAINE

09.00 – 11.00 Conference Suite II – MC2

Parallel Oral Session 4D

RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM

Chairpersons:  
M.J. Brown (Cambridge, UNITED KINGDOM)  
L.M. Burrell (Melbourne, AUSTRALIA)

09.00 • CARDIOPROTECTIVE ACTION OF ALDOSTERONE RECEPTOR ANTAGONISTS: ROLE OF REDOX BALANCE  
A. Ashton 1, T. Le 1, M. Mardini 1, C. Gomez-Sanchez 1, M. Mihailidou 1  
1 Sydney, AUSTRALIA

09.10 • ACE2 INDEPENDENT PATHWAYS IN ANGIOTENSIN 1–7 FORMATION IN MICE  
O. Domenig 1, A. Manzel 2, J. Stegbauer 3, S. Gurley 4, M. Antlanger 5, J. Kovarik 5, R. Linker 5, M. Saemann 1, M. Poglitsch 1  
1 Vienna, AUSTRIA, 2 Erlangen, 3 Düsseldorf, GERMANY, 4 Durham, NC, USA

09.20 • DETERMINANTS OF PLASMA RENIN ACTIVITY. ROLE OF A HUMAN RENIN GENE VARIANT AS A GENETIC FACTOR  
T. Konoshita 1, T. Nakaya 1, K. Yamamoto 1, M. Yamada 1, M. Ichikawa 1, S. Sato 1, M. Imagawa 1, Y. Makino 1, M. Fujii 1, Y. Zenimaru 1, K. Arakawa 1, J. Suzuki 1, T. Ishizuka 1, H. Nakamura 1  
1 Fukui, 2 Kanazawa, JAPAN

09.30 • INHIBITION OF PHOSPHODIESTERASE 5 ATTENUATES ANGIOTENSIN II-DEPENDENT HYPERTENSION AND RENAL VASCULAR DYSFUNCTION IN C57BL/6 MICE  
M. Thieme 1, S. Sivritas 1, S. Potthoff 1, S. Mende 1, M. Hoffmann 1, S. Stamer 1, L. Rump 1, E. Mergia 1, J. Stegbauer 1  
1 Düsseldorf, 2 Bochum, GERMANY

09.40 • TORCETRAPIB, DALCETRAPIB, AND ANACETRAPIB INDUCE ADIPOCYTE–DERIVED ALDOSTERONE PRODUCTION THROUGH REDOX SENSITIVE MECHANISMS  
F. Biss 1, A. Nguyen Dinh Cat 1, R. Palacios 1, C. Jenkins 1, A. Carswell 1, A. Montezano 1, R.M. Touyz 1  
1 Glasgow, UNITED KINGDOM, 2 Madrid, SPAIN

09.50 • ALISKIREN REDUCES MYOCARDIAL ISCHEMIA–REPERFUSION INJURY BY A BRADYKININ B2 RECEPTOR– AND ANGIOTENSIN AT2 RECEPTOR–MEDIATED MECHANISM  
S. Koid 1, J. Ziogas 2, D. Campbell 1  
1 Fitzroy, 2 Parkville, AUSTRALIA
Parallel Oral Session

ISH AUSTIN DOYLE AWARD

Chairpersons: F.J. Charchar (Ballarat, AUSTRALIA)
S.B. Harrap (Melbourne, AUSTRALIA)

Judges: J. Chalmers (Sydney, AUSTRALIA)
S. Laurent (Paris, FRANCE)
N.R. Poulter (London, UNITED KINGDOM)
A.E. Schutte (Potchefstroom, SOUTH AFRICA)

09.00 – 11.00  Conference Suite II – MC3

09.00 • HIGHER INCIDENCE OF ARTERIAL HYPERTENSION IN SALT SENSITIVE NORMOTENSIVE OFFSPRING OF HYPERTENSIVE PARENTS. A 18 YEARS FOLLOW-UP. RESPONSE TO ANGIOTENSIN II RECEPTOR BLOCKADE
A.J. Ramirez, P. Fischer, L. Masnatta, J. Sánchez, R. Sánchez
Buenos Aires, ARGENTINA

09.10 • THE ROLE OF SOX6 TRANSCRIPTION FACTOR IN RENIN CELL FATE SPECIFICATION
J. Gomez, K. Arthikanareeswaran, V. Dzau, M. Mirotsou
Durham, NC, USA

09.20 • ASSOCIATION OF URINARY ANGIOTENSINOGEN EXCRETION WITH BLOOD PRESSURE IN A GROUP OF AFRICAN ANCESTRY
F. Michel, G. Norton, M. Maseko, M. Badenhorst, A. Woodiwick
Johannesburg, SOUTH AFRICA

09.30 • ALDOSTERONE MODULATES THE ASSOCIATION BETWEEN ASYMPTOMATIC ORGAN DAMAGE AND SODIUM INTAKE IN ESSENTIAL HYPERTENSIVES
Shanghai, CHINA

09.40 • IMPACT AND FUNCTION OF A MINERALOCORTICOID RECEPTOR NON-CODING VARIANT ON ARTERIAL STIFFNESS
M. Lenders, B. Schmitz, B. Kasprzak, S. Brand, E. Brand
Münster, GERMANY

09.50 • BENEFICIAL EFFECTS OF COMBINED ANGIOTENSIN AT2 RECEPTOR STIMULATION AND PHOSPHODIESTERASE 5 INHIBITION ON CARDIAC ANTI-REMODELLING
E. Jones, Y. Wang, R. Widdop
Melbourne, AUSTRALIA

09.00 • AMBULATORY RECORDING OF WAVE REFLECTIONS AND ARTERIAL STIFFNESS DURING INTRA– AND INTERDIALYTIC PERIODS IN END-STAGE RENAL DISEASE PATIENTS UNDER HEMODIALYSIS
P. Georgiannos 1, P. Sarafidis 1, A. Karpetas 1, G. Koutroumpas 2, V. Sgouropoulou 1, G. Tzanis 1, K. Raptopoulou 1, A. Protogerou 1, V. Liakopoulos 1, P. Zebekakis 1, A. Lazaridis 1
1 Thessaloniki, 2 Volos, 3 Athens, GREECE

09.10 • REFERENCE INTERVALS FOR LOCAL ARTERIAL STIFFNESS: THE CAROTID ARTERY
L. Engelen 1, J. Bossuyt 2, I. Ferreira 1, L.M. Van Bortel 2, C. Stehouwer 1, K. Reesink 1, P. Segers 1, S. Laurent 1, P. Boutouyrie 1
1 Maastricht, NETHERLANDS, 2 Ghent, BELGIUM, 3 Paris, FRANCE

09.20 • ENDOSTATIN– A NOVEL MARKER FOR HYPERTENSIVE TARGET ORGAN DAMAGE?
A. Carlsson 1, T. Ruge 2, J. Ärnlöv 1
1 Uppsala, 2 Umeå, SWEDEN

09.30 • ANGIOTENSIN II TYPE2 RECEPTOR ACTIVATION PLAYS A ROLE IN BINGE EATING DISORDER
H. Nakaoka, M. Mogi, H. Kan-No, K. Tsukuda, K. Ohshima, T. Chisaka, X. Wang, H. Bai, L. Min, J. Iwanami, M. Horiuichi
Tohoku, JAPAN

09.40 • DOES RENAL DENERVATION AFFECT NEURO-HORMONAL AND HEMODYNAMIC RESPONSE TO ORTHOSTATIC STRESS IN PATIENTS WITH RESISTANT HYPERTENSION?
Y. Vuignier, N. Vakilzadeh, O. Muller, E. Grouzmann, M. Maillard, S. Qanadli, M. Burnier, G. Wuerzner
Lausanne, SWITZERLAND
09.50 • RENAL EXPRESSION AND CIRCULATING LEVELS OF MICRORN A MIR-181A IN REGULATION OF RENIN AND BLOOD PRESSURE
F. Marques 1, 2, M. Denniff 3, J. Garrelds 1, C. Nelson 1, L. Wojnar 1, K. Musialik 1, N. Samani 1, P. Bogdanski 1, E. Zukowska-Szczechowska 1, A.H.J. Danser 1, F.J. Charchar 1, M. Tomaszewski 1
1 Ballarat, AUSTRALIA; 2 Leicester, UNITED KINGDOM; 3 Poznan, Zabrze, POLAND

10.00 • SHORTER STATURE AND HIGH PREVALENCE OF LOW BMD AND FRACTURES AMONG HYPERTENSIVES SUGGEST A FORM OF ACCELERATED AGING
R. El Bikai 1, J. Tremblay 1, R. Tahir 1, M. Johfres 1, O. Seda 1, L. Sedova 1, P. Awadalla 1, C. Laberge 3, B. Knoppers 1, P. Duimun 1, D. Gaudet 1, L. Ste-Marie 1, P. Hamet 1
1 Montreal, 2 British Columbia, 3 Ste-Foy, CANADA

10.10 • THE PROGNOSTIC ROLE OF NON-DIPPING BLOOD PRESSURE PROFILE IN SLEEP APNEA PATIENTS
L. Korostovtseva, Y. Sviryaev, N. Zvartau, O. Rotar, A.O. Konradi, E. Shlyakhto
Saint-Petersburg, RUSSIA

10.20 • N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE, BLOOD PRESSURE AND COGNITIVE DECLINE IN THE OLDEST OLD: THE LEIDEN 85-PLUS STUDY
P. Van Vliet, R. Sabayan, L. Wijsman, R. Poortvliet, S. Mooijaart, W. De Ruijter, J. Gussekloo, A. De Craen, R. Westendorp
Leiden, NETHERLANDS

10.30 • DIETARY NITRATE TO REDUCE BLOOD PRESSURE IN HYPERTENSIVE PATIENTS (DINA-HTN): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
V. Kapil, R. Khambata, M.J. Caulfield, A. Ahluwalia
London, UNITED KINGDOM

10.40 • EFFECTS OF BLOOD PRESSURE LOWERING TREATMENT WITH CANDESARTAN IN ACUTE STROKE ON VASCULAR EVENTS DURING LONG-TERM FOLLOW-UP
A. Hornslien 1, J. Iglind 1, E. Sandset 1, A. Terent 1, G. Boysen 1, E. Berge 1
1 Oslo, 2 Bergen, NORWAY; 3 Uppsala, SWEDEN; 4 Copenhagen, DENMARK

Topical Workshop

THE ROLE OF HYPERTENSION SPECIALIST AROUND THE WORLD

Chairpersons:
E. Agabiti Rosei (Brescia, ITALY)
R. Sánchez (Buenos Aires, ARGENTINA)

09.30 ESH
B. Jelakovic (Zagreb, CROATIA)

09.50 ISH
R. Sánchez (Buenos Aires, ARGENTINA)

10.10 ASH
D.A. Sica (Richmond, VA, USA)

10.30 General Discussion
Joint Session
ESH (European Society of Hypertension) / ISH (International Society of Hypertension) / ISVH (International Society of Vascular Health and Aging)

NEW APPROACHES FOR ASSESSING ARTERIAL AGING

Chairpersons: A. Avolio (Sydney, AUSTRALIA)
G. Mancia (Milan, ITALY)

09.30 New opportunities for the evaluation of arterial stiffness
K. Shirai (Sakurashi, JAPAN)

09.50 Central and peripheral hemodynamics in cardiovascular prognosis
C. Vlachopoulos (Athens, GREECE)

10.10 Contribution of arterial stiffness in age-related diseases in the elderly
A. Benetos (Nancy, FRANCE)

10.30 Therapeutic approaches of arterial stiffness
R. Asmar (Paris, FRANCE)

10.50 General Discussion

Parallel Oral Session 5A
BLOOD PRESSURE MEASUREMENT

Chairpersons: D. Czarnecka (Kraków, POLAND)
M.G. Myers (Toronto, CANADA)

11.00 • RELATIONSHIP BETWEEN CARDIO-ANKLE VASCULAR STIFFNESS INDEX (CAVI) AND 24H BLOOD PRESSURE PARAMETERS IN HYPERTENSIVE PATIENTS
B. Cuko, I. Lonati, G. Bilo, F. Negri, A. Giglio, G. Caldara, S. Salerno, G. Parati
Milan, ITALY

11.10 • THE INTER-ARM DIFFERENCE IN BLOOD PRESSURE: PREVALENCE VARIES FOR DIFFERENT POPULATIONS
C. Clark, A. Shore, R. Taylor, J. Campbell
Exeter, UNITED KINGDOM

11.20 • EFFECTIVENESS OF A SUPPORT PROGRAM DESIGNED TO SENSITIZE AND ASSIST HYPERTENSIVE PATIENTS TO DECREASE THEIR SALT CONSUMPTION
S. Jain
Vancouver, CANADA

11.30 • PROGNOSTIC IMPACT OF A GENDER-AMBULATORY BLOOD PRESSURE INTERACTION IN 10 COHORTS OF 17,312 PATIENTS DIAGNOSED WITH HYPERTENSION. SYSTEMATIC REVIEW AND META-ANALYSIS
Terrassa, SPAIN

11.40 • DIURNAL VARIATION OF CENTRAL BLOOD PRESSURE IN ADOLESCENTS AND YOUNG ADULTS: A PILOT STUDY
A. Ntineri, A. Kollias, A. Vazeou, A. Achimastos, G.S. Stergiou
Athens, GREECE

11.50 • EFFECTS OF SMOKING ON CENTRAL BLOOD PRESSURE AND PRESSURE AMPLIFICATION IN HYPERTENSION OF THE YOUNG
F. Saladini 1, E. Benetti 1, C. Fania 1, L. Mos 2, A. Mazzer 3, A. Bortolazzi 4, E. Casiglia 1, P. Palatini 1
1 Padua 2 San Daniele del Friuli, 3 Vittorio Veneto, 4 Rovigo, ITALY
Industry Sponsored Minisymposium*

BREAKING NEW GROUND IN FIRST LINE MANAGEMENT OF HYPERTENSION

Chairpersons:  
G. Mancia (Milan, ITALY)  
A.J. Manolis (Athens, GREECE)

11.00  Introduction  
G. Mancia (Milan, ITALY)

11.03  Optimizing strategy to control more patients faster  
S. Laurent (Paris, FRANCE)

11.21  Overcoming pharmacological challenges  
R. Ferrari (Ferrara, ITALY)

11.39  From concept to clinical evidence  
V. Papademetriou (Washington, DC, USA)

11.57  Conclusion  
A.J. Manolis (Athens, GREECE)

12.00 • DEBATE:  
A CLINICAL ROLE FOR CENTRAL BP?

- YES  
J.K. Cruickshank  
London, UNITED KINGDOM

- NO  
G.F. Mitchell  
Waltham, MA, USA

*please see page: 22
Parallel Oral Session 5B

COMBINATION TREATMENT AND ADHERENCE THERAPY

Chairpersons: S. Erdine (Istanbul, TURKEY)
R. Hernandez-Hernandez (Barquisimeto, VENEZUELA)

11.00 • PREVENTION OF CORONARY AND STROKE EVENTS WITH PERINDOPRIL, AMLODIPINE AND ATORVASTATIN IN COMBINATION: SUB-GROUP ANALYSIS OF THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT)
S. Watsoo, A. Gupta, N.R. Poulter
London, UNITED KINGDOM

11.10 • THE INFLUENCE OF ELECTRONIC VERSION OF SCORE ON THE TREATMENT ADHERENCE IN HYPERTENSIVE PATIENTS
D. Nebieridze, A. Safarian, A. Saricheva
Moscow, RUSSIA

11.20 • COMBINATION THERAPY WITH LERCANIDIPINE AND ENALAPRIL IMPROVES WAVE REFLECTION IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME
Pisa, ITALY

11.30 • HIGH RATES OF NON-ADHERENCE TO ANTIHYPERTENSIVE TREATMENT DEMONSTRATED BY MASS SPECTROMETRY URINALYSIS: THE NEGATIVE CORRELATION BETWEEN THE NUMBER OF DRUGS PRESCRIBED AND THE NUMBER TAKEN
Leicester, UNITED KINGDOM

11.40 • THE ASSESSMENT OF SERUM ANTIHYPERTENSIVE DRUG LEVELS TO EVALUATE ADHERENCE TO TREATMENT IN PATIENTS WITH RESISTANT HYPERTENSION
E. Florczak, K. Mala, B. Tokarczyk, E. Waroch-Celinska, E. Szwener-Pietrasz, A. Preibisz, M. Kabat, K. Narkiewicz, A. Januszewicz
1 Warsaw, 2 Kraków, 3 Gdańsk, POLAND

11.50 • IMPROVEMENT IN BP CONTROL IN HYPERTENSIVE PARTICIPANTS WHO WERE SWITCHED TO NIFEDIPINE GITS/CANDESARTAN CILEXETIL FROM PREVIOUS MONOTHERAPY OR COMBINATION ANTIHYPERTENSIVE THERAPY
S. Kjeldsen 1, D.A. Sica 2, G. Cha 3, B. Gil-Extremera 4, P. Harvey 5, F. Heyvaert 6, A. Lewin 6, G. Villa 7, G. Mancia 10
1 Oslo, NORWAY, 2 Richmond, VA, USA, 3 Hannover, GERMANY, 4 Dallas, TX, USA, 5 Granada, SPAIN,
6 Addlestone, UNITED KINGDOM, 7 Antwerp, BELGIUM, 8 Los Angeles, CA, USA, 9 Pavia, 10 Milan, ITALY

12.00 • ADHERENCE TO TREATMENT AND ASSOCIATED FACTORS IN UNCONTROLLED HYPERTENSIVE ADULT MALE AND FEMALE PATIENTS: A FRENCH STUDY
G. Reach 1, D. Guedi-Meynier 1, A. Tabellion 3, B. Darné 4, D. Herpin 5
1 Bobigny, 2 Paris, 3 Rungis, 4 Maisons Laffitte, 5 Poitiers, FRANCE

12.10 • LECTURE: ADHERENCE AND CARDIOVASCULAR RISK: REAL LIFE DATA
G. Mancia
Milan, ITALY
Industry Sponsored Minisymposium*

MOVING FORWARD IN RENAL DENERVATION AND SETTING NEW HORIZONS

Chairperson: M.J. Caulfield (London, UNITED KINGDOM)

11.00 Introduction and objectives
M.J. Caulfield (London, UNITED KINGDOM)

11.05 The foundation for renal denervation and pre-clinical data for this emerging therapy
F. Mahfoud (Homburg, GERMANY)

11.15 Advancing the practice of medicine through evidence–based approach: an analysis of the HTN–3 clinical results and the EnlightHTN clinical program
M. Lobo (London, UNITED KINGDOM)

11.30 EnlightHTN next generation renal denervation system – renal denervation technology that can improve clinical outcomes
C. Tsiloufs (Athens, GREECE)

11.45 A practical guide to building a multi–disciplinary, clinically rigorous effort to establish the promising therapy of renal denervation
V. Papademetriou (Washington, DC, USA)

11.55 Conclusion and next steps
M.J. Caulfield (London, UNITED KINGDOM)

*please see page: 22

Parallel Oral Session 5C

ATHEROSCLEROSIS

Chairpersons: P. Aranda (Málaga, SPAIN)
K. Shimamoto (Sapporo, JAPAN)

11.00 • LECTURE:
GLOBAL RISK AND THE HYPERTENSIVE PATIENT
F.H. Messerli
New York, NY, USA

11.20 • DIRECT AT2R STIMULATION PREVENTS ENDOTHELIAL INFLAMMATION AND LEUKOCYTE ADHESION AND IMPROVES PLAQUE STABILITY
A. Sampson 1, J. Irvine 1, W. Shihata 1, N. Lumsden 1, D. Huet 1, U. Steckelings 2, R. Widdop 3, J. Chin-Dusting 1
1 Melbourne, AUSTRALIA, 2 Odense, DENMARK, 3 Clayton, AUSTRALIA

11.30 • THE MAGNITUDE, BUT NOT THE TIME COURSE, OF THE FLOW–MEDIATED DILATATION AT BRACHIAL ARTERY WAS ASSOCIATED WITH CAROTID INTIMA–MEDIA THICKNESS
L. Zhang, F. Li, F. Wei, T. Xu, J. Wang, Y. Li
Shanghai, CHINA

11.40 • PREDICTORS FOR THE DEVELOPMENT OF MICROALBUMINURIA AND INTERACTION WITH RENAL FUNCTION
C. Chatziyiorkou 1, J. Izzo 1, J. Menne 2, G. Viberti 3, T. Rabelink 4, E. Ritz 5, L.M. Ruilope 5, L. Rump 7, H. Haller 1
1 Hannover, GERMANY, 2 Buffalo, NY, USA, 3 London, UNITED KINGDOM, * Leiden, NETHERLANDS, 4 Leiden, NETHERLANDS, 5 Madrid, SPAIN, 7 Düsseldorf, GERMANY

11.50 • SIGNIFICANT RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND RETINAL ARTERIOLES ABNORMALITY IN PATIENTS WITH ATHEROSCLEROTIC DISEASE
J. Iwaseki 1, S. Sakuragi 2, K. Enkoh 1, T. Takamura 1, H. Kobayashi 1
1 Onomichi, 2 Iwakuni, JAPAN

12.00 • HIGH INTRALUMINAL PRESSURE PROMOTES VASCULAR INFLAMMATION AND ATHEROSCLEROTIC PLAQUE INSTABILITY VIA A CAVEOLAE–DEPENDENT MECHANISM
J. Chin-Dusting 1, D. Michell 1, K. Andrews 1, A. Sampson 1, K. Woolard 2, N. Lumsden 1, D. Huet 1, X. Moore 1, K. Jackson 1, M. Parat 5, G.A. Head 1, R. Parton 1
1 Melbourne, AUSTRALIA, 2 London, UNITED KINGDOM, 1 Brisbane, AUSTRALIA
Parallel Oral Session 5D

ENDOTHELIUM AND MICROCIRCULATION

Chairpersons: A. Nassrallah (Beirut, LEBANON) A.J. Ramirez (Buenos Aires, ARGENTINA)

11.00 • RETINAL MICROPERFUSION ONE YEAR AFTER RENAL ARTERY DENERVATION IN TREATMENT RESISTANT HYPERTENSIVE PATIENTS
B. E. Schmieder 1, C. Ott 1, M. Uder 1, A. Schmid 1, A. Jumar 1, G. Michelson 1, J. Harazny 1
1 Erlangen, GERMANY, 2 Olsztyn, POLAND

11.10 • DELETION OF OSTEOGLYCIN GENE PROMOTES ISCHEMIA-INDUCED BLOOD FLOW RECOVERY VIA MODULATING REDOX BALANCE
Q. Wu, X. Liu, P. Gao, Y. Ma
Shanghai, CHINA

11.20 • INTEGRIN-MEDIATED ADHESION IN ACUTE MYOCARDIAL INFARCTION PATIENTS
C. Bueno-Beti 1, D. Perez-Cremades 1, A. Mompeon 1, X. Vidal-Gomez 1, M. Heras 2, J. Sanchis 1, C. Hermenegildo 1, S. Novella 1
1 Valencia, 2 Barcelona, SPAIN

11.30 • ASSOCIATIONS BETWEEN THE RETINAL MICROCIRCULATION AND 24-HOUR AMBULATORY PULSE WAVE VELOCITY: A PILOT STUDY IN HYPERTENSIVE AND NORMOTENSIVE INDIVIDUALS
E. Aissopou, A. Argyris, M. Papathanassiou, E. Nasothimiou, G. Konstantonis, K. Tampakis, N. Tentolouris, T. Papaioannou, P. Skiakis, A. Protogerou
Athens, GREECE

11.40 • RETINAL ARTERIOAL REMODELING AS ASSESSED BY ADAPTATIVE OPTICS IS LINKED TO LEFT VENTRICLE REMODELING IN HYPERTENSION
D. Rosenbaum, E. Koch, N. Kachenoura, A. Redheuil, P. Cluzel, M. Paques, X. Girerd
Paris, FRANCE

11.50 • RETINAL ARTERIOAL INJURY BY SALT INTAKE CAUSES "SALT MEMORY"
Tokyo, JAPAN
Joint Session
ESH (European Society of Hypertension) / ASH (American Society of Hypertension)

TREATMENT OF RESISTANT HYPERTENSION

Chairpersons:  
G. Parati (Milan, ITALY)  
D.A. Sica (Richmond, VA, USA)

11.00  
Use of spironolactone from the 80’s until now  
D.A. Sica (Richmond, VA, USA)

11.20  
Treatment of resistant hypertension  
S.E. Kjeldsen (Oslo, NORWAY)

11.40  
Ambulatory blood pressure monitoring from the perspective of ESH/ESC guidelines  
G. Parati (Milan, ITALY)

12.00  
General Discussion

11.00 – 12.30 Conference Suite II – MC3

12.00  
ASSOCIATION OF ENDOTHELIAL DYSFUNCTION WITH MICRO- AND MACRO-VASCULAR ALTERATIONS IN ESSENTIAL HYPERTENSION  
E. Gavrilaki 1, E. Gkaliagkousi 1, A. Triantafyllou 1, B. Nikolaidou 1, F. Chatzopoulou 1, P. Anyfanti 1, X. Zabulis 1, S. Douma 1  
1 Thessaloniki, 2 Heraklion, GREECE

12.10  
CYCLOOXYGENASE-2-DERIVED PROSTANOIDS CONTRIBUTES TO ENDOTHELIAL DYSFUNCTION IN SMALL VESSELS FROM PATIENTS WITH PHEOCHROMOCYTOMA  
Pisa, ITALY

12.20  
EFFECT OF COMBINATION OF TELMISARTAN AND ATORVASTATIN ON ANGIogenic RESPONSIVENESS IN CORONARY ENDOTHELIAL CELLS OF ISCHEMIA REPERFUSED RAT HEART  
K. Chaudagar 1, A. Mehta 2, N. Tribulova 1  
1 Bratislava, SLOVAK REPUBLIC, 2 Ahmedabad, INDIA
Teaching Seminar - Session 2

**MANAGEMENT OF HYPERTENSION**

**Chairpersons:**
- T.O. Morgan (Melbourne, AUSTRALIA)
- G. Parati (Milan, ITALY)

**12.45** A difficult clinical case with resistant hypertension: how to manage?
S. Erdine (Istanbul, TURKEY)

**13.00** How to look for secondary hypertension in children?
E. Lurbe (Valencia, SPAIN)

**13.15** What is the actual goal pressure in treated hypertension?
P.M. Nilsson (Malmö, SWEDEN)

**13.30** Dementia and hypertension
A. Coca (Barcelona, SPAIN)

**13.45** General Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
<th>Posters From</th>
<th>Chairperson</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 15.30</td>
<td>Attended Poster Sessions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PS 16.</td>
<td>CARDIOVASCULAR RISK FACTORS</td>
<td>1</td>
<td>1 to 42</td>
<td>V. Tikhonoff (London, UNITED KINGDOM)</td>
</tr>
<tr>
<td>PS 17.</td>
<td>BLOOD PRESSURE MEASUREMENT</td>
<td>2</td>
<td>1 to 44</td>
<td>G. Norton (Johannesburg, SOUTH AFRICA)</td>
</tr>
<tr>
<td>PS 18.</td>
<td>OBESITY</td>
<td>3</td>
<td>1 to 44</td>
<td>J. Al-Said (Manama, BAHRAIN)</td>
</tr>
<tr>
<td>PS 19.</td>
<td>THERAPEUTIC ASPECTS</td>
<td>4</td>
<td>1 to 51</td>
<td>C. Delles (Glasgow, UNITED KINGDOM)</td>
</tr>
<tr>
<td>PS 20.</td>
<td>CHILDREN AND ADOLESCENTS – PREGNANCY</td>
<td>5</td>
<td>1 to 50</td>
<td>V. Katsi (Athens, GREECE)</td>
</tr>
<tr>
<td>PS 21.</td>
<td>BLOOD PRESSURE VARIABILITY</td>
<td>6</td>
<td>1 to 52</td>
<td>A.J. Ramirez (Buenos Aires, ARGENTINA)</td>
</tr>
<tr>
<td>PS 22.</td>
<td>CORONARY HEART DISEASE</td>
<td>7</td>
<td>1 to 37</td>
<td>K. Dimitriadis (Athens, GREECE)</td>
</tr>
<tr>
<td>PS 23.</td>
<td>CLINICAL TRIALS – GUIDELINES</td>
<td>8</td>
<td>1 to 43</td>
<td>C. Sierra (Barcelona, SPAIN)</td>
</tr>
<tr>
<td>PS 24.</td>
<td>HAEMODYNAMICS</td>
<td>9</td>
<td>1 to 27</td>
<td>T. Iliopoulos (Athens, GREECE)</td>
</tr>
<tr>
<td>PS 25.</td>
<td>EPIDEMIOLOGY</td>
<td>10</td>
<td>1 to 41</td>
<td>B. Jelakovic (Zagreb, CROATIA)</td>
</tr>
<tr>
<td>PS 26.</td>
<td>EXPERIMENTAL PHARMACOLOGY</td>
<td>11</td>
<td>1 to 20</td>
<td>A. Nishiyama (Kagawa, JAPAN)</td>
</tr>
<tr>
<td>PS 27.</td>
<td>DIABETES</td>
<td>12</td>
<td>1 to 39</td>
<td>K. Shimamoto (Sapporo, JAPAN)</td>
</tr>
<tr>
<td>PS 28.</td>
<td>IMAGING MODALITIES – NEW THERAPEUTIC DEVELOPMENTS</td>
<td>13</td>
<td>1 to 23</td>
<td>E. Pisimisis (Athens, GREECE)</td>
</tr>
<tr>
<td>PS 29.</td>
<td>RESISTANT HYPERTENSION</td>
<td>14</td>
<td>1 to 37</td>
<td>G. Salles (Rio de Janeiro, BRAZIL)</td>
</tr>
<tr>
<td>PS 30.</td>
<td>GENETICS, GENOMICS, PROTEOMICS, METABOLOMICS</td>
<td>15</td>
<td>1 to 38</td>
<td>D. Lovic (Niš, SERBIA)</td>
</tr>
<tr>
<td>PS 31.</td>
<td>LATE-BREAKER POSTERS’ SESSION 2</td>
<td>16</td>
<td>1 to 37</td>
<td></td>
</tr>
</tbody>
</table>
**Industry Sponsored Minisymposium**

**FILLING A GAP IN THE MANAGEMENT OF SYSTOLIC HYPERTENSION**

*please see page: 22*

**Meet-The-Expert Session**

**HOW TO READ A SCIENTIFIC PAPER**

**The Expert:** P. Sleight (Oxford, UNITED KINGDOM)
Sunday 15

Topical Workshop

THE POLYPILL IN THE ESH–ESC GUIDELINES AND THE CLINICAL PRACTICE IN EUROPE

Chairpersons: A. Coca (Barcelona, SPAIN)
              A.J. Manolis (Athens, GREECE)

14.30  Adherence to antihypertensive treatment, morbidity and mortality
       J. Redon (Valencia, SPAIN)

14.40  Role of the polypill in the 2013 ESH–ESC Guidelines
       G. Mancia (Milan, ITALY)

14.50  General Discussion

Clinical Case

SESSION 2

14.30   An adolescent with systolic hypertension
        R. Cifková (Prague, CZECH REPUBLIC)

15.00   Familial hypertension in a 14–year old boy
        E. Lurbe (Valencia, SPAIN)

14.30 – 15.30 Dimitris Mitropoulos Hall

14.30 – 15.30 Nikos Skalkotas Hall
Industry Sponsored How-To Session*

LONG TERM BLOOD PRESSURE MEASUREMENT: IS RIVA-ROCCI STILL ACCEPTABLE? A NEW METHOD FOR CONTINUOUS, UNDISTURBED BLOOD PRESSURE MEASUREMENT (BEAT-TO-BEAT)

14.30 Blood Pressure measurement during sleep. Problems and perspectives
G. Parati (Milan, ITALY)

14.45 Continuous nocturnal blood pressure measurement using the Pulse Transit Time (PTT):
- Why to measure by PTT instead of RR?
- How valid is this method?
- Nocturnal blood pressure behaviour on patients with disturbed sleep
G. Küchler (Randersacker, GERMANY)

15.00 Validation according to ESH International Protocol of SOMNOtouch NIBP, a device for non-invasive continuous blood pressure monitoring
G. Bilo (Milan, ITALY)

15.15 Hands on training with the smallest continuous blood pressure recorder and cardio-vascular screener, SOMNOtouch NIBP
G. Küchler (Randersacker, GERMANY)

*please see page: 23
Parallel Oral Session 6A

RENNER NURANCE: AN OPTION FOR TREATMENT OF RESISTANT HYPERTENSION

Chairpersons: S. Julius (Ann Arbor, MI, USA)
C. Tsoutsis (Athens, GREECE)

Panelists: S.E. Kjelesen (Oslo, NORWAY)
V. Papademetriou (Washington, DC, USA)

15.30 – 17.00 Christos Lambrakis Hall

Topical Workshop

RENAL DENERVATION: AN OPTION FOR TREATMENT OF RESISTANT HYPERTENSION

Chairpersons: S. Julius (Ann Arbor, MI, USA)
C. Tsoutsis (Athens, GREECE)

Panelists: S.E. Kjelesen (Oslo, NORWAY)
V. Papademetriou (Washington, DC, USA)

15.30 – 17.00 Alexandra Trianti Hall

Parallel Oral Session 6A

PREGNANCY, CHILDREN AND ADOLESCENTS

Chairpersons: S. Filipova (Bratislava, SLOVAK REPUBLIC)
N. Martell-Claros (Madrid, SPAIN)

15.30 • ARTERIAL STIFFNESS IS INCREASED IN YOUNG SUBJECTS WITH MASKED CENTRAL HYPERTENSION
S. Totaro 1, P. Khoury 2, T. Kimball 2, L. Dolan 2, E. Urbina 2
1 Turin, ITALY, *Cincinnati, OH, USA

15.40 • ASSOCIATIONS OF BIRTH WEIGHT AND POSTNATAL WEIGHT GAIN WITH CARDIOMETABOLIC RISK PARAMETERS AT FIVE YEARS OF AGE
E. Lurbe 1,2, C. García-Vicent 1, M. Torró 1,2, F. Aguilar 1,2, J. Alvarez 1,2, J. Redon 1,2
1 Valencia, 2 Madrid, SPAIN

15.50 • CARDIOVASCULAR EVENTS IN WOMEN WITH A HISTORY OF PRE-ECLAMPSIA IN THE GENERATION SCOTLAND: SCOTTISH FAMILY HEALTH STUDY
D. Carty 1, C. Brown 1, S. Robinson 1, M. Schneider 1, S. Kerr 2, P. Linksted 2, A. Campbell 2, A.F. Dominiczak 1, S. Padmanabhan 1, C. Delles 1, Generation Scotland 3
1 Glasgow, 2 Edinburgh, 3 Aberdeen, Dundee, Edinburgh and Glasgow, UNITED KINGDOM

16.00 • CREATININE AND URIC ACID LEVELS DURING PREGNANCY PREDICT LONG TERM ATHEROSCLEROTIC MORBIDITY DURING NON-PREGNANT LIFE
T. Wolak, I. Shoham-Vardi, R. Sergienko, Y. Henkin, E. Paran, E. Sheiner
Beer Sheva, ISRAEL

16.10 • PULSE WAVE AMPLIFICATION AND VELOCITY ACROSS BLOOD PRESSURE CATEGORIES IN YOUTHS
M. Torró 1,2, J. Alvarez 1,2, C. García-Vicent 1, F. Aguilar 1,2, J. Redon 1,2, E. Lurbe 1,2
1 Valencia, 2 Madrid, SPAIN

16.20 • ROLE OF AMBULATORY BLOOD PRESSURE MONITORING IN LONG-TERM FOLLOW-UP OF GESTATIONAL HYPERTENSION
V. Gesi 1, A. Maresca, C. Mongiardi, L. Merletti, F. Annovi, V. Vaccirca, C. Gadaleta, L. Robustelli Test, V. Ferrari, E. Ferrario, P. Messina, A. Grandi
Varese, ITALY
15.30 • CORRELATION BETWEEN PLACENTAL GROWTH FACTOR AND URINARY TETRAHYDROALDOSTERONE EXCRETION IN EARLY PREGNANCY
G. Currie 1, N. Eisele 1, H. Small 1, G. Escher 2, C. Gennari-Moser 1, D. Carty 1, M. Mohaupt 1, C. Delles 1
1 Glasgow, UNITED KINGDOM, 2 Bern, SWITZERLAND

16.40 • LECTURE:
PRE-ECLAMPSIA AND CARDIOVASCULAR DISEASE
E.M. George
Jackson, MS, USA

15.30 – 17.00 Banqueting Hall

Industry Sponsored Educational Session*

WHAT’S THE ROLE OF HYPERURICEMIA IN PATIENTS’ CV RISK PROFILE?

Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM) A.J. Manolis (Athens, GREECE)

15.30 Introduction
A.J. Manolis (Athens, GREECE)

15.35 The impact of urate levels on CV risk
C. Borghi (Bologna, ITALY)

15.55 Urate Lowering Drugs: just a matter of gout attacks?
T. Bardin (Paris, FRANCE)

16.15 Renoprotective effects of hyperuricemia treatment
J. Kielstein (Hannover, GERMANY)

16.35 Targeting Serum Urate levels: do we have a Consensus?
G. Mancia (Milan, ITALY)

16.50 Discussion

*please see page: 23
15.30 – 17.00 Nikos Skalkotas Hall

Parallel Oral Session 6B

**EPIDEMIOLOGY**

**Chairpersons:**
- A. Lasaridis (Thessaloniki, GREECE)
- A.E. Schutte (Potchefstroom, SOUTH AFRICA)

---

**16.30 • DEVELOPMENT AND VALIDATION OF PREDICTION MODEL FOR INCIDENT HYPERTENSION IN KOREAN POPULATION**

N. Lim 1, M. Cho 1, H. Park 1
1 Chungcheongbuk-Do, 2 Cheongju, SOUTH KOREA

**16.40 • CLINIC AND AMBULATORY HYPERTENSION AMONG HIGH ALTITUDE DWELLERS. HIGHCARE-ANDES HIGHLANDERS STUDY**

G. Bilo 1, F. Villafuerte 2, C. Anza-Ramirez 2, J. Macarlupu 2, G. Vizcardo-Galindo 2, M. Revera 1, A. Giuliano 1, A. Faini 1, S. Caravita 1, F. Gregorini 1, G. Parati 1
1 Milan, ITALY, 2 Lima, PERU

**16.50 • INFLAMMATORY MARKER AND RISK OF INCIDENT HYPERTENSION, DIABETES AND METABOLIC SYNDROME IN 96,622 EAST ASIANS**

K. Sung, S. Ryu
Seoul, SOUTH KOREA

---

**15.30 • LECTURE:**

**CARDIOVASCULAR DISEASE IN EASTERN EUROPEAN COUNTRIES**

I. Chazova
Moscow, RUSSIA

**15.50 • ENDOTHELIAL DYSFUNCTION PLAYS A KEY ROLE IN INCREASING CARDIOVASCULAR EVENT RISK IN TYPE 2 DIABETES, IMPAIRED GLUCOSE METABOLISM AND THE INSULIN RESISTANT STATE. THE HOORN STUDY**

T. Van Sloten 1, R. Henry 1, J. Dekker 1, G. Nijpels 1, M. Schram 1, C. Stehouwer 1
1 Maastricht, 2 Amsterdam, NETHERLANDS

**16.00 • LONG-TERM STROKE RISK IN THE GENERAL POPULATION DUE TO TRUE AND PARTIAL WHITE-COAT HYPERTENSION BASED ON HOME AND AMBULATORY BLOOD PRESSURE MEASUREMENTS**

M. Satoh 1, M. Kikuya 1, M. Hosaka 1, K. Asayama 1, R. Inoue 1, H. Metoki 1, M. Utsugi 1, T. Obara 1, T. Hirose 1, A. Hara 1, K. Totsune 1, H. Hoshi 1, N. Mano 1, Y. Imai 1, T. Ohkubo 1
1 Sendai, JAPAN, 2 Leuven, BELGIUM, 3 Tokyo, JAPAN, 4 Paris, FRANCE, 5 Iwate, JAPAN

**16.10 • ANALYSIS OF SOME RECENT DATA THAT COULD EXPLAIN THE REDUCTION OF STROKE MORTALITY IN PORTUGAL DURING THE 2003–2011 INTERVAL**

J. Polonia, L. Martins
Porto, PORTUGAL

**16.20 • ETHNIC DIFFERENCES IN SYSTOLIC BLOOD PRESSURE IN EUROPE: A SYSTEMATIC REVIEW AND META-ANALYSIS**

P.A. Modesti 1, C. Ayemang 1, F. Cappuccio 1, E. Perruolo 1, G. Remuzzi 1, G. Parati 1, G. Reboldi 1, on behalf of ESH WG on CVR in LRS 1
1 Florence, ITALY, 2 Amsterdam, NETHERLANDS, 3 Coventry, UNITED KINGDOM, 4 Bergamo, 5 Milan, 6 Perugia, ITALY, 7 EUROPEAN UNION
Parallel Oral Session 6C

NEURAL AND REFLEX MECHANISMS

Chairpersons:  P.W. de Leeuw (Maastricht, NETHERLANDS)
               G. Grassi (Milan, ITALY)

15.30 • PVN G-ALPHA I2 PROTEIN-MEDIATED RENAL NERVE DEPENDENT REGULATION OF NOREPINEPHRINE SECRETION AND NCC ACTIVITY: IMPLICATIONS FOR SALT-SENSITIVE HYPERTENSION
   R. Wainford, S. Mahne, J. Kuwabara
   Boston, MA, USA

15.40 • AMBULATORY BLOOD PRESSURE VARIABILITY PREDICTS OUTCOME AFTER RENAL DENERVATION
   Paris, FRANCE

15.50 • LOW-INTENSITY AEROBIC TRAINING AVOIDS AGE-RELATED LOSS OF CARDIAC VAGAL PREGANGLIONIC NEURONS IN SPONTANEOUSLY HYPERTENSIVE RATS
   A. Ruggeri, C. Santos, R. Pinheiro, S. Aguiar, A. Ceroni, L. Michelini
   São Paulo, BRAZIL

16.00 • LECTURE:
   BARORECEPTOR CONTROL OF THE CIRCULATION AND INFLUENCE IN BLOOD PRESSURE
   T.E. Lohmeier
   Jackson, MS, USA

16.20 • RENAL SYMPATHETIC REGULATION IN A CONSCIOUS RABBIT MODEL OF CHRONIC KIDNEY DISEASE
   G.A. Head, S. Burke, P. Davern, L. Van Rensch, M.P. Schlaich
   Melbourne, AUSTRALIA

16.30 • DECREASED CAROTID DISTENSIBILITY IS PRESENT BUT DOES NOT EXPLAIN THE IMPAIRMENT OF BAROREFLEX-FUNCTION IN SCHIZOPHRENIC PATIENTS
   A. Sárákzi, B. Mersich, D. Cseh, M. Kollai, A. Pintér
   Budapest, HUNGARY

16.40 • THE EFFECTS OF POSITIVE ALLOSTERIC MODULATION OF GABAA RECEPTORS UPON STRESS AND HYPERTENSION IN SCHLAGER HYPERTENSIVE MICE
   E. Stevenson, K. Jackson, B. Abegaz, J. Moretti, C. Gueguen, P. Davern
   Melbourne, AUSTRALIA

16.50 • BEYOND PRESSURE-NATRIURESIS: INSIGHTS INTO THE RENAL NERVE MEDIATED MECHANISMS RESPONSIBLE FOR MAINTAINING SODIUM AND VOLUME HOMEOSTASIS DURING AN ACUTE SODIUM CHALLENGE
   R. Wainford, J. Kuwabara, S. Mahne
   Boston, MA, USA
Parallel Oral Session 6D

NEW THERAPEUTIC DEVELOPMENTS AND PERIPHERAL VASCULAR DISEASE

Chairpersons: I. Kantola (Turku, FINLAND)  
F. Pinto (Santa Maria Feira, PORTUGAL)

15.30 • PDE3 INHIBITOR, CILOSTAZOL IMPROVES BLOOD FLOW IN HIND LIMB ISCHEMIA THROUGH PPAR/HGF/ENOS PATHWAY  
Suita, JAPAN

15.40 • ARE INTERMEDIATE ANKLE–BRACHIAL INDEX VALUES IMPORTANT IN HYPERTENSION? INSIGHTS FROM A LARGE COHORT OF NEVER-TREATED HYPERTENSIVES  
P. Xaplanteris, A. Aggelakas, M. Abdallah, N. Ioakimidis, A. Synodinos, G. Vyssoulis, C. Stefanadis  
Athens, GREECE

15.50 • SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH UNCONTROLLED HYPERTENSION: 1 MONTH RESULTS OF THE FIRST 100 PATIENTS IN THE ENLIGHTN II STUDY  
S. Worthley 1, J. Montarello 1, M. Saxena 2, A. Jain 1, D. Walters 1, M. Pincus 3, M. Lobo 1  
1 Adelaide, AUSTRALIA, 2 London, UNITED KINGDOM, 3 Brisbane, AUSTRALIA

16.00 • LCZ696, A NOVEL ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR: THE FIRST TRIAL IN PATIENTS WITH SEVERE HYPERTENSION  
K. Kario 1, Y. Tamaki 2, H. Kim 2, H. Gotou 2, M. Zhu 3, J. Zhang 4  
1 Tochigi, 2 Tokyo, JAPAN, 3 Beijing, CHINA, 4 East Hanover, NJ, USA

16.10 • THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF MOUTH OPENING: EVIDENCE IN AN ANIMAL MODEL  
D. Lapi 1,2, C. Del Seppia 1, S. Ghione 2, A. Colantuoni 1, R. Scuri 2  
1 Naples, 2 Pisa, ITALY

16.20 • COMPARATIVE EFFICACY OF VALSARTAN AND LCZ696, AN ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI), IN HYPERTENSIVE INDIVIDUALS OVER AGE 65  
J. Izzo Jr 1, L.M. Ruilope 2, L. Conde 2, D. Zappe 1, Y. Zhang 1, J. Zhang 4  
1 New York, NY, USA, 2 Madrid, SPAIN, 3 Basel, SWITZERLAND, 4 East Hanover, NJ, USA

16.30 • A NOVEL ANTI-HYPERTENSIVE THERAPY: EVIDENCE FOR FLAXSEED AS A SOLUBLE EPOXIDE HYDROLASE INHIBITOR IN A RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED CLINICAL TRIAL  
S. Caligiuri, H. Aukema, A. Ravandi, R. Guzman, G. Pierce  
Winnipeg, CANADA

16.40 • SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF QGC001, A CENTRALLY-ACTING AMINOPEPTIDASE A INHIBITOR, IN HEALTHY VOLUNTEERS  
F. Balavoine 1, M. Azizi 1, D. Bergerot 1, N. De Mota 1, R. Patouret 1, B. Roques 1, C. Llorens-Cortes 1  
1 Massy, 2 Paris, FRANCE

16.50 • ACTIVATED PROTEIN C–PROTEIN C INHIBITOR COMPLEX FOR DETECTION OF ABDOMINAL AORTIC ANEURYSM IN 65 YEARS OLD MEN  
M. Zarrour, A. Gottschäfer, J. Holst, B. Lindblad, M. Sterner  
Malmö, SWEDEN
15.30 - 17.00  Conference Suite II - MC2

Late-Breakers

SESSION 2

Chairpersons:  
R.H. Fagard (Leuven, BELGIUM)  
P. Stylianou (Nicosia, CYPRUS)

15.30 • RENAL DENERVATION VERSUS INTENSIFIED MEDICAL TREATMENT INCLUDING SPIRONOLACTONE IN PATIENTS WITH TRUE RESISTANT HYPERTENSION: 6–MONTHS RESULTS OF MULTICENTER RANDOMIZED PRAGUE  
1 Prague, 2 Olomouc, 3 Trinec, CZECH REPUBLIC

15.40 • THE EARLY CORRECTION OF METABOLIC SYNDROME IMPROVES ORGAN DAMAGE, IRRESPECTIVELY OF BLOOD PRESSURE REDUCTION IN PATIENTS WITH HYPERTENSION: K–METS STUDY  
1 Seoul, 2 Kwnagju, 3 Sungnam, SOUTH KOREA

15.50 • NON-INVASIVE HEMODYNAMIC MONITORING AS A GUIDE TO DRUG TREATMENT: RELATION BETWEEN CHANGES IN HEMODYNAMIC PARAMETERS AND IN BLOOD PRESSURE VALUES, THE BEAUTY STUDY  
T. Camotti 1, P. Rebora 1, F. Fadl Elmula 2, A. Talvik 3, S. Salerno 1, E. Miszewska-Nagorna 4, X. Liu 5, M. Heinpalu-Kuum 6, A.C. Larstorp 6, M.G. Valsecchi 7, S.E. Kjeldsen 8, M. Viigimaa 9, K. Narkiewicz 10, G. Parati 1, S. Laurent 11  
1 Milan, ITALY, 2 Oslo, NORWAY, 3 Tallinn, ESTONIA, 4 Gdansk, POLAND, 5 Paris, FRANCE

16.00 • EFFECTS OF THE LERCANIDIPINE-ENALAPRIL COMBINATION ON HOME BLOOD PRESSURE AND ITS DAY-BY-DAY VARIABILITY  
1 Varese, ITALY, 2 Barcelona, SPAIN, 3 Moscow, RUSSIA, 4 Paris, FRANCE, 5 Hannover, GERMANY,  
6 Padua, ITALY, 7 Poznan, POLAND, 8 Kiev, UKRAINE, 9 Milan, ITALY

16.10 • THE PROGRESSION FROM NORMAL BLOOD PRESSURE TO RESISTANT HYPERTENSION IS ATTENUATED BY FITNESS  
P. Kokkinos 1, M. Doumas 1, C. Faselis 1, A. Tsimploulis 1, A. Pittaras 1, A.J. Manolis 2, P. Narayan 3  
1 Washington, DC, USA, 2 Thessaloniki, 3 Athens, GREECE

16.20 • EFFECTS OF BLOOD PRESSURE LOWERING IN PATIENTS WITH ACUTE ISCHEMIC STROKE AND CAROTID ARTERY STENOSIS  
M. Jusufovic 1, E.C. Sandset 1, P.M.W. Barth 2, B.W. Karlson 3, E. Berge 1, on behalf of the Scandinavian Candesartan Acute Stroke Trial (SCAST) Study Group  
1 Oslo, NORWAY, 2 Nottingham, UNITED KINGDOM, 3 Gothenburg, SWEDEN

16.30 • FACTORS IMPACTING BLOOD PRESSURE RESPONSE TO A SHAM PROCEDURE: AN ANALYSIS FROM THE SYMPPLICITY HTN–3 RANDOMIZED CLINICAL TRIAL  
G.L. Bakris 1, D. Bhatt 2  
1 Chicago, IL, 2 Boston, MA, USA

16.40 • THE FRENCH DENER-HTN TRIAL: RENAL DENERVATION + STANDARDIZED ANTIHYPERTENSIVE TREATMENT VS. STANDARDIZED ANTIHYPERTENSIVE TREATMENT ALONE IN PATIENTS WITH RESISTANT HYPERTENSION  
M. Azizi 1, M. Monge 1, H. Pereira 1, M. Sapoval 1, on behalf of DENER-HTN Investigators 2  
1 Paris, FRANCE, 2 The French network of ESH Excellence Centers, FRANCE

16.50 • RELATIONSHIPS BETWEEN PHARMACOKINETICS OF ANTIANGIOGENIC DRUGS, LARGE ARTERIES PROPERTIES AND CANCER PROGRESSION  
M. Alivon, B. Blanchet, J. Giroux, M. Vidal, F. Goldwasser, S. Laurent, P. Boutouyrie  
Paris, FRANCE

17.00 – 18.00  Conference Suite II - MC2
Joint Session
WHL (World Hypertension League) /
WHO (World Health Organization) coordinating
Centre for Salt Reduction /
ISH (International Society of Hypertension)

**SODIUM REDUCTION**

Chairpersons: 
- D.T. Lackland (Charleston, SC, USA)
- E.L. Schiffrin (Montreal, CANADA)

15.30  **Science of dietary sodium**
G.A. MacGregor (London, UNITED KINGDOM)

15.45  **Update on the status of salt reduction globally**
J. Breda (Geneva, SWITZERLAND)

16.00  **What health care professionals and scientists can do to aid salt reduction efforts**
N. Campbell (Calgary, CANADA)

16.15  **General Discussion**

---

17.00 – 18.30  Christos Lambrakis Hall

**Plenary Session**

**FRANZ VOLHARD AWARD LECTURE**
**ISH PRESENTATION OF AWARDS AND PRIZES**
**PRESIDENTIAL LECTURE**

**Chairpersons:**
- S.B. Harrap (Melbourne, AUSTRALIA)
- E.L. Schiffrin (Montreal, CANADA)

17.00  **Franz Volhard Award Lecture (for Outstanding Research)**
Mechanisms of salt-sensitive hypertension
T. Fujita (Tokyo, JAPAN)

17.25  **Presentation of ISH Awards and Prizes**
(see pages 27-28)

18.05  **Presidential Lecture**
Immune mechanisms and vascular remodeling in hypertension
E.L. Schiffrin (Montreal, CANADA)

18.30  **Launch ISH 2016 Seoul Meeting**
ESH Working Group on

HYPERTENSION AND CARDIOVASCULAR RISK ASSESSMENT IN
SUBJECTS LIVING IN OR EMIGRATING FROM LOW RESOURCE
SETTINGS

Diaspora and health: from infections to non-communicable diseases,
a paradigm shift?

Chairpersons:
PA. Modesti (Florence, ITALY)
G. Parati (Milan, ITALY)

18.30 Southeast Asian diaspora
F.P. Cappuccio (Coventry, UNITED KINGDOM)

18.45 African diaspora
L.M. Van Bortel (Ghent, BELGIUM)

19.00 Differences in anthropometric measures in immigrants and Swedish-born
individuals — Results from two community based cohort studies
A. Carlsson (Stockholm, SWEDEN)

19.15 Cross-national variations in universal health coverage
B. Kumar (Oslo, NORWAY)

19.30 Business Meeting

ESH Working Group on

OBESITY, DIABETES AND THE HIGH RISK PATIENTS

Obesity and the high risk patient: a call for action

Chairpersons:
V. Kotsis (Thessaloniki, GREECE)
P.M. Nilsson (Malmö, SWEDEN)

18.30 Obesity and hypertension. Mechanisms and treatment
V. Kotsis (Thessaloniki, GREECE)

18.45 EVA: focus on obesity
P.M. Nilsson (Malmö, SWEDEN)

19.00 The role of mediterranean diet in the management of obesity
D.B. Panagiotakos (Athens, GREECE)

19.15 Pharmacological obesity management
S. Engeli (Hannover, GERMANY)
Monday, June 16

07.45 – 08.45  Banqueting Hall

Breakfast Workshop

HYPERTENSION AND COPD

Chairpersons:
C. Farsang (Budapest, HUNGARY)
T. Mountokalakis (Athens, GREECE)

07.45 Hypertension and COPD: what’s new?
C. Farsang (Budapest, HUNGARY)

08.05 New insights into COPD management
C. Borghi (Bologna, ITALY)

08.25 General Discussion

ESH Working Group on

HYPERTENSION AND THE KIDNEY

Chairperson: P.W. de Leeuw (Maastricht, NETHERLANDS)

18.30 Are there still indications for renal artery stenting after CORAL?
P.W. de Leeuw (Maastricht, NETHERLANDS)

18.45 Assessing functionality of renal artery stenosis in 2014
A. Morganti (Milan, ITALY)

19.00 FMD revisited: lessons from the French and US registries
P.F. Plouin (Paris, FRANCE)

19.15 The European consensus on FMD
A. Persu (Brussels, BELGIUM)

19.30 Spontaneous coronary artery dissection and FMD: a novel association
J. Saw (Vancouver, CANADA)

19.45 Unraveling the pathophysiology of FMD: the European FIDJI initiative
P.F. Plouin (Paris, FRANCE)
### Breakfast Workshop

#### IMAGING OF THE HEART IN HYPERTENSION

**Chairpersons:**
- R. Hernandez-Hernandez (Barquisimeto, VENEZUELA)
- J. Lekakis (Athens, GREECE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45</td>
<td>Detection of heart organ damage in hypertension: limitations, pitfalls and solutions</td>
</tr>
<tr>
<td></td>
<td>D. Piskorz (Rosario, ARGENTINA)</td>
</tr>
<tr>
<td>08.05</td>
<td>Detection of heart organ damage in hypertension: clinical value during antihypertensive treatment</td>
</tr>
<tr>
<td></td>
<td>M.L. Muiesan (Brescia, ITALY)</td>
</tr>
<tr>
<td>08.25</td>
<td>General Discussion</td>
</tr>
</tbody>
</table>

#### AGE, GENDER, RACE AND GEOGRAPHY AS FACTORS FOR MANAGEMENT OF HYPERTENSION

**Chairpersons:**
- R. Cifková (Prague, CZECH REPUBLIC)
- J.B. Kostis (New Brunswick, NJ, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45</td>
<td>The effect of immigration and acculturation on blood pressure</td>
</tr>
<tr>
<td></td>
<td>T. Rosenthal (Tel Aviv, ISRAEL)</td>
</tr>
<tr>
<td>08.05</td>
<td>Hypertension management – China experience</td>
</tr>
<tr>
<td></td>
<td>L. Liu (Beijing, CHINA)</td>
</tr>
<tr>
<td>08.25</td>
<td>General Discussion</td>
</tr>
</tbody>
</table>
Breakfast Workshop

PERIOPERATIVE MANAGEMENT OF HYPERTENSION

Chairpersons: T. Kahan (Stockholm, SWEDEN)
M. Volpe (Rome, ITALY)

07.45 Diagnostic approach
J. Brugižan (Ljubljana, SLOVENIA)

08.05 Therapy
P. van de Borne (Brussels, BELGIUM)

08.25 General Discussion

ORTHOSTATIC HYPOTENSION

Chairpersons: K. Kario (Tochigi, JAPAN)
F. Pinto (Santa Maria Feira, PORTUGAL)

07.45 Prevalence, pathophysiology and causes
D.A. Sica (Richmond, VA, USA)

08.05 Prognostic implications and therapeutic approach
R.H. Fagard (Leuven, BELGIUM)

08.25 General Discussion
Parallel Oral Session 7A

THERAPEUTIC ASPECTS

Chairpersons:
J. Bruguljan (Ljubljana, SLOVENIA)
B. Carlberg (Umeå, SWEDEN)

09.00 • EFFECTS OF BETA-BLOCKERS WITH OR WITHOUTVASODILATING PROPERTIES ON CENTRAL BLOOD PRESSURE: A NETWORK META-ANALYSIS OF RANDOMIZED TRIALS IN HYPERTENSION
G. Pucci 1, M. Ranalli 1, F. Battista 1, F. Anastasio 1, M. Crapa 1, G. Schillaci 1
1 Terni, 2 Perugia, ITALY

09.10 • DARK CHOCOLATE INTAKE IMPROVES ENDOTHELIAL FUNCTION AND CENTRAL ARTERIAL HEMODYNAMICS IN YOUNG HEALTHY PEOPLE: A RANDOMIZED AND CONTROLLED TRIAL
T. Pereira, J. Maldonado
Coimbra, PORTUGAL

09.20 • EFFECTS OF THIAZIDE-TYPE AND THIAZIDE-LIKE DIURETICS ON CARDIOVASCULAR EVENTS AND MORTALITY. A SYSTEMATIC REVIEW AND META-ANALYSIS
R. Olde Engberink, W. Frenkel, B. Van Den Bogaard, L. Vogt, B. Van Den Born
Amsterdam, NETHERLANDS

09.30 • EFFECT OF ANTI-VEGF AGENTS FOR DIABETIC RETINOPATHY AND SUB-CLINICAL ATHEROSCLEROSIS IN HYPERTENSIVE PATIENTS WITH DIABETIC NEPHROPATHY IN EARLY STAGES
G. Dimas, G. Balanikas, F. Iliadis, C. Savopoulos, A. Alexandridis, V. Karampatakis, A. Hatziotilios, D. Grekas
Thessaloniki, GREECE

09.40 • INFLUENCE OF PRETREATMENT BLOOD PRESSURE LEVELS ON ANTIHYPERTENSIVE DRUG BENEFITS IN DIABETICS: THE ROADMAP EXPERIENCE AT ONE YEAR
C. Chatzikyrkou 1, J. Izzo 2, J. Menne 1, G. Viberi 1, T. Rabelink 3, E. Ritz 5, L.M. Ruilope 6, L. Rump 7, H. Haller 7
1 Hannover, GERMANY; 2 Buffalo, NY, USA; 3 London, UNITED KINGDOM; 4 Leiden, NETHERLANDS; 5 Heidelberg, GERMANY; 6 Madrid, SPAIN; 7 Düsseldorf, GERMANY

09.50 • ASSOCIATION BETWEEN INSOMNIA AND USE OF BP-LOWERING DRUGS IN HYPERTENSIVE PATIENTS: A CROSS-SECTIONAL COHORT STUDY
Pisa, ITALY

10.00 • QUALITY OF LIFE IN PATIENTS WITH CAROTID BAROREFLEX ACTIVATION THERAPY
Maastricht, NETHERLANDS

10.10 • THE COMMON CONTROL OF HYPERTENSION AND THERAPEUTIC ATTITUDES IN BELGIUM AND LUXEMBOURG STUDY (COME STAI)
P. van de Borne 1, L. Missault 2, A. Persu 1, W. Van Mieghem 3
1 Brussels, 2 Brugge, 3 Genk, BELGIUM

10.20 • EFFECTS OF SINGLE LOW DOSE OF BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
L. Ratova, O. Asgatov, K. Zykov, B. Nazarov, Y. Dolgusheva, I. Chazova
Moscow, RUSSIA

10.30 • DEBATE: BLOOD PRESSURE CONTROL: HOW FAST WE NEED TO BE
- PRO
S. Julius
Ann Arbor, MI, USA

- CON
G. Schillaci
Perugia, ITALY
Parallel Oral Session 7B

HEART AND HAEMODYNAMICS

Chairpersons: Z.K. Al-Hergani (Baghdad, IRAQ) K. Yusoff (Shah Alam, MALAYSIA)

09.00 • LIPOCALIN-2 IS A NOVEL DETERMINANT OF CARDIAC HYPERTROPHY
F. Marques 1, P. Prestes 1, I. Rana 1, E. Porrello 1, P. Lewandowski 1, L. Delbridge 1, S.B. Harrap 1, F.J. Charchar 1
1 Ballarat, 2 Brisbane, 3 Geelong, 4 Melbourne, AUSTRALIA

09.10 • RELATIONSHIP BETWEEN VASCULAR DAMAGE AND LEFT VENTRICULAR GEOMETRY IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY
M. Salvetti 1, A. Paini 1, M. Cesana 1, A. Moreo 1, R. Facchetti 1, P. Faggiano 1, S. Carej 1, G. Mureddu 1, N. Galancci 1, F. Rigo 1, C. Giannattasio 1, M.L. Muiesan 1
1 Brescia, 2 Milan, 3 Messina, 4 Rome, 5 Parma, 6 Mestre-Venezia, ITALY

09.20 • PROGNOSTIC VALUE OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN A GENERAL POPULATION
I. Kuznetsova 1, L. Thijs 1, J. Krez 1, L. Herbots 1, J.A. Staessen 1
Leuven, BELGIUM

09.30 • VASOCONSTRICTOR EFFECT OF MRS2159, A PURINORECEPTOR P2X1 ANTAGONIST, ON RENAL MEDULLARY CIRCULATION IS REVERSED IN ANGI-INDUCED HYPERTENSIVE RATS
M. Krzyniak 1, A. Walkowska 1, L. Dobrowolski 1
Warsaw, POLAND

09.40 • ANGIOTENSINERGIC INNERVATION OF THE HUMAN RIGHT ATRIUM, ATRIAL ANGIOTENSINS AND IMPLICATIONS FOR BARORECEPTOR FUNCTION
J. Bohlender 1, J. Nussberger 2, H. Tevaearai 1, H. Imboden 1
1 Bern, 2 Lausanne, SWITZERLAND

09.50 • ESTROGEN REGULATES ANGIOTENSIN II RECEPTOR EXPRESSION PATTERNS AND PROTECTS THE HEART FROM ISCHEMIC INJURY IN FEMALE RATS
J. Zhang 1, Q. Xue 1, D. Xiao 1, S. Yang 2
1 Loma Linda, CA, 2 San Bernardino, CA, USA

10.00 • DETERMINANTS OF EARLY CHANGES IN LEFT VENTRICULAR SYSTOLIC FUNCTION IN PATIENTS WITH ESSENTIAL HYPERTENSION AND NORMAL EJECTION FRACTION

10.10 • ECHOCARDIOGRAPHY ESTIMATION OF RIGHT ATRIAL PRESSURE: COMPARISON AND CLINICAL VALIDATION AMONG SEVERAL MODELS
Turin, ITALY

10.20 • HIGHER PULSE PRESSURE AS PREDICTOR OF LOWER INTRAHOSPITAL MORTALITY IN NYHA II/III PATIENTS
V. Iric-Cupic, G. Davidovic, S. Milanov, M. Pavlovic, M. Petrovic
Kragujevac, SERBIA

10.30 • EFFECTS OF ACUTE, SYMPATHETIC-INDEPENDENT INCREASES IN HEART RATE ON ARTERIAL STIFFNESS, CENTRAL HAEMODYNAMICS AND CARDIAC FUNCTION
I. Tan, M. Butlin, H. Kiat, E. Barin, A. Avolio
Sydney, AUSTRALIA

10.40 • COMPUTATIONAL MODELLING OF THE AORTIC PULSE WAVEFORM IN THE CLINICAL SETTING
S. Epstein, H. Fok, P. Chowienczyk, J. Alastruey
London, UNITED KINGDOM

10.50 • THE ASSOCIATION OF DIASTOLIC DYSFUNCTION WITH LEFT VENTRICULAR MASS INDEX ACCORDING TO GLUCOMETABOLIC STATUS: A CROSS-SECTIONAL STUDY
M. Pareek 1, M. Nielsen 1, M. Leósdóttir 2, R. Kruger 1, S. Greve 1, M. Blicher 1, T. Sehestedt 1, K. Wachtell 5, P.M. Nilsson 2, M.H. Olsen 1
1 Odense, DENMARK, 2 Malmö, SWEDEN, 3 Botchefstrom, SOUTH AFRICA, 4 Herlev, DENMARK, 5 Glostrup, DENMARK
Parallel Oral Session 7C

CARDIOVASCULAR RISK FACTORS

Chairpersons:
D. Gaita (Timisoara, ROMANIA)
T. Rosenthal (Tel Aviv, ISRAEL)

09.00 • PROGNOSTIC IMPORTANCE OF VASCULAR AGE ESTIMATED FROM PULSE WAVE VELOCITY
M. Blicher 1, S. Greve 1, R. Kruger 1, M. Pareek 1, T. Sehestedt 1, J. Vishram 1, T. Joergensen 1, M.H. Olsen 1
1 Odense, DENMARK

09.10 • MAGNESIUM IN 24-HOUR URINE IS INVERSELY RELATED WITH CARDIOVASCULAR RISKS IN MIDDLE AGED SUBJECTS IN 50 POPULATIONS IN THE WORLD
Y. Yamori 1,2, M. Sagara 1, S. Mizushima 1,2, L. Liu 1,2, K. Ikeda 1,2, Y. Nara 2
1 Nishinomiya, 2 Kyoto, JAPAN

09.20 • MORBIDITY AND MORTALITY RISK AMONG SUBJECTS WITH SCREENING-DETECTED SEVERE HYPERTENSION IN THE MALMÖ PREVENTIVE PROJECT
C. Westerlund 1, B. Zoller 1, A. Asrani 1, S. Erdine 1, P.M. Nilsson 1
1 Lund, SWEDEN

09.30 • RECLASSIFICATION IMPROVEMENT AND DISCRIMINATION BY TESTOSTERONE IN HYPERTENSIVE MALES
N. Ioakeimidis, C. Vlachopoulos, A. Aggelis, P. Pietri, D. Terentes-Printzios, M. Abdelrasoul, I. Gourgouli, I. Androutsos, C. Stefanadis
Athens, GREECE

09.40 • OBESITY RELATED HYPERTENSION: ALTERED DOWNSTREAM REGULATION OF LEPTIN ON HAEMODYNAMIC AND RENAL SYMPATHETIC NERVE ACTIVITY IN HIGH FAT FED RABBITS
K. Ling, B. Barzel, S. Burke, G.A. Head
Melbourne, AUSTRALIA

09.50 • A GOOD LEFT VENTRICULAR DIASTOLIC PERFORMANCE IS PREDICTIVE OF BETTER OUTCOME IN YOUNG SUBJECTS IN THE EARLY STAGE OF HYPERTENSION
O. Vriz 1, P. Visentin 1, F. Saladini 1, C. Fania 1, S. Martina 1, L. Mos 1, A. Mazzer 1, F. Dorigatti 2, A. Bartolazzi 1, P. Palatini 2
1 San Daniele del Friuli, 2 Padua, ITALY

10.00 • INCREASED AORTIC WAVE REFLECTION AND SMALLER PULSE PRESSURE AMPLIFICATION IN SMOKERS AND PASSIVE SMOKERS CONFIRMED BY URINARY COTININE LEVELS: THE NAGAHAMA STUDY
Kyoto, JAPAN

10.10 • COMPARISON OF CARDIOVASCULAR RISK OF RESISTANT HYPERTENSION AGAINST THAT OF SMOKING: A 3.6 YEAR FOLLOW-UP STUDY
Athens, GREECE

10.20 • DO DIETARY SUGARS RAISE BLOOD PRESSURE AND BLOOD LIPIDS?
L. Te Morenga, A. Howatson, R. Jones, J. Mann
Dunedin, NEW ZEALAND

10.30 • CARDIOVASCULAR RISK MARKERS PREDICT INSULIN SENSITIVITY IN YOUNG MEN AFTER 17 YEARS
S. Skårn, M. Rostrup, S.E. Kjeldsen, A. Flaa, T. Aksnes
Oslo, NORWAY

10.40 • FAMILY STRESS IN WOMEN LEAD TO ARTERIAL HYPERTENSION AND MYOCARDIAL INFARCTION OVER 16 YEARS IN RUSSIA (BASED ON WHO EPIDEMIOLOGICAL PROGRAM MONICA-PSYCHOSOCIAL)
V. Gafarov, D. Panov, E. Gromova, I. Gagulin, A. Gafarova
Novosibirsk, RUSSIA

10.50 • IMPACT OF THE METABOLIC SYNDROME ON STRUCTURAL AND FUNCTIONAL ARTERIAL CHANGES: GENDER DIFFERENCES
M. Loboz-Rudnicka 1, J. Jaroch 1, Z. Bociaga 1, E. Kruszynska 1, K. Dudek 2, I. Uchmanowicz 1, K. Loboz-Grudzien 1
1 Wroclaw, 2 Jelenia Gora, POLAND
Parallel Oral Session 7D

ENDOCRINE HYPERTENSION

Chairpersons: E. Grossman (Tel Hashomer, ISRAEL) P.F. Plouin (Paris, FRANCE)

09.00 • COMMON SOMATIC MUTATIONS IN CAV1.3, ADRENAL IMMUNOHISTOCHEMISTRY, AND INHIBITION OF ALDOSTERONE SECRETION BY CAV1.3 BLOCKADE, INDICATE A ZONA GLOMERULOSA-LIKE SUBSET OF ALDOSTERONE

E. Azizan 1, A. Teo 1, C. Xie 1, L. Haris Shaikh 1, J. Zhou 1, S. Garg 1, W. Zhou 1, S. Kang 1, R. Silverman 1, M. Brown 1
1 Cambridge, UNITED KINGDOM

09.10 • HIGHLY SELECTIVE EXPRESSION OF NEPHRONECTIN DELINATES A COMMON SUBTYPE OF ALDOSTERONE-PRODUCING ADENOMAS OF ZONA GLOMERULOSA ORIGIN, AND A PUTATIVE ROLE IN ALDOSTERONE PRODUCTION

A. Teo, E. Azizan, L. Shaikh, J. Zhou, D. Walters, S. Neogi, I. McFarlane, M. Brown
Cambridge, UNITED KINGDOM

09.20 • PREVALENCE AND CLINICAL CHARACTERISTICS OF SOMATIC MUTATIONS IN CHINESE PATIENTS WITH ALDOSTERONE-PRODUCING ADENOMA

Shanghai, CHINA

09.30 • ANGIOTENSIN 1–7 IS A NOVEL REGULATOR OF ALDOSTERONE SECRETION AND A MODULATOR OF THE ALDOSTERONE RESPONSE TO SALT RESTRICTION

Y. Marcus, G. Shefer, R. Limor, E. Knoll, S. Braun, P. Zadicario, N. Stern
Tel Aviv, ISRAEL

09.40 • PRIMARY ALDOSTERONISM IS MAJOR CAUSE OF HYPERTENSION IN PATIENTS WITH SUBCLINICAL CUSHING’S SYNDROME

J. Saito 1, M. Obara 1, K. Makita 1, S. Matsui 1, M. Nagata 1, T. Toki 1, Y. Matsuzawa 1, N. Ishikawa 1
1 Yokohama, JAPAN

09.50 • PATHOLOGICAL SUBCLASSIFICATION AND STEROIDOGENIC PATHOPHYSIOLOGY OF PRIMARY ALDOSTERONISM

F. Satoh 1, Y. Ono 1, R. Morimoto 1, M. Kudo 1, Y. Iwakura 1, K. Omatani 1, K. Seiji 1, K. Takase 1, Y. Nakamura 1, M. Doi 1, H. Okamura 1, C. Gomez-Sanchez 1, H. Sasano 1, S. Ito 1
1 Sendai, 2 Kyoto, JAPAN, 3 Jackson, MS, USA

10.00 • STEM CELL MARKER, LGR5 AND ITS LIGAND Rspo3 ARE SELECTIVELY EXPRESSED IN ZONA GLOMERULOSA OF THE HUMAN ADRENAL AND MAY EXPLAIN HIGH PREVALENCE OF SMALL ALDOSTERONE-PRODUCING ADENOMAS

L. Haris Shaikh, A. Teo, J. Zhou, E. Azizan, S. Guha Neogi, I. McFarlane, N. Figg, A. Davenport, M. Brown
Cambridge, UNITED KINGDOM

10.10 • TESTOSTERONE DEFICIENCY: A DETERMINANT OF AORTIC STIFFNESS IN MEN

Athens, GREECE

10.20 • THE OVARIAN CYCLE AS A SOURCE OF VARIABILITY IN THE SCREENING FOR HYPERALDOSTERONISM AND IN THE ASSESSMENT OF INSULIN RESISTANCE IN HYPERTENSIVE WOMEN IN FERTILE AGE

K. Chatzianagnostou, S. Ghione, E. Fommei
Pisa, ITALY

10.30 • GENETIC SPECTRUM AND CLINICAL CORRELATES OF SOMATIC MUTATIONS IN ALDOSTERONE-PRODUCING ADENOMA

F. Fernandes-Rosa 1, T.A. Williams 2, F. Beuschlein 3, A. Riester 3, S. Boulkroun 1, S. Monticone 2, L. Amar 1, T. Meachi 3, F. Mantero 4, M. Quinkler 5, F. Mantero 4, M. Reinecke 1, M. Zennaro 1
1 Paris, FRANCE, 2 Turin, ITALY, 3 Munich, GERMANY, 4 Padua, ITALY, 5 Berlin, Germany

10.40 • AMBULATORY BLOOD PRESSURE MONITORING AND KYNURENIC ACID IN FEMALE PATIENTS WITH PRIMARY HYPERPARATHYROIDISM

A. Tomaschitz 1, N. Verheyen 2, M. Gaksch 2, M. Grubler 2, J. Wetzel 2, E. Belyavskiy 2, C. Contolantioni 2, E. Kragher-Krairner 2, W. Mervz 2, I. Grammer 1, A. Meinritz 1, J. Rus-Machan 1, A. Fahrleitner-Pammer 1, B. Pieske 2, S. Pilz 2, 3
1 Bad Aussee, 2 Graz, AUSTRIA, 3 Mannheim, GERMANY

10.50 • NEW GERM–LINE MUTATIONS AND A RARE CODING SINGLE NUCLEOTIDE POLYMORPHISM WITHIN KCNJ5 IN “APPARENTLY SPORADIC” PRIMARY ALDOSTERONISM: A POSSIBLE ROLE IN PATHOGENESIS

S. Xu 1, M. Murthy 1, G. Massimo 2, R. Gordon 3, M. Stowasser 1, K. O’Shaughnessy 2
1 Brisbane, AUSTRALIA, 2 Cambridge, UNITED KINGDOM
**Topical Workshop**

**ENVIRONMENTAL FACTORS IN HYPERTENSION**

**Chairpersons:**
C. Faselis (Washington DC, USA)
A.E. Schutte (Potchefstroom, SOUTH AFRICA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30</td>
<td>Mediterranean diet and hypertension</td>
<td>M. Domenech (Barcelona, SPAIN)</td>
</tr>
<tr>
<td>09.50</td>
<td>Bariatric surgery</td>
<td>G. Grassi (Milan, ITALY)</td>
</tr>
<tr>
<td>10.10</td>
<td>The role of exercise in high risk patients</td>
<td>P. Kokkinos (Washington, DC, USA)</td>
</tr>
<tr>
<td>10.30</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Topical Workshop**

**PENDING ISSUES WITH BLOOD PRESSURE MEASUREMENT**

**Chairpersons:**
E. O’Brien (Dublin, IRELAND)
G. Parati (Milan, ITALY)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30</td>
<td>Automated office blood pressure measurement: a step forward?</td>
<td>M.G. Myers (Toronto, CANADA)</td>
</tr>
<tr>
<td>09.50</td>
<td>Atrial fibrillation and oscillometric readings: should ABPM and HBPM be implemented?</td>
<td>G.S. Stergiou (Athens, GREECE)</td>
</tr>
<tr>
<td>10.10</td>
<td>Telemedicine and pharmacies: how to improve blood pressure control in the field</td>
<td>S. Omboni (Milan, ITALY)</td>
</tr>
<tr>
<td>10.30</td>
<td>Blood pressure control during day and night. Place of chronotherapy in practice</td>
<td>B. Waeger (Lausanne, SWITZERLAND)</td>
</tr>
<tr>
<td>10.50</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>
**Joint Session**

ESH (European Society of Hypertension) / ESC (European Society of Cardiology)

**RESISTANT HYPERTENSION IN 2014**

Chairpersons: A. Coca (Barcelona, SPAIN)  
A.F. Dominiczak (Glasgow, UNITED KINGDOM)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30</td>
<td>Diagnosis of resistant hypertension</td>
<td>R.E. Schmieder (Erlangen, GERMANY)</td>
</tr>
<tr>
<td>09.50</td>
<td>Secondary causes of resistant hypertension</td>
<td>M. Azizi (Paris, FRANCE)</td>
</tr>
<tr>
<td>10.10</td>
<td>Pharmacological treatment</td>
<td>B. Williams (London, UNITED KINGDOM)</td>
</tr>
<tr>
<td>10.30</td>
<td>Renal denervation 4 years on: focus on long term results</td>
<td>M.P. Schlaich (Melbourne, AUSTRALIA)</td>
</tr>
<tr>
<td>10.50</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>

---

**Topical Workshop**

**HYPERTENSION AND COMORBIDITIES**

Chairpersons:  
E. Apetrei (Bucharest, ROMANIA)  
M. Dorobantu (Bucharest, ROMANIA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30</td>
<td>Blood pressure control and variability in type 2 diabetes: experience from a clinical setting</td>
<td>C. Bala (Cluj Napoca, ROMANIA)</td>
</tr>
<tr>
<td>09.40</td>
<td>Pathogenic mechanisms of myocardial ischemia in hypertension and therapeutic implications</td>
<td>D. Dimulescu (Bucharest, ROMANIA)</td>
</tr>
<tr>
<td>09.50</td>
<td>Hypertension and peripheral artery disease</td>
<td>C. Sinescu (Bucharest, ROMANIA)</td>
</tr>
<tr>
<td>10.00</td>
<td>Comorbidities role in assessing cardiovascular risk in hypertensive patients</td>
<td>R. Darabont (Bucharest, ROMANIA)</td>
</tr>
<tr>
<td>10.10</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Monday 16

Teaching Seminar – Session 3

Plenary Session

DEBATE

DIFFERENT NEW GUIDELINES: WHERE IS THE EVIDENCE?

Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM)
H.P. Gavras (Boston, MA, USA)
E.L. Schiffrin (Montreal, CANADA)

11.00 ESH/ESC
G. Mancia (Milan, ITALY)

11.20 JNC 8
J.B. Kostis (New Brunswick, NJ, USA)

11.40 ASH/ISH 2014
E.L. Schiffrin (Montreal, CANADA)

12.00 General Discussion

12.45 – 14.15 Christos Lambrakis Hall

Teaching Seminar – Session 3

PARTICULAR QUESTIONS

Chairpersons: G.F. Mitchell (Waltham, MA, USA)
L.M. Van Bortel (Ghent, BELGIUM)

12.45 Shall we prefer central blood pressure above peripheral pressure in hypertensive patients?
S. Laurent (Paris, FRANCE)

13.00 Salt and hypertension
M. Burnier (Lausanne, SWITZERLAND)

13.15 What is new on ABPM and Home Pressure in the 2014 practice guidelines
M.G. Myers (Toronto, CANADA)

13.30 Insufficient blood pressure control: how to improve?
D.L. Clement (Ghent, BELGIUM)

13.45 General Discussion
**Poster Area**

**14.00 – 15.30**

**Poster Area**

**14.00 – 15.30**

**Attended Poster Sessions**

**PS 31. CARDIOVASCULAR RISK FACTORS**
- Room 1, Posters from 1 to 42
- Chairperson: H. Triantafyllidi (Athens, Greece)

**PS 32. HEART FAILURE**
- Room 2, Posters from 1 to 41
- Chairperson: R. Zimlichman (Holon, Israel)

**PS 33. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM**
- Room 3, Posters from 1 to 51
- Chairperson: A.O. Konradi (Saint-Petersburg, Russia)

**PS 34. ORGAN DAMAGE**
- Room 4, Posters from 1 to 40
- Chairperson: M. Kallistratos (Athens, Greece)

**PS 35. CEREBROVASCULAR DISEASES AND COGNITIVE DYSFUNCTION**
- Room 5, Posters from 1 to 44
- Chairperson: M. Horiuchi (Ehime, Japan)

**PS 36. COMBINATION TREATMENT**
- Room 6, Posters from 1 to 44
- Chairperson: E. Oshepkova (Moscow, Russia)

**PS 37. INFLAMMATION AND IMMUNITY – PEPTIDES**
- Room 7, Posters from 1 to 29
- Chairperson: J. Chin-Dusting (Melbourne, Australia)

**PS 38. DIAGNOSTIC ASPECTS – EDUCATIONAL PROGRAMMES**
- Room 8, Posters from 1 to 42
- Chairperson: M.V. Papavasileiou (Athens, Greece)
Meet-The-Expert Session

EVALUATION OF RESISTANT HYPERTENSION

The Expert: R.E. Schmieder (Erlangen, GERMANY)

Monday

14.30 - 15.30

Meet-The-Expert Session

EVALUATION OF RESISTANT HYPERTENSION

The Expert: R.E. Schmieder (Erlangen, GERMANY)

Monday

16

Meet-The-Expert Session

EVALUATION OF RESISTANT HYPERTENSION

The Expert: R.E. Schmieder (Erlangen, GERMANY)
**How-To Session**

**HOW TO DETECT AND MANAGE WHITE COAT AND MASKED HYPERTENSION IN PRACTICE**

Chairperson: M.G. Myers (Toronto, CANADA)

---

**Clinical Case**

**SESSION 3**

14.30  Primary aldosteronism  
N. Stern (Tel Aviv, ISRAEL)

15.00  Stepwise management of difficult resistant hypertension  
C. Tsioufis (Athens, GREECE)
Parallel Oral Session 8A

LIFESTYLE CHANGES AND SPORT

Chairpersons: S. Torbova (Sofia, BULGARIA) and C. Zamboulis (Thessaloniki, GREECE)

15.30 • FIVE RANDOM CASUAL URINES ARE SUFFICIENT TO ESTIMATE DAILY URINARY SODIUM/POTASSIUM RATIO IN HYPERTENSIVES
T. Iwahori 1, H. Ueshima 2, S. Torii 2, Y. Saito 2, T. Ohkubo 2, K. Miura 2
1 Muko, 2 Otsu, JAPAN

15.40 • PERSONALIZED WORKPLACE WALKING PROGRAM IMPROVES BLOOD GLUCOSE LEVELS
P. Veeralahadraja 1, H. Weiss 1, S. Bhat 2, R. Alweis 2
1 Shippenburg, PA 2 Reading, PA, USA

15.50 • BLOOD PRESSURE RECOVERY AFTER MAXIMAL EXERCISE AT HIGH ALTITUDE IN MILD HYPERTENSIVE SUBJECTS AND EFFECTS OF ANTHYPERTENSIVE COMBINATION TREATMENT
A. Faini 1, S. Caravita 1, M. Lang 2, J. Macarlupu 1, C. Anza 1, E. Salvioni 1, M. Revera 1, A. Giuliano 1, F. Gregorini 1, L. Rossi 1, C. Lombardi 1, G. Bilo 1, F. Villafruente 1, G. Mancia 1, P. Agostoni 1, G. Parati 1
1 Milan, ITALY 2 Antofagasta, CHILE

16.00 • TEN-YEAR CAMPAIGN FOR EATING SOY AND SEA-FOOD RICH TRADITIONAL JAPANESE DIETS WITH LESS SALT REDUCED CARDIOVASCULAR RISKS IN HYOGO PREFECTURE, ONE TWENTIETH OF JAPANESE POPULATION
Y. Yamori 1,2, S. Sagara 2, M. Mori 2, Y. Arai 2, H. Kobayashi 1, I. Hayashi 1, S. Onishi 1, S. Nagata 1
1 Kobe, 2 Kyoto, 3 Nishinomiya, JAPAN

16.10 • POST-EXERCISE THROMBOTIC AND FIBRINOLYTIC CHANGES IN PATIENTS WITH ESSENTIAL HYPERTENSION: THE EFFECT OF TREATMENT WITH AN ANGIOTENSIN II RECEPTOR BLOCKER
G. Triantafyllou, E. Gkaliagkousi, E. Gavriilaki, B. Nikolaidou, F. Chatzopoulou, P. Anyfanti, A. Triantafyllou, S. Douma
Thessaloniki, GREECE
Parallel Oral Session 8B

Public Health and Pharmacoeconomics

Chairpersons:
E. Ambrosioni (Bologna, ITALY)
P. Efstathiou (Athens, GREECE)

15.30 - 17.00 Alexandra Trianti Hall

15.30 • IS IT TIME TO TREAT POPULATIONS VERSUS PATIENTS TO CONTROL HYPERTENSION?
R. Lewanczuk
Edmonton, CANADA

15.40 • ECONOMIC EVALUATION OF COMBINED THERAPY OF ARTERIAL HYPERTENSION WITH MARKOV'S MODELING
E. Tarlovskaya, N. Maksimchuk-Kolobova, S. Malchicova
Kirov, RUSSIA

15.50 • THE MANAGEMENT OF THE HYPERTENSIVE PATIENT: FROM PREVENTION TO MANAGEMENT OF THE COMPLICATIONS
M. De Rosa 1, A. Esposito 1, M. Melissa 1, L. Cerini 2
1 Naples, 2 Milan, ITALY

16.00 • VALIDITY OF EQUATIONS USED TO ESTIMATE POPULATION SALT CONSUMPTION FROM SPOT URINE SAMPLES
M. Crino 1, L. Huang 1, P. Jeffery 1, W. Woodward 1, F. Barzi 1, R. McLean 1, M. Land 1, B. Neal 1
1 Sydney, 2 Melbourne, AUSTRALIA, 3 Dunedin, NEW ZEALAND

16.10 • LECTURE:
ELECTRONIC HEALTH RECORDINGS AND HYPERTENSION RESEARCH
J. Redon
Valencia, SPAIN

16.30 • DIRECT MEDICAL COSTS OF HYPERTENSION AND ASSOCIATED CO-MORBIDITIES IN SOUTH KOREA: A RETROSPECTIVE ANALYSIS
S. Ong 1, B. Yang 1, J. Min 1, K. Min 1, S. Seo 1, H. Kim 2, Y. Kim 2, E. Yu 2, G. Machnicki 4
1 Basel, SWITZERLAND, 2 Seoul, 3 Suwon, SOUTH KOREA, 4 Buenos Aires, ARGENTINA

16.40 • CAN SPOT URINE BE USED TO REPLACE 24-HOUR URINE FOR MONITORING POPULATION SALT INTAKE?
L. Huang 1, M. Crino 1, P. Jeffery 1, W. Woodward 1, F. Barzi 1, R. McLean 1, M. Land 1, N. Bruce 1
1 Sydney, 2 Melbourne, AUSTRALIA, 3 Dunedin, NEW ZEALAND

16.50 • COST-UTILITY ANALYSIS OF A SINGLE PILL TRIPLE ANTIHYPERTENSIVE THERAPY WITH VALSARTAN, AMLODIPINE, AND HYDROCHLOROTHIAZIDE AGAINST ITS DUAL COMPONENTS
P. Stafylas 1, G. Kourlaba 1, A. Mavrodi 1, M. Hatzikou 4, D. Georgiopoulou 4, P. Sarafidis 1, N. Maniadakis 1
1 Thessaloniki, 2 Athens, GREECE
Parallel Oral Session 8C

**MOLECULAR BIOLOGY AND PEPTIDES**

**Chairpersons:**
- X. Jeunemaître (Paris, FRANCE)
- A.S Mihailidou (Sydney, AUSTRALIA)

**15.30**

**OXYTOCIN REDUCES CARDIOMYOCYTE HYPERTROPHY**
M. Jankowski, A. Menouar, J. Gutkowska
Montreal, CANADA

**15.40**

**INCREASE OF ALDOSTERONE-INDUCED C-SRC PHOSPHORYLATION IN SHR VASCULAR SMOOTH MUSCLE CELLS IS ASSOCIATED WITH C-TERMINAL SRC-KINASE (CSK) AND CSK-BINDING PROTEIN (CBP) DOWNREGULATION**
G. Callera 1, A. Montezano 1, T. Bruder-Nascimento 1, R.M. Touyz 2
1 Ottawa, CANADA, 2 Glasgow, UNITED KINGDOM

**15.50**

**A CROSS-SECTIONAL INVESTIGATION AND GENETIC VARIATION STUDY OF METABOLIC SYNDROME AMONG UYGUR POPULATION IN XINJIANG**
Z. Ling, D. Zhang, L. Wang, T. Yin, J. Zhang, L. Cai, J. Meng, N. Li
Urumqi, CHINA

**16.00**

**INCREASED CIRCULATING SERUM LEVELS OF MATRIX METALLO PROTEINASE-2 ARE ASSOCIATED WITH HYPERHOMOCYSTEINEMIA IN HYPERTENSIVE PATIENTS IN EARLY STAGES OF CKD AND GLOMERULONEPHRITIS**
Thessaloniki, GREECE

**16.10**

**BK CHANNEL ON DIFFERENTIATION OF VASCULAR SMOOTH MUSCLE CELLS INDUCED BY MECHANICAL STRETCH**
Y. Qi 1, X. Wan 1, H. Zhao 1, Z. Jiang 1
1 Shanghai, 2 Beijing, CHINA

**16.20**

**INDUCTION OF THE EXPRESSION OF ENDOThelin−1 IN THE ENDOTHELIAL CELLS INCREASES BLOOD PRESSURE IN AN ENDOThelin TYPE A RECEPTOR-DEPENDENT MANNER**
P. Paradis 1, Y. Rautureau 1, S. Coelho 1, A. Rehman 1, S. Offermanns 2, E.L. Schiffrin 1
1 Montreal, CANADA, 2 Bad Nauheim, 3 Frankfurt, GERMANY

**16.30 • ENHANCED EXPRESSION OF GQ ALPHA AND PLC BETA 1 PROTEINS CONTRIBUTE TO VASCULAR SMOOTH MUSCLE CELL HYPERTROPHY IN SPONTANEOUSLY HYPERTENSIVE RATS: MOLECULAR MECHANISM**
M. Atef, M. Anand-Srivastava
Montreal, CANADA

**16.40 • SPECIFIC NOX−2 INHIBITION DECREASES OXIDATIVE STRESS AND IMPAIRS VASCULAR SMOOTH MUSCLE CELL PROLIFERATION**
J. Martinez-Pereira 1, A. Redondo 1, I. Quesada 1, M. Cifuentes 1, P. Pagano 1, C. Castro 1
1 Mendoza, ARGENTINA, 2 Pittsburgh, PA, USA

**16.50 • SERUM CYSTATIN C AND BRAIN NATRIURETIC PEPTIDE AS MARKERS FOR HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY**
S. Charfeddine, L. Abid, M. Turki, L. Charni, S. Ben Kahla, S. Kammoun
Sfax, TUNISIA
**Late-Breakers**

**SESSION 3**

**Chairpersons:**
L. Liu (Beijing, CHINA)  
J. Widimsky (Prague, CZECH REPUBLIC)

**16.30** • 24-HOUR AMBULATORY CENTRAL BLOOD PRESSURE AND PRECLINICAL TARGET ORGAN DAMAGE IN ADOLESCENTS AND YOUNG ADULTS  
Athens, GREECE

**16.40** • THE ROLE OF B3-ADRENERGIC RECEPTORS ON CARDIOVASCULAR FUNCTION  
F. Santos, N.Z. Preite, M.O. Ribeiro, M.C. Irigoyen, P. Fiorino, V. Farah  
São Paulo, BRAZIL

**16.50** • DIFFERENTIAL EFFECT OF EMBRYO TRANSFER AND IN VITRO CULTURE ON THE PHOSPHATIDYL-3 KINASE (PI3K) SIGNALLING PATHWAY IN THE HEART IN FETAL AND POSTNATAL LIFE  
M. Pudney, C. McMillen, S. Macloughlin, S. Zhang, D. Kleemann, S. Walker, K. Botting, J. Morrison  
Adelaide, AUSTRALIA

**17.00** • ELEVATED AORTIC STIFFNESS IS ASSOCIATED WITH MORE ADVANCED CARDIOVASCULAR DISEASE IN STROKE PATIENTS  
D. Gasecki 1, E. Swierbiewska 1, A. Roje 1, M. Kwarciany 1, K. Kowalczuk 1, P. Boutouyrie 2, W.M. Nyka 1, S. Laurent 1, K. Narkiewicz 1  
1 Gdansk, POLAND, 2 Paris, FRANCE

**17.10** • HOME BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING ANTHYPERTENSIVE DRUG THERAPY: A LARGE-SCALE PROSPECTIVE OBSERVATIONAL STUDY IN A REAL-WORLD SETTING  
K. Kato 1, I. Saito 1, T. Kusihoro 1, S. Teramukai 1, Y. Ishikawa 1, Y. Mori 1, F. Kobayashi 1, K. Shimada 1  
1 Tochigi, 2 Kanagawa, 3 Tokyo, 4 Kanazawa, JAPAN

**17.20** • BETA BLOCKAGE LEADS TO LESS ASYMPTOMATIC CARDIAC DAMAGE IN CORONARY PATIENTS UNDERGOING CAROTID ENDARTECETOXY  
Athens, GREECE
Parallel Oral Session 8D

LARGE ARTERIES

Chairpersons: P. Nihoyannopoulos (London, UNITED KINGDOM)
G. Vyssoulis (Athens, GREECE)

15.30 • LECTURE:
HAEMODYNAMIC IMPORTANCE OF CARDIOVASCULAR STIFFNESS
G.F. Mitchell
Waltham, MA, USA

15.50 • REFERENCE INTERVALS FOR FEMORAL ARTERY STIFFNESS, OBTAINED FROM
5,069 SUBJECTS
J. Bossuyt 1, L. Engelen 1, I. Ferreira 2, C. Stehouwer 2, P. Boutouyrie 3, S. Laurent 3, P. Segers 3, K. Reesink 4, L.M. Van Bortel 1
1 Ghent, BELGIUM, 2 Maastricht, NETHERLANDS, 3 Paris, FRANCE

16.00 • PULSE WAVE VELOCITY. BIOLOGICAL BEHAVIOUR AND CHARACTERISTICS IN
HEALTHY SUBJECTS. A PROSPECTIVE STUDY OF 3243 SUBJECTS
D. Lovic 1, M.S. Kallistratos 2, A. Skyrlas 2, L. Poulimenos 2, V. Stojanov 3, M. Zdravkovic 3, G. Koracevic 3, E. Chamodraka 1, N. Kouremenos 1, I. Zacharopoulou 1, P. Tsivizov 1, K. Kyfnidis 1, A. Pittaras 1
1 Niš, SERBIA, 2 Athens, GREECE, 3 Belgrade, SERBIA

16.10 • A COMPARISON OF PULSE WAVE VELOCITY IN COHORTS FROM EUROPE AND
ARGENTINA. AN EFFORT TO SETTLE REFERENCE VALUES
P. Forcada, S. Gonzalez, J. Chibaut Svane, S. Orengon, C. Castellaro, F. Inseria, C. Kotliar
Pilar, ARGENTINA

16.20 • NON-HAEMODYNAMIC PREDICTORS OF VARIATION IN ARTERIAL STIFFNESS
AFTER 17 YEARS
M. Gottsäter, G. Östling, M. Persson, G. Engström, O. Melander, P.M. Nilsson
Lund, SWEDEN

16.30 • DIASTOLIC BLOOD FLOW REVERSAL IN THE DESCENDING AORTA DETERMINES
RENAL FUNCTION: POTENTIAL EXPLANATION FOR RENAL DYSFUNCTION DUE TO AORTIC
STIFFENING
J. Hashimoto, S. Ito
Sendai, JAPAN

16.40 • GREATER CENTRAL-TO-PERIPHERAL PULSE PRESSURE AMPLIFICATION IN
DIABETES AND OBESITY: THE RELATIVE MEDIATING ROLE OF ARTERIAL STIFFNESS, HEART
RATE AND WAVE REFLECTION. THE CODAM STUDY
P. Vaidya, R. Van De Laar, M. Van Greevenbroek, C. Van Der Kallen, C. Schalkwijk, M. Prins, C. Stehouwer, I. Ferreira
Maastricht, NETHERLANDS

16.50 • NON-INVASIVE ASSESSMENT OF CAROTID PULSE WAVE VELOCITY BY MEANS
OF ACCELEROMETRIC SENSORS: VALIDATION OF A NEW DEVICE
N. Di Lascio, F. Stea, R.M. Bruno, E. Bianchini, V. Gemignani, L. Ghiadoni, F. Faita
Pisa, ITALY
Parallel Oral Session 9A

RESISTANT HYPERTENSION

Chairpersons:
- B.K. Al Kadhemi (Baghdad, IRAQ)
- S. Douma (Athens, GREECE)

17.00 • PROGNOSTIC IMPACT OF AORTIC STIFFNESS IN PATIENTS WITH RESISTANT HYPERTENSION
G. Salles, C. Roderjan, M. Ferreira, E. Muxfeldt
Rio de Janeiro, BRAZIL

17.10 • RENAL DENERVATION STOPS THE DECLINE OF RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND RESISTANT HYPERTENSION
C. Ott 1, F. Mahfoud 1, A. Schmid 1, T. Ditting 1, R. Veelken 1, M. Uder 1, M. Böhm 1, R.E. Schmieder 1
1 Erlangen, 2 Homburg/Saar, GERMANY

17.20 • PRELIMINARY EXPERIENCE WITH AN IRRIGATED BALLOON-BASED RADIOFREQUENCY DEVICE FOR RENAL DENERVATION
Milan, ITALY

17.30 • SHOULD HOME BP MEASUREMENTS BE A STANDARD END POINT IN RENAL DENERVATION STUDIES? RESULTS FROM ENLIGHTN I FIRST-IN-HUMANS STUDY
V. Papademetriou 2,5, C. Tsioufis 2,6, M. Worthley 1, A. Sinhal 3, D. Chew 3, I. Meredith 4, Y. Malaiapan 4, S. Worthley 1
1 Adelaide, 2 Sydney, 3 Bedford Park, 4 Melbourne, 5 Washington, DC, USA

17.40 • UNMASKING THE DISRUPTION OF THE RENAL NERVES AT THE CATHETER BASED RENAL DENERVATION PROCEDURE. DOES ELECTRICAL STIMULATION ON RENAL ARTERIAL AUTONOMIC NERVES REALLY WORK?
Athens, GREECE

The Balkanian Symposium

PARTICULAR QUESTIONS

Chairpersons:
- S. Erdine (Istanbul, TURKEY)
- V. Stojanov (Belgrade, SERBIA)
- S. Erdine (Istanbul, TURKEY)
- V. Stojanov (Belgrade, SERBIA)

15.30 • Introduction and future perspective in a Balkan network
A.J. Manolis (Athens, GREECE)

15.42 • CV risk assessment of Romanian Hypertension population. What’s new?
M. Dorobantu (Bucharest, ROMANIA)

15.54 • Patient involvement in prevention strategies – a major goal for Romanian Heart Foundation!
D. Gaita (Timisoara, ROMANIA)

16.06 • Blood pressure management at Balkan (EUROASPIRE and other studies)
D. Lovic (Niš, SERBIA)

16.18 • Cardiac alterations in hypertension and health system
A. Pittaras (Athens, GREECE)

16.30 • Low birth weight as a cardiovascular and renal risk factor. Could telomeres be a crystal ball?
M. Laganovic (Zagreb, CROATIA)

16.42 • Arterial stiffness in some specific group of patients
B. Jelakovic (Zagreb, CROATIA)
17.50 • PROGNOSTIC IMPACT OF TREATMENT RESISTANT HYPERTENSION ON CLINICAL EVENTS DURING 2 YEAR FOLLOW-UP IN ELDERLY PATIENTS. RESULTS OF THE 3 A REGISTRY
I. Kistner 1, U. Zeymer 1, R. Dechend 1, T. Riemer 1, I. Hagedorn 1, R.E. Schmieder 1
1 Erlangen, 2 Ludwigshafen, 3 Berlin, 4 Nürnberg, GERMANY

18.00 • HYPER-RESPONDER VS. NON-RESPONDER PATIENTS AFTER RENAL DENERVATION: DO THEY DIFFER?
A. Persu 1, M. Azizi 2, Y. Jin 3, S. Volz 4, J. Rosà 5, F. Fadl Elmula 6, M. Burnier 7, P. Mark 8, A. Elvan 9, J. Rennik 1, M. Sapoval 1, I. Kahan 10, E. Kjeldsen 11, J.A. Staessen 12
1 Brussels, BELGIUM, 2 Paris, FRANCE, 3 Leuven, BELGIUM, 4 Gothenburg, SWEDEN, 5 Prague, CZECH REPUBLIC, 6 Oslo, NORWAY, 7 Lausanne, SWITZERLAND, 8 Glasgow, UNITED KINGDOM, 9 Zwolle, NETHERLANDS, 10 Stockholm, SWEDEN

18.10 • NON-INVASIVE HEMODYNAMIC MONITORING AS A GUIDE TO DRUG TREATMENT IN PATIENTS WITH UNCONTROLLED HYPERTENSION: THE BEAUTY STUDY
1 Milan, ITALY, 2 Oslo, NORWAY, 3 Tallinn, ESTONIA, 4 Gdansk, POLAND, 5 Paris, FRANCE

18.20 • DIFFERENT PROFILE OF NEUROADRENERGIC ACTIVATION AND BAROREFLEX FUNCTION IN RESISTANT HYPERTENSION AND PSEUDORESISTANT HYPERTENSION: A MICRONEUROGRAPHIC STUDY
G. Seravalle 1, S. Buzzi 2, L. Magni 1, C. Ciuffarella 1, M. Macchiariulo 1, M. Bombelli 2, G. Brambilla 2, R. Dell’Oro 1, G. Mancia 1, G. Grassi 12
1 Milan, 2 Monza, ITALY
18.00 • PODOCYTE MICROPARTICLES INDUCE P38 ACTIVATION AND REACTIVE OXYGEN SPECIES PRODUCTION IN HUMAN CULTURED PROXIMAL TUBULE CELLS
D. Burger, S. Akbari, M. Turner
Ottawa, CANADA

18.10 • LONG-TERM OUTCOME AFTER ANGIOPLASTY IN PATIENTS WITH RENAL ARTERY STENOSIS AND HIGH RESISTIVE INDEX: A PROSPECTIVE COHORT STUDY
N. Scherer 1, F. Limbourg 2, F. Rauch 1, M. Hiss 1, H. Haller 1, J. Radermacher 2
1 Minden, 2 Hannover, GERMANY

18.20 • PREDICTIVE VALUE OF MARKERS OF VASCULAR DAMAGE FOR RENAL OUTCOME IN TYPE 2 DIABETES AND ESSENTIAL HYPERTENSION
R. Bruno, A. Salvati, M. Barzacchi, K. Raimo, L. Ghiadoni, A. Solini
Pisa, ITALY

17.00 • Parallel Oral Session 9C

17.00 - 18.30  Conference Suite II - MC2

Parallel Oral Session 9C

BLOOD PRESSURE VARIABILITY

Chairpersons: M. Dorobantu (Bucharest, ROMANIA)
T. Ogihara (Osaka, JAPAN)

17.00 • ARTERIAL STIFFNESS AND AUTONOMIC NERVOUS FUNCTION IN ORTHOSTATIC BLOOD PRESSURE CHANGES
Wakayama, JAPAN

17.10 • OUTCOME BASED THRESHOLD VALUES FOR INCREASED BLOOD PRESSURE VARIABILITY. DATA FROM DUBLIN OUTCOME STUDY
G. Bilo 1, E. Dolan 2, R. Facchetti 1, E. O’Brien 2, G. Mancia 1, G. Parati 1
1 Milan, 2 Dublin, IRELAND

17.20 • PREDICTIVE VALUE OF DIFFERENT INDICES OF BLOOD PRESSURE VARIABILITY ON CARDIOVASCULAR MORTALITY AND ORGAN DAMAGE: DATA FROM THE PAMELA STUDY
G. Brambilla 1, M. Bombelli 1, R. Facchetti 1, F. Nicoli 1, D. Fodri 1, E. Tosio 1, F. Ganz 1, R. Dell’Oro 1, G. Seravalle 1, G. Grassi 1,2, G. Mancia 2
1 Monza, 2 Milan, ITALY

17.30 • PREFERABLE EFFECTS OF OLMESARTAN/CALCIUM CHANNEL BLOCKER TO OLMESARTAN/DIURETIC ON BLOOD PRESSURE VARIABILITY IN VERY ELDERLY HYPERTENSION: A SUB-ANALYSIS OF THE COLM STUDY
H. Rakugi 1, T. Ogihara 2, I. Saito 3, S. Teramukai 4, T. Saruta 4
1 Suita, 2 Osaka, 3 Tokyo, 4 Kanazawa, JAPAN

17.40 • CARDIAC AUTONOMIC IMPAIRMENT AND CHRONOTROPIC INCOMPETENCE IN DIPPER AND NONDIPPER HYPERTENSION
C. Yildiz, A. Yildiz, F. Tekiner, Y. Gunes
Istanbul, TURKEY

17.50 • VISIT-TO-VISIT VARIABILITY OF SYSTOLIC BLOOD PRESSURE IN HYPERTENSIVE PATIENTS TREATED EXCLUSIVELY WITH A COMBINATION TREATMENT IN THE ANGLO–SCANDINAVIAN CARDIAC OUTCOMES TRIAL–BPLA
S. Watson, A. Gupta, N.R. Poulter
London, UNITED KINGDOM
18.00 • POSTPRANDIAL HYPERTENSION, AN OVERLOOKED RISK MARKER FOR ARTERIOSCLEROSIS
Y Tabara 1, E. Uetani 2, M. Igase 2, G. Haiyan 2, T. Kido 2, N. Ochi 2, R. Takita 2, K. Kohara 2, T. Miki 2
1 Kyoto, 2 Toon, JAPAN

18.10 • PREDICTORS OF VISIT-TO-VISIT VARIABILITY OF SYSTOLIC BLOOD PRESSURE IN THE “REAL LIFE”: RESULTS OF THE VOLTAGE STUDY
J.J. Mourad 1, D. Agnoletti 1, J. Kerihuel 1, J. Blacher 2
1 Bobigny, 2 Paris, FRANCE

18.20 • THE CORRELATION BETWEEN BEAT-TO-BEAT HEART RATE VARIABILITY/CIRCADIAN BLOOD PRESSURE VARIABILITY AND AtherosclEROSCLEROTIC CHANGE OR HEMODYNAMIC STATUS
Osaka, JAPAN

17.00 • 24-HOUR CALCIUM EXCRETION IS ASSOCIATED WITH DIASTOLIC BLOOD PRESSURE: THE STYRIAN HYPERTENSION STUDY
M. Gaksch 1, K. Kienreich 1, N. Verheyen 1, M. Gruber 1, J. Gregorenz 1, B.O. Hartagh 1, T.R. Pieber 1, A. Tomaschitz 1, S. Pilz 1
1 Graz, AUSTRIA, 2 New Haven, CT, USA, 3 Bad Aussee, AUSTRIA, 4 Amsterdam, NETHERLANDS

17.10 • HYPERTENSION PREVALENCE AND CONTROL IN RUSSIA: AN UP-DATE FROM NEW RUSSIAN EPIDEMIOLOGY SURVEY ESSE-RF
A.O. Konradi 1, S. Shalnova 2, Y. Balanova 2, A. Deev 2, O. Rotar 1, E. Oschepkova 2, S. Boitsov 1, Y. Karpov 2, E. Shlyakhto 1
1 Saint-Petersburg, 2 Moscow, RUSSIA

17.20 • BLOOD PRESSURE VARIABILITY, METABOLIC PROFILE AND CARDIOVASCULAR RISK IN CENTRAL AND EASTERN EUROPE: DATA FROM THE BP-CARE STUDY
G. Brambilla 1, M. Bombelli 1, G. Seravalle 1, M. Volpe 1, R. Facchetti 1, S. Buzzi 1, R. Dell’Oro 1, S. Laurent 1, J. Redon 1, G. Mancia 1, G. Grassi 1
1 Monza, 2 Milan, ITALY, 3 Paris, FRANCE, 4 Valencia, SPAIN

17.30 • HYPERTENSION IS AN INDEPENDENT RISK FACTOR FOR TYPE 2 DIABETES
N. Lim 1, H. Park 2, S. Choi 1, M. Cho 1
1 Chungcheongbuk-Do, 2 Cheongju, SOUTH KOREA

17.40 • THE HYPERTENSIVE ROMA PATIENT. PERSPECTIVES FROM THE LARGEST HYPERTENSION STUDY ON THE ROMA POPULATION. DATA FROM THE ROMA STUDY
Bucharest, ROMANIA

17.50 • PREVALENCE OF HYPERTENSION IN SOUTH ASIA: SYSTEMATIC REVIEW AND META-ANALYSIS
D. Neupane 1, P. Kallestrup 1, B. Christensen 1, V. Khanal 1, B. Gyawali 2, S. Mishra 3, C. McLachlan 4
1 Aarhus, 2 Esbjerg, DENMARK, 3 Kathmandu, NEPAL, 4 Perth, 5 Sydney, AUSTRALIA
18.00 • GENDER DIFFERENCES OF HYPERTENSION INCIDENCE ACCORDING TO SOCIOECONOMIC STATUS
N. Lim 1, M. Cho 2, H. Park 2
1 Chungcheongbuk-Do, 2 Cheongju, SOUTH KOREA

18.10 • ADDITIVE INTERACTION OF ORAL HEALTH DISORDERS ON RISK OF HYPERTENSION IN A JAPANESE URBAN POPULATION: THE SUITA STUDY
Y. Iwashima, Y. Kokubo, T. Ono, Y. Yoshimuta, M. Kida, T. Kosaka, Y. Maeda, Y. Kawano, Y. Miyamoto
Osaka, JAPAN

18.20 • ASSOCIATION BETWEEN FREE TESTOSTERONE AND HYPERTENSION, METABOLIC SYNDROME AND SUBCLINICAL ORGAN DAMAGE IN PERIMENOPAUSAL WOMEN
A. Olszanecka, K. Kawecka-Jaszcz, D. Czarnecka
Kraków, POLAND
INVESTIGATOR GENERATED SATELLITE SYMPOSIA
Investigator Generated Satellite Symposia

June 6–7, 2014 • Thessaloniki (Greece)
Working group on Obesity, Diabetes and the High Risk Patients – Satellite symposium and consensus meeting
V. Kotsis

June 10–12, 2014 • Santorini (Greece)
Putting the A back into RAAS
L. Burrell, A.S. Mihailidou

June 11–12, 2014 • Athens (Greece)
Update on Resistant Hypertension & related comorbidities
C. Tsioufis

June 13, 2014 • Athens (Greece)
The Pulse of Asia 2014 in Athens
A. Yamashina

June 13, 2014 • Athens (Greece)
Methodology and Technology for Peripheral and Central Blood Pressure Measurement: current status, practical application and future research
G.S. Stergiou

June 18, 2014 • Rome (Italy)
Cardiovascular Genetics Satellite – The 16th International SHR Symposium
M. Volpe

September 26–27, 2014 • Costa Navarino, Pylos (Greece)
Hot topics in Hypertension and Cardiovascular Disease
A.J. Manolis

Complete programmes are available on www.hypertension2014.org under the menu Scientific Info.
INDEX OF CHAIRPERSONS, SPEAKERS AND AUTHORS
Abdelrasoul M. 153, 194, 212, 215
Abdulaleeva G. 101
Abegaz B. 193
Abid L. 233
Aboushamala A. 213
Abram S. 235
Abu-Alfa A. 152
Achilleus D. 93
Achimastos A. 165
Acimovic T. 157
Ademiz N. 110, 134
Adirugun D. 130
Agabiti Rosei C. 154
Agabiti Rosei E. 106, 138, 141, 154, 163
Agapova O. 209
Aggelakas A. 194
Aghelis A. 212, 215
Aggiusti C. 154
Aggiusti C. 154
Aggelakas A. 194
Aghelis A. 212, 215
Aggiusti C. 154
Agnoletti D. 110, 244
Agostiris M. 153
Agostoni P. 228
Aquilari C. 84
Aguir S. 192
Aguilar F. 187
Agymenag C. 190
Ahmimastos A. 87
Ahluwalia A. 162
Ahm N. 155
Ahn S. 155
Aissopou E. 173
Aitman T. 96
Aizawa K. 130
Ajayi S. 134
Akbari S. 242
Akgumus A. 98
Aksnes T. 213
Al kadhemi B.K. 239
Al-Hegariki Z.K. 210
Al-Said J. 178
Alastrety J. 144, 211
Alesi A. 94
Alexandrides A. 208
Alfie J. 100
Alfieri C. 241
Alite C. 111
Alivon M. 197
Allollio B. 215
Alnima T. 209
Alonzo C. 112, 113
Alsanoz M. 96
Alvarez J. 187
Alweis R. 228
Amor L. 142, 215
Amaro A. 130
Ambrosioni E. 230
Amehe V. 101
Anand-Srivastava M. 233
Anastasio F. 208
Anastasiou-Nana M. 110
Andreetti F. 124
Andrews K. 171
Andriulli M. 113
Androulatsios L. 212, 215
Anev E. 95
Angeli E. 94
Anisbiou B. 114
Annoni F. 187
Anzumi A. 153
Antic M. 157
Antlanger M. 159
Antza C. 154
Anyfanti P. 92, 153, 174, 228
Anza C. 228
Anza-Ramirez C. 191
Aparicio L. 100
Apetrei E. 218
Arar Y. 228
Arakawa K. 159
Aranda P. 154, 171
Arhanareeswaran K. 160
Arygri A. 173
Arri C. 173
Arita M. 243
Armitage J. 98
Arianlou J. 161
Arruda-Olson A. 235
Arlan E. 212
Asyama K. 101, 190
Ashimova B. 158
Ashton A. 159
Aslanidis S. 153
Asmar R. 123, 164, 180
Atanor S. 96
Atef M. 233
Auer J. 107
Aukema H. 195
Avolio A. 99, 116, 120, 201
Awadalla P. 162
Ayamuqu R. 130
Azebel J. 173
Azizan E. 103, 214, 215
Azizi M. 192, 195, 197, 219, 240, 241
Aznaouridis K. 130, 215
Azuma J. 111, 194
Bacca A. 174
Badenhorst M. 160
Badila E. 245
Baeve A. 128
Bai H. 93, 161, 172
Bakker S. 115
Bakris G.L. 84, 128, 152, 186, 197
Bala C. 218
Balafa O. 211
Balanikas G. 208
Balanova Y. 245
Balavoine F. 195
Ball C. 130
Baranova E. 94, 119
Bardin T. 189
Barhoumi T. 97, 104, 107
Barin E. 211
Baroehori J. 100
Bartos D. 245
Barzacchi M. 242
Barzel B. 212
Barzi F. 230, 231
Bascelli A. 112
Barth P.M.W. 197
Battista F. 208
Brattke W. 96
Bechiliouls A. 211
Becker S. 99
Bellin L. 101
Beime B. 235
Behlerad M. 155
Belkikhina T. 158
Belloni A. 241
Belynskii E. 157, 215
Ben Kahla S. 233
Benetos A. 110, 123, 164
Benetti E. 165
Berbari A.E. 89
Berent R. 107
Berezin A. 157, 158
Berge E. 162, 197
Bergerot D. 195
Bernard S. 99
Bernini G. 174
Bertacchini F. 154
Bertolini A. 153
Beuschel F. 215
Bhat S. 228
Bhatt D. 197
Bianchi S. 94
Bianchini E. 237
Bieniaszewska L. 112
Bigierini S. 94
Bilo G. 165, 184, 191, 228, 243
Bisognano J. 128
Blacher J. 244
Blanc M. 154
Blanchard A. 241
Blanchet B. 197
Bllicher M. 172, 211, 212
Blizzard L. 101
Bobhie G. 192
Bociaga Z. 213
Bogdanski P. 162
Bohringer J. 210
Bohm M. 129, 239
Boisot S. 245
Bombelli M. 153, 240, 243, 245
Borges S. 133, 157
Borghi C. 89, 189, 203
Bortolazzi A. 165, 212
Bortolotto L. 130
Boschetti G. 112
Boss F. 99
Bosuyt J. 161, 236
Bottiger K. 234
Boudoulas H. 133
Boudoulas K.D. 90
Boukroun S. 215
Bourguignon L. 111
Boutouyrie P. 122, 144, 161, 197, 234, 236
Bouziana S. 112
Bouzina E. 148
Bowles E. 93
Boyraz B. 98
Boyesen G. 162
Bozic B. 229
Bradley T. 241
Bramante A. 99
Brambilla G. 240, 243, 245
Braniage P. 93, 235
Brand S. 160
Brandorff M. 103
Branney M. 196
Braun S. 214
Brund P. 158
Breda J. 198
Breitling R. 96
Brekke M. 128
Brescacin L. 112, 113
Brewster L. 208
Breguian J. 206, 208
Briet M. 104
Brighton C. 103
Broer J. 133
<table>
<thead>
<tr>
<th>Chairpersons, Speakers and Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hagedorn I. 128, 240</td>
</tr>
<tr>
<td>Haiyan G. 244</td>
</tr>
<tr>
<td>Halimi J. M. 107</td>
</tr>
<tr>
<td>Hall I. 96</td>
</tr>
<tr>
<td>Haller H. 92, 128, 169, 171, 196, 208, 242</td>
</tr>
<tr>
<td>Haller S. 104</td>
</tr>
<tr>
<td>Hamet P. 162</td>
</tr>
<tr>
<td>Hamodraka E. 155</td>
</tr>
<tr>
<td>Han Y. 104</td>
</tr>
<tr>
<td>Hannah-Shmouni F. 103</td>
</tr>
<tr>
<td>Hanon O. 110</td>
</tr>
<tr>
<td>Hara A. 190</td>
</tr>
<tr>
<td>Harazny J. 93, 173</td>
</tr>
<tr>
<td>Haris Shaikh L. 214, 215</td>
</tr>
<tr>
<td>Harrap S. B. 96, 103, 104, 106, 161, 199, 210</td>
</tr>
<tr>
<td>Hartaligh B. O. 245</td>
</tr>
<tr>
<td>Harvey P. 169</td>
</tr>
<tr>
<td>Hashimoto J. 236</td>
</tr>
<tr>
<td>Hattangady N. 97</td>
</tr>
<tr>
<td>Hattori S. 243</td>
</tr>
<tr>
<td>Hatzikou M. 231</td>
</tr>
<tr>
<td>Hatzihloios A. 112, 208, 232</td>
</tr>
<tr>
<td>Hayashi I. 228</td>
</tr>
<tr>
<td>Hayashi K. 173</td>
</tr>
<tr>
<td>Hayashi S. 229</td>
</tr>
<tr>
<td>He D. 104</td>
</tr>
<tr>
<td>He J. 96</td>
</tr>
<tr>
<td>Head G. A. 133, 134, 140, 171, 192, 212</td>
</tr>
<tr>
<td>Heagerty A. M. 100, 128</td>
</tr>
<tr>
<td>Heinpuli-Kuum M. 196, 240</td>
</tr>
<tr>
<td>Heils L. 132</td>
</tr>
<tr>
<td>Henkin Y. 187</td>
</tr>
<tr>
<td>Henriques E. 93, 157</td>
</tr>
<tr>
<td>Henry A. 96</td>
</tr>
<tr>
<td>Henry R. 190</td>
</tr>
<tr>
<td>Hepworth J. 168</td>
</tr>
<tr>
<td>Heras M. 173</td>
</tr>
<tr>
<td>Herbots L. 210</td>
</tr>
<tr>
<td>Hering D. 129</td>
</tr>
<tr>
<td>Hermetregildo C. 111, 173</td>
</tr>
<tr>
<td>Hermida R. 100, 165</td>
</tr>
<tr>
<td>Hernandez Marrero D. 154</td>
</tr>
<tr>
<td>Hernandez-Hernandez R. 168, 204</td>
</tr>
<tr>
<td>Herpin D. 189</td>
</tr>
<tr>
<td>Heyvaert F. 169</td>
</tr>
<tr>
<td>Hideyo O. 173</td>
</tr>
<tr>
<td>Higaki J. 114</td>
</tr>
<tr>
<td>Hilliard L. 103</td>
</tr>
<tr>
<td>Hirohama D. 158</td>
</tr>
<tr>
<td>Hirose T. 190</td>
</tr>
<tr>
<td>Hiss M. 242</td>
</tr>
<tr>
<td>Hixson J. 96</td>
</tr>
<tr>
<td>Hjernholm U. 128</td>
</tr>
<tr>
<td>Hoffmann M. 159</td>
</tr>
<tr>
<td>Hoffmann P. 128</td>
</tr>
<tr>
<td>Hoffman A. 107, 112</td>
</tr>
<tr>
<td>Heiegggen A. 128</td>
</tr>
<tr>
<td>Holaj R. 196</td>
</tr>
<tr>
<td>Holst J. 195</td>
</tr>
<tr>
<td>Hong G. 196</td>
</tr>
<tr>
<td>Hong S. 93</td>
</tr>
<tr>
<td>Hoon S. J. 85</td>
</tr>
<tr>
<td>Horiuichi M. 93, 149, 161, 172, 223</td>
</tr>
<tr>
<td>Hornslien A. 162</td>
</tr>
<tr>
<td>Hosaka M. 190</td>
</tr>
<tr>
<td>Hoshi H. 190</td>
</tr>
<tr>
<td>Hostucc M. 245</td>
</tr>
<tr>
<td>Houben A. J. H. M. 98</td>
</tr>
<tr>
<td>Howatson A. 213</td>
</tr>
<tr>
<td>Hu B. 95</td>
</tr>
<tr>
<td>Hu M. 101</td>
</tr>
<tr>
<td>Hu X. 98</td>
</tr>
<tr>
<td>Hu Y. 160</td>
</tr>
<tr>
<td>Huang D. 94</td>
</tr>
<tr>
<td>Huang H. 157</td>
</tr>
<tr>
<td>Huang L. 230, 231</td>
</tr>
<tr>
<td>Huang Q. 95</td>
</tr>
<tr>
<td>Huet O. 171</td>
</tr>
<tr>
<td>Hughes A. 154</td>
</tr>
<tr>
<td>Huq M. 134</td>
</tr>
<tr>
<td>Hwang K. 196</td>
</tr>
<tr>
<td>Ichikawa M. 159</td>
</tr>
<tr>
<td>Idris-Khodja N. 97, 107</td>
</tr>
<tr>
<td>Igase M. 244</td>
</tr>
<tr>
<td>Iglund J. 162</td>
</tr>
<tr>
<td>Ikeda K. 212</td>
</tr>
<tr>
<td>Ikeda-Iwabe Y. 111, 194</td>
</tr>
<tr>
<td>Ikonomidis I. 110</td>
</tr>
<tr>
<td>Ikram M. 107, 112</td>
</tr>
<tr>
<td>Ilardi A. 95</td>
</tr>
<tr>
<td>Illadis F. 208</td>
</tr>
<tr>
<td>Iliopoulos T. 179</td>
</tr>
<tr>
<td>Imagawa M. 159</td>
</tr>
<tr>
<td>Imai Y. 101, 134, 190</td>
</tr>
<tr>
<td>Imboden H. 210</td>
</tr>
<tr>
<td>Inoue R. 190</td>
</tr>
<tr>
<td>Inserra F. 236</td>
</tr>
<tr>
<td>Ioaikemidiou N. 143, 153, 194, 212, 215</td>
</tr>
<tr>
<td>Iric-Cupic V. 211</td>
</tr>
<tr>
<td>Irigoyen M. C. 234</td>
</tr>
<tr>
<td>Jackson K. 171, 193</td>
</tr>
<tr>
<td>Jacobs L. 114</td>
</tr>
<tr>
<td>Jain A. 194</td>
</tr>
<tr>
<td>Jain S. 165</td>
</tr>
<tr>
<td>Jankowski J. 92</td>
</tr>
<tr>
<td>Jankowski M. 156, 232</td>
</tr>
<tr>
<td>Januszewicz A. 142, 168</td>
</tr>
<tr>
<td>Jaroch J. 213</td>
</tr>
<tr>
<td>Jatsuk D. 94</td>
</tr>
<tr>
<td>Jeffery P. 230, 231</td>
</tr>
<tr>
<td>Jelakovic B. 141, 163, 179, 229, 236</td>
</tr>
<tr>
<td>Jenkins C. 159</td>
</tr>
<tr>
<td>Jennings G. L. 139, 224</td>
</tr>
<tr>
<td>Jeon E. S. 85</td>
</tr>
<tr>
<td>Jeunemaître X. 215, 232</td>
</tr>
<tr>
<td>Jiang Z. 232</td>
</tr>
<tr>
<td>Jimbo R. 158</td>
</tr>
<tr>
<td>Jin Y. 240</td>
</tr>
<tr>
<td>Jiravsky O. 196</td>
</tr>
<tr>
<td>Joe B. 97, 104, 179</td>
</tr>
<tr>
<td>Joergensen T. 212</td>
</tr>
<tr>
<td>Joffres M. 162</td>
</tr>
<tr>
<td>Jones E. 160</td>
</tr>
<tr>
<td>Jones R. 213</td>
</tr>
<tr>
<td>Joo H. 93</td>
</tr>
<tr>
<td>Joo S. 196</td>
</tr>
<tr>
<td>Jordan J. 156</td>
</tr>
<tr>
<td>Jørgensen T. 172</td>
</tr>
<tr>
<td>Josipovic J. 229</td>
</tr>
<tr>
<td>Jozifova M. 113</td>
</tr>
<tr>
<td>Julo A. 100</td>
</tr>
<tr>
<td>Julius S. 186, 209</td>
</tr>
<tr>
<td>Jumar A. 173</td>
</tr>
<tr>
<td>Jusufovic M. 197</td>
</tr>
<tr>
<td>Kabat M. 168</td>
</tr>
<tr>
<td>Kachenoura N. 173</td>
</tr>
<tr>
<td>Kahan T. 206, 240</td>
</tr>
<tr>
<td>Kahraman F. 98</td>
</tr>
<tr>
<td>Kaila M. 168</td>
</tr>
<tr>
<td>Kalaitzidis R. 82, 211</td>
</tr>
<tr>
<td>Kallestrup P. 245</td>
</tr>
<tr>
<td>Kallikazaros L. 239</td>
</tr>
<tr>
<td>Kallikazaros J. 88</td>
</tr>
<tr>
<td>Kalilistratos M. 82, 94, 223, 236</td>
</tr>
<tr>
<td>Kalogeropoulos P. 100, 110</td>
</tr>
</tbody>
</table>
Index of Chairpersons, Speakers and Authors

A

Kazantzidou P. 112
Kefala A. 239
Kelly T. 96
Keriuel J. 244
Kerimkulova A. 158
Kerr S. 187
Khambata R. 162
Khamidulliava G. 101
Khanal V. 245
Khoury P. 187
Kiat H. 211
Kida M. 246
Kido T. 244
Kielstein J. 189
Kienreich K. 245
Kikuya M. 190
Kim B. 101
Kim C.H. 85, 157
Kim D. 196
Kim E. 230
Kim H. 194, 230
Kim J. 155
Kim K. 196
Kim M. 101
Kim S.H. 85
Kim Y. 230
Kimball T. 187
Kimtis K. 213, 239
Kishida M. 229
Kistner I. 93, 240
Kiyakbaev G. 94
Kjaer V. 128
Kjeldsen S.E. 128, 169, 175, 186, 196, 213, 240
Kleemann D. 98, 234
Knez J. 210
Knoll E. 214

Knoppers B. 162
Kobayashi F. 234
Kobayashi H. 171, 228
Kobayashi T. 95, 133
Koch E. 173
Kohara K. 93, 244
Koid S. 159
Kokkinos J. 94
Kokkinos P. 94, 99, 110, 155, 160, 216, 224
Kokubo Y. 95, 133, 224, 246
Kollai M. 192
Kollai A. 100, 165, 234
Kolovou G. 106
Kong Y. 160
Konig I. 158
Kono H. 173
Konoshita T. 159
Konradi A.O. 112, 162, 223, 245
Konstantinides S.V. 185
Konstantinidis G. 232
Konstantonidis G. 173
Kontas S. 110
Kopel E. 158
Koracevic G. 236
Kordalis A. 213, 239
Kosaka T. 246
Kotliar C. 236
Kotronis G. 154
Kotsa A. 211

Kotsis V. 154, 201, 252
Kouchaki Z. 99
Kouremenos N. 82, 94, 155, 236
Kouriaba G. 231
Koutra E. 213
Koutroumpas G. 161, 241
Koutsaki M. 82
Kovariik J. 159
Kowalczczyk K. 234
Kraigher-Krainer E. 157, 215
Krajcirovecova A. 113
Kremastinos D. 110
Kremser A. 157, 158
Kreutz R. 96
Kroon A. 98, 130, 209
Kruger R. 172, 211, 212
Krum H. 110
Kruszynska E. 213
Krylov A. 128
Küchler G. 184
Kuzcerisaka M. 210
Kudo M. 214
Kumar B. 200
Kumaramsamy S. 97, 104
Kuricka K. 112
Kurbanov R. 101
Kusanu K. 95, 133
Kushiro T. 234
Kuwabara J. 192, 193
Kuznetsova T. 210
Kvariany M. 234
Kwitek A. 97
Kynfis K. 94, 110, 155, 236

L

Labat C. 110
Laberge C. 162
Lackland D.T. 120, 198
Laganovic M. 229, 238
Lakas L. 211
Lambert G. 129
Lambert T. 107
Land M. 230, 231
Landsberg L. 98, 224
Lang D. 107
Lang M. 228
Langham R. 110
Lankhorst S. 135
Lanzani C. 97, 239
Lapi D. 194
Larstorp A.C. 128, 196, 240
Lasaridis A. 161, 190
Latib A. 239
Laucevicius A. 114
Laurent S. 84, 114, 122, 138, 144, 161, 167, 196, 197, 221, 234, 236, 240, 245
Lazarava I. 133
Lazaridis A. 92
Lazzaretto D. 94
Le T. 159
Lee J. 155
Lee S. 155, 196
Lee Y. 101
Leeson P. 123
Leete N. 92
Lekakis J. 110, 204
Lenegoum D. 114
Lenders M. 160
Leone D. 130
Leósóstotir M. 211
Levanczuk R. 230
Lewandowski P. 210
Lewin A. 169
Li C. 96
Li F. 171
Li G. 95
Li H. 160
Li K. 95, 130, 157
Li N. 232
Li X. 214
Li Y. 94, 95, 130, 171
Liakopoulos V. 161
Liang L. 153
Lichikaki V. 128
Lim D. 93
Lim K. 212
Lim N. 191, 245, 246
Limbourg F. 242
Limor R. 156, 214
Lindblad B. 195
Lindhardt M. 92
Lindholm LH. 121, 153
Ling Z. 232
Linker R. 159
Linksted P. 187
Listopad Q. 94
Liu F. 154
Liu L. 104, 205, 212, 234
Liu M. 95
Liu S. 95
Liu X. 173, 196, 240
Llornens-Cortes C. 195
Lobo M. 170, 194
Loboz-Grudzin K. 213
Loboz-Rudnicka M. 213
<table>
<thead>
<tr>
<th>Name</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Logan A.G.</td>
<td>241</td>
</tr>
<tr>
<td>Loh M.</td>
<td>94</td>
</tr>
<tr>
<td>Lohmeier TE.</td>
<td>116, 192</td>
</tr>
<tr>
<td>Lombardi C.</td>
<td>228</td>
</tr>
<tr>
<td>Lonati L.</td>
<td>165</td>
</tr>
<tr>
<td>London G.</td>
<td>135, 137</td>
</tr>
<tr>
<td>Lopez-Campos G.</td>
<td>96, 104</td>
</tr>
<tr>
<td>Lopez-Jaramillo J.P.</td>
<td>105</td>
</tr>
<tr>
<td>Lorenzi Filo G.</td>
<td>130</td>
</tr>
<tr>
<td>Losano I.</td>
<td>130</td>
</tr>
<tr>
<td>Loue C.</td>
<td>111</td>
</tr>
<tr>
<td>Loufa T.</td>
<td>83</td>
</tr>
<tr>
<td>Lovett E.</td>
<td>128</td>
</tr>
<tr>
<td>Łoew D.</td>
<td>110, 143, 149, 155, 179, 236, 238</td>
</tr>
<tr>
<td>Low Z.</td>
<td>94</td>
</tr>
<tr>
<td>Lu X.</td>
<td>104, 241</td>
</tr>
<tr>
<td>Lumsden N.</td>
<td>171</td>
</tr>
<tr>
<td>Luo H.</td>
<td>241</td>
</tr>
<tr>
<td>Lurber E.</td>
<td>145, 176, 182, 187</td>
</tr>
<tr>
<td>Luzzi A.</td>
<td>113</td>
</tr>
<tr>
<td>Ma Y.</td>
<td>173</td>
</tr>
<tr>
<td>Macarilupu J.</td>
<td>191, 228</td>
</tr>
<tr>
<td>Macchiariulo M.</td>
<td>240</td>
</tr>
<tr>
<td>MacGregor G.A.</td>
<td>198</td>
</tr>
<tr>
<td>Machnicki G.</td>
<td>230</td>
</tr>
<tr>
<td>Macia J.</td>
<td>107</td>
</tr>
<tr>
<td>MacLaughlin S.</td>
<td>98, 234</td>
</tr>
<tr>
<td>Madira W.</td>
<td>168</td>
</tr>
<tr>
<td>Maeda Y.</td>
<td>246</td>
</tr>
<tr>
<td>Magagna A.</td>
<td>168</td>
</tr>
<tr>
<td>Magni L.</td>
<td>240</td>
</tr>
<tr>
<td>Maglini C.</td>
<td>211</td>
</tr>
<tr>
<td>Mahfoud F.</td>
<td>128, 146, 170, 186, 239</td>
</tr>
<tr>
<td>Mahne S.</td>
<td>192, 193</td>
</tr>
<tr>
<td>Maier A.B.</td>
<td>98</td>
</tr>
<tr>
<td>Mailhac A.</td>
<td>239</td>
</tr>
<tr>
<td>Maillard M.</td>
<td>161</td>
</tr>
<tr>
<td>Makar O.</td>
<td>107</td>
</tr>
<tr>
<td>Mäki J.</td>
<td>100</td>
</tr>
<tr>
<td>Makino Y.</td>
<td>159</td>
</tr>
<tr>
<td>Makita K.</td>
<td>214</td>
</tr>
<tr>
<td>Maikri T.</td>
<td>82</td>
</tr>
<tr>
<td>Maksimchuk-Kolobova N.</td>
<td>230</td>
</tr>
<tr>
<td>Malaiapan Y.</td>
<td>99, 239</td>
</tr>
<tr>
<td>Mallichiova S.</td>
<td>230</td>
</tr>
<tr>
<td>Maldonado J.</td>
<td>101, 208</td>
</tr>
<tr>
<td>Malindretos P.</td>
<td>241</td>
</tr>
<tr>
<td>Mammen V.</td>
<td>134</td>
</tr>
<tr>
<td>Manakos K.</td>
<td>239</td>
</tr>
<tr>
<td>Mancia G.</td>
<td>83, 102, 124, 129, 153, 164, 167, 169, 183, 189, 196, 220, 228, 240, 243, 245</td>
</tr>
<tr>
<td>Mancoqounia P.</td>
<td>110</td>
</tr>
<tr>
<td>Mancuso V.</td>
<td>209</td>
</tr>
<tr>
<td>Manginio M.</td>
<td>96</td>
</tr>
<tr>
<td>Maniadakis N.</td>
<td>231</td>
</tr>
<tr>
<td>Maniero C.</td>
<td>103</td>
</tr>
<tr>
<td>Manios E.</td>
<td>88</td>
</tr>
<tr>
<td>Mann J.</td>
<td>213</td>
</tr>
<tr>
<td>Mano N.</td>
<td>190</td>
</tr>
<tr>
<td>Manolis A.J.</td>
<td>83, 94, 95, 99, 102, 106, 110, 139, 141, 155, 167, 183, 189, 196, 236, 238, 252</td>
</tr>
<tr>
<td>Manolopoulos J.</td>
<td>109</td>
</tr>
<tr>
<td>Mantero F.</td>
<td>215</td>
</tr>
<tr>
<td>Manunta P.</td>
<td>97, 239</td>
</tr>
<tr>
<td>Manzel A.</td>
<td>159</td>
</tr>
<tr>
<td>Maratou K.</td>
<td>96</td>
</tr>
<tr>
<td>Marcus C.</td>
<td>156</td>
</tr>
<tr>
<td>Marcus Y.</td>
<td>155, 156, 214</td>
</tr>
<tr>
<td>Mardini M.</td>
<td>159</td>
</tr>
<tr>
<td>Maresca A.</td>
<td>153, 187</td>
</tr>
<tr>
<td>Margaliot M.</td>
<td>155, 156</td>
</tr>
<tr>
<td>Margonato A.</td>
<td>239</td>
</tr>
<tr>
<td>Marin M.</td>
<td>100</td>
</tr>
<tr>
<td>Marini C.</td>
<td>113</td>
</tr>
<tr>
<td>Mark P.</td>
<td>240</td>
</tr>
<tr>
<td>Markabayeva A.</td>
<td>158</td>
</tr>
<tr>
<td>Markatou M.</td>
<td>82</td>
</tr>
<tr>
<td>Markava L.</td>
<td>133</td>
</tr>
<tr>
<td>Marques F.</td>
<td>96, 104, 162, 210</td>
</tr>
<tr>
<td>Martell-Caros N.</td>
<td>187</td>
</tr>
<tr>
<td>Martin J.</td>
<td>153</td>
</tr>
<tr>
<td>Martina S.</td>
<td>212</td>
</tr>
<tr>
<td>Martinez Garcia F.</td>
<td>119</td>
</tr>
<tr>
<td>Martinez-Pereira J.</td>
<td>233</td>
</tr>
<tr>
<td>Martins L.</td>
<td>190</td>
</tr>
<tr>
<td>Martovitskaya Y.</td>
<td>157, 158</td>
</tr>
<tr>
<td>Marcelli G.</td>
<td>154</td>
</tr>
<tr>
<td>Marulanda Carvajal J.</td>
<td>107</td>
</tr>
<tr>
<td>Marusic P.</td>
<td>129</td>
</tr>
<tr>
<td>Marz W.</td>
<td>157, 215</td>
</tr>
<tr>
<td>Masca N.</td>
<td>168</td>
</tr>
<tr>
<td>Maseko M.</td>
<td>160</td>
</tr>
<tr>
<td>Masnatta L.</td>
<td>160</td>
</tr>
<tr>
<td>Massimo G.</td>
<td>215</td>
</tr>
<tr>
<td>Mastroiacovo D.</td>
<td>113</td>
</tr>
<tr>
<td>Masuda F.</td>
<td>213</td>
</tr>
<tr>
<td>Materazzi G.</td>
<td>174</td>
</tr>
<tr>
<td>Matsui S.</td>
<td>214</td>
</tr>
<tr>
<td>Matsuoka H.</td>
<td>114</td>
</tr>
<tr>
<td>Matsuaki M.</td>
<td>115</td>
</tr>
<tr>
<td>Matsuava Y.</td>
<td>214</td>
</tr>
<tr>
<td>Mattace-Raso F.</td>
<td>112</td>
</tr>
<tr>
<td>Maukayeva S.</td>
<td>158</td>
</tr>
<tr>
<td>Mauri M.</td>
<td>209</td>
</tr>
<tr>
<td>Mavrodi A.</td>
<td>231</td>
</tr>
<tr>
<td>Mawson D.</td>
<td>130</td>
</tr>
<tr>
<td>Mayer O.</td>
<td>113</td>
</tr>
<tr>
<td>Mazaraki A.</td>
<td>213</td>
</tr>
<tr>
<td>Mazic S.</td>
<td>157</td>
</tr>
<tr>
<td>Mazza A.</td>
<td>112</td>
</tr>
<tr>
<td>Mazzer A.</td>
<td>165, 212</td>
</tr>
<tr>
<td>M’Buyamba-Kabangu J.</td>
<td>114</td>
</tr>
<tr>
<td>McBride M.</td>
<td>91, 96, 97</td>
</tr>
<tr>
<td>McClure J.</td>
<td>96</td>
</tr>
<tr>
<td>McCully R.</td>
<td>235</td>
</tr>
<tr>
<td>McFarlane I.</td>
<td>103, 214, 215</td>
</tr>
<tr>
<td>McClaghan C.</td>
<td>245</td>
</tr>
<tr>
<td>McLean R.</td>
<td>230, 231</td>
</tr>
<tr>
<td>McMillen C.</td>
<td>98, 234</td>
</tr>
<tr>
<td>McPherson R.</td>
<td>158</td>
</tr>
<tr>
<td>Meachi T.</td>
<td>215</td>
</tr>
<tr>
<td>Medina P.</td>
<td>111</td>
</tr>
<tr>
<td>Mehta A.</td>
<td>174</td>
</tr>
<tr>
<td>Meinzer A.</td>
<td>157, 215</td>
</tr>
<tr>
<td>Mela A.</td>
<td>82</td>
</tr>
<tr>
<td>Melander O.</td>
<td>96, 236</td>
</tr>
<tr>
<td>Melissa M.</td>
<td>230</td>
</tr>
<tr>
<td>Mell B.</td>
<td>97</td>
</tr>
<tr>
<td>Mendorca M.</td>
<td>93, 133, 157</td>
</tr>
<tr>
<td>Meneghini M.</td>
<td>241</td>
</tr>
<tr>
<td>Meng J.</td>
<td>232</td>
</tr>
<tr>
<td>Mengden T.</td>
<td>235</td>
</tr>
<tr>
<td>Mennie J.</td>
<td>92, 171, 208</td>
</tr>
<tr>
<td>Menini C.</td>
<td>96</td>
</tr>
<tr>
<td>Menouar A.</td>
<td>232</td>
</tr>
<tr>
<td>Mensink M.</td>
<td>115</td>
</tr>
<tr>
<td>Meredith L.</td>
<td>99, 239</td>
</tr>
<tr>
<td>Mergia E.</td>
<td>103, 159</td>
</tr>
<tr>
<td>Merletti L.</td>
<td>187</td>
</tr>
<tr>
<td>Mersich B.</td>
<td>192</td>
</tr>
<tr>
<td>Messa F.</td>
<td>241</td>
</tr>
<tr>
<td>Messeri F.H.</td>
<td>171, 180</td>
</tr>
<tr>
<td>Messina P.</td>
<td>187</td>
</tr>
<tr>
<td>Metoki H.</td>
<td>190</td>
</tr>
<tr>
<td>Mezzetti E.</td>
<td>136</td>
</tr>
<tr>
<td>Miadzdvedzeva A.</td>
<td>133</td>
</tr>
<tr>
<td>Mian M.</td>
<td>97, 104, 107</td>
</tr>
<tr>
<td>Michalis L.</td>
<td>211</td>
</tr>
<tr>
<td>Michel F.</td>
<td>160</td>
</tr>
<tr>
<td>Michelini L.C.</td>
<td>136, 192</td>
</tr>
<tr>
<td>Michel D.</td>
<td>171</td>
</tr>
<tr>
<td>Michelson G.</td>
<td>173</td>
</tr>
<tr>
<td>Mihailidou A.S.</td>
<td>159, 232, 252</td>
</tr>
<tr>
<td>Miki T.</td>
<td>93, 244</td>
</tr>
<tr>
<td>Milkolajczyk T.</td>
<td>107</td>
</tr>
<tr>
<td>Mikusova T.</td>
<td>155</td>
</tr>
<tr>
<td>Milan A.</td>
<td>130, 211, 235</td>
</tr>
<tr>
<td>Milanov S.</td>
<td>211</td>
</tr>
<tr>
<td>Min J.</td>
<td>230</td>
</tr>
<tr>
<td>Min K.</td>
<td>230</td>
</tr>
<tr>
<td>Min L.</td>
<td>93, 161, 172</td>
</tr>
<tr>
<td>Mirotsou M.</td>
<td>160</td>
</tr>
<tr>
<td>Mischak H.</td>
<td>92</td>
</tr>
<tr>
<td>Mishima M.</td>
<td>213</td>
</tr>
<tr>
<td>Mishra S.</td>
<td>245</td>
</tr>
<tr>
<td>Missault L.</td>
<td>209</td>
</tr>
<tr>
<td>Miszkowska-Nagóka E.</td>
<td>196, 240</td>
</tr>
<tr>
<td>Moffa J.</td>
<td>108, 128, 142, 202</td>
</tr>
<tr>
<td>Mori F.</td>
<td>158</td>
</tr>
<tr>
<td>Mori M.</td>
<td>228</td>
</tr>
<tr>
<td>Mori Y.</td>
<td>234</td>
</tr>
<tr>
<td>Morimoto R.</td>
<td>214</td>
</tr>
<tr>
<td>Morishita R.</td>
<td>111, 194</td>
</tr>
<tr>
<td>Morita S.</td>
<td>173</td>
</tr>
</tbody>
</table>
Zabulis X. 153, 174
Zacharopoulou I. 236
Zadicario P. 214
Zamboni M. 110
Zamboulis C. 228
Zamfir T. 110, 155
Zanchetti A. 105, 114
Zannad F. 139
Zanoni F. 241
Zappe D. 194
Zarmakoupis C. 234
Zarrouk M. 195
Zarzoulas F. 211
Zdravkovic M. 157, 236
Zebekakis P. 114, 161
Zelinka T. 196
Zeljkovic Vrkic T. 229
Zeng C. 104, 157
Zeng C. 241
Zeng W. 95, 101
Zenimaru Y. 159
Zeniodi M. 100
Zennaro M. 215
Zeymer U. 128, 240
Zhang D. 232
Zhang J. 160, 194, 194, 232
Zhang K. 214
Zhang L. 95, 171, 210
Zhang S. 98, 234
Zhang X. 98
Zhang Y. 102, 194
Zhao H. 232
Zhao Q. 96
Zheng F. 214
Zheng S. 241
Zhi H. 98
Zhou J. 103, 214, 215
Zhou L. 241
Zhou W. 214
Zhu D. 214
Zhu L. 214
Zhu M. 194
Zhu Y. 214
Zhygalina V. 241
Zimlichman R. 223
Zingler M. 107
Ziogas J. 159
Zirlik A. 124
Zoccali C. 137
Zografas G. 234
Zöller B. 212
Zub J. 107
Zukowska-Szczekowska E. 162
Zurre M. 112, 113
Zvartau N. 162
Zyatenkova E. 155
Zykov K. 209